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Biopharmaceutical Solidarity:  
Cuban Cancer Vaccines and 21st Century Socialist Science 
 
 Naomi Schoenfeld 
 
Abstract 
This dissertation examines the social, political and economic context of Cuba’s 
biopharmaceutical sector and its expanding global footprint, shaped by socialism. I examine 
the counter-current technology transfer of Cuban biopharmaceutical innovation, specifically, 
their novel therapeutic cancer vaccines. My research brings together the anthropology of 
pharmaceuticals, science and technology studies of the Global South and post-socialist studies, 
affording a new analysis of the relationship between political economy and scientific 
innovation. I conducted ten months of ethnographic research over four years with clinicians, 
researchers, administrators, regulators, drug marketers, tobacco workers, former patients and 
others involved with Cuban cancer vaccines, both in Cuba and in a collaborating cancer center 
in the US.   
 
Investigating the expansion of socialist biopharmaceutical innovation, I found new ways of 
thinking about the relationship between people, tumors and tobacco. My findings reveal a 
pharmaceutical sector growing through medical solidarity, offering an alternative approach to 
thinking about value. I show how Cuban “therapeutic vaccines” are linked to a term 
increasingly circulating in Cuba known as “cronicidad,” referring to the goal for the patient 
with terminal cancer to be reintegrated into their social milieu. Drawing on interviews with 
Cubans involved in tobacco production as well as biotech researchers working in cancer 
vaccine development, I develop a new term, “biocompanion,” to conceptualize chronic 
relations between humans, tumors and tobacco.  
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  Introduction  
September 27, 2017  
 In the ballroom of a boutique hotel in Niagara-on-the-Lake, Canada, about thirty 
scientists from Cuba and the US gather for a meeting.  The nascent Trump presidency is rapidly 
closing windows of opportunity afforded by the 2014 US-Cuban agreement negotiated between 
Barack Obama and Raul Castro, rendering collaborative efforts between the US and Cuba more 
difficult.  Meeting in Canada, just over the border, entails far fewer bureaucratic hassles than 
bringing the Cuban scientists to the US. The hotel is about an hour’s drive away from the US, in 
a cutesey tourist town. The hotel ballroom is set up like a traditional biomedical educational 
conference, rows of long tables with water glasses and pitchers, notepads and pens. This group of 
researchers is coming together around a novel project: the first US-based clinical trial of a Cuban 
pharmaceutical product.  The pharmaceutical is a therapeutic cancer vaccine called CIMAvax-
EGF (henceforth, Cimavax), which slows or stops the growth of tumors. The vaccine has been in 
use in Cuba for almost two decades, usually for lung cancer, and it is reportedly easy to 
administer and inexpensive to make.  The trial had been underway for several months, but an 
unexpected complication arose in the first group of patients.   
 I was invited to this small, working group-style conference by Dr. Mary Reid, 
epidemiologist at Roswell Park Cancer Research Institute (RPCI) in Buffalo, New York.  Dr. 
Reid is one of the key researchers involved in a collaboration with the Center for Molecular 
Immunology (CIM) in Havana, Cuba. Up front is the projector and laptop with PowerPoint 
loaded up. The first speaker is Dr. Candace Johnson, CEO of RCPI. She inaugurates this two-day 
intensive conference addressing the scientists from both countries:  
We all know we need to get the appropriate excitement in the US…Before I did this, I was 
a drug developer. A drug that may have utility may just be gone…The design of the trial 
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may not have been the best…we had toxicity with the first patient….I charge all of you 
[at] this meeting…we need to have Cimavax in man in a way to have some positive 
results…Many times science and business go like this (points in different directions). We 
need to keep the science and the business going forward (keeps hands together)…to have 
something more unique. We are looking at the brains of all of you…  
 
 The trial they were discussing was what is called a phase two clinical trial which is a 
small test of drug safety. Cimavax has been in use as part of the system of universal free medical 
care in Cuba since 2011, while initial safety and efficacy trials began in the 1990s. It is also 
available in Colombia, Peru, Paraguay and Bosnia-Herzegovina. The complication with the first 
patient, explained a junior oncology-immunology researcher from RPCI, had nothing to do with 
Cimavax, but instead, with a deadly combination of the already approved immune modulating 
therapy used alongside it, nivolumab (Bristol-Myers Squibb) and the inclusion of a patient with a 
pre-existing heart condition.  Nevertheless, it was not an auspicious start.   
Dr. Johnson turns to Dr. Agustin Lage-Dávila, Director of the Cuban entity, 
BioCubaFarma, charged with commercialization of Cuban innovative pharmaceutical products. 
Dr. Lage starts: 
We must build a link between the business path and the scientific path…it is easy to lose 
that link. We must go beyond…reinforce the science and business on one side and reinforce 
the connection [on the other]…this is the first idea I would like to highlight…to provoke 
the scientists gathering here [to]…go beyond the product and go to the concepts behind the 
product…this is exciting especially for me because I injected the first mouse with Cimavax, 
(dramatic pause) and it bit me. 
 
 The audience laughed in response. Referred to by his colleagues as, simply, “Lage,” this 
avuncular figure commands enormous respect and admiration by his Cuban and American 
colleagues in the ballroom. He is, by many accounts, the founder of Cuban biotechnology 
(although Fidel Castro is usually afforded that title in official Cuban presentations). Lage 
continues,   
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There are several conceptual breakthroughs behind [Cimavax]: First, the concept of 
chronic vaccination and long-term immune response…; second, the concept of 
manipulating the internal milieu through the immune system; and third, the joint 
stimulation of T-cell and B-cell immunity at the same time. This is the concept of 
immunosenescence1 in cancer immunotherapy. Now we know it’s not age, it’s the number 
of CD4 cells…This is just to provoke you to think… 
 
We scientists have had many collaborations…in my experience I’ve never seen anything 
like [this collaboration]. This personal chemistry, the enthusiastic atmosphere…my 
feelings is that we are in a good place at a good moment….[that is] the story of 
Roswell…Cancer immunotherapy is entering in the mainstream….Let me end with 
something from a movie I remember called Apollo 13---“failure is not an option..” (Field 
notes, Sept 27th, 2017). 
 
 Dr. Lage’s closing words were loaded.  This was not Cuba’s first go-round with a US 
entity in an attempt to bring this Cuban cancer vaccine into the world’s most lucrative 
pharmaceutical market. There was a lot at stake for both parties, but much more so, politically 
and economically, for the Cuban side.  “Failure is not an option” is a motivational phrase to 
convey urgency: this project, person, etc… cannot fail.  Here, it conveyed the seriousness of 
Cuba’s biotechnology endeavors, the optimism in the early years of a turn in US-Cuba relations, 
and the ongoing weight of economic precarity in the context of Cuban economic conditions in 
the post-Soviet period amidst the crippling, persistent US embargo.   
 In this dissertation, I examine the social, political and economic context of Cuba’s 
biopharmaceutical sector and its expanding global footprint, shaped by socialism. One particular 
biopharmaceutical product, Cimavax, is at the center of this dissertation, yet the aim and scope of 
my project is broader.  Through my research with the interlocutors involved with the circulation 
of Cuban cancer vaccines, I found a story that upsets conventional wisdom on the conditions for 
drug research, regulation, marketing and globalizing pharmaceuticals.  In examining the 
expansion of socialist biopharmaceutical innovation, I found new ways of thinking about the 
 
1 Immunoscenesence is the concept that the immune system response wanes with age. 
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relationship between people, tumors and tobacco. I found a pharmaceutical sector growing 
through medical solidarity, offering an alternative approach to thinking about value.  My 
findings run counter to certain conventional assumptions about pharmaceutical development, 
such as the idea that biomedical innovation requires competition, financial incentives and 
abundant financial resources. This dissertation shows how the system that produced this cancer 
vaccine disturbs normative constructions of scientific progress, technology transfer and the 
conditions of living (with) and dying (from) cancer.   
This introduction sets up the remainder of the dissertation in four ways. First, I offer an 
overview of Cuban science and medicine in general, considering the mode of analysis often 
short-handed as so-called Cuban ‘exceptionalism,’ alongside the place and use of statistics in 
consideration of Cuban health achievements and their global recognition. Second, I consider how 
this dissertation both emerges and departs from relevant social science scholarship. Third, I offer 
a portrait of Cuba during the years of my fieldwork, highlighting some of the most significant 
events bearing on Cuban science, the Cuban economy, US-Cuban relations, and their impact on 
the form and content of my research. Finally, I offer a summary of the remaining chapters.   
 
When a Shot is not Exactly a Shot 
This dissertation examines a very specific technology, a therapeutic cancer vaccine called 
Cimavax, in relation to an extremely broad concept, socialism. Given the considerable spectrum 
of specialized knowledge between which these two entities sit, some basic explanation of both 
may be helpful for readers without a background in either biomedicine or socialist studies.  
Cimavax is a cancer treatment developed, tested and commercialized in Cuba’s state run 
biopharmaceutical sector. It is called a vaccine, and to a certain extent, it acts like one. Yet, it is 
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not a vaccine in the usual way we think of vaccines. That is, it is not administered to prevent an 
infectious agent like influenza, polio or measles, from causing serious illness in the body. 
Vaccines, generally, are a tool of population health. They are administered to prevent widespread 
illness. They involve putting something known as an antigen, usually a foreign substance, into a 
body to mimic the way a real pathogen provokes a corresponding antibody response. Antibodies, 
produced by a type of white blood cell called a B cell, bind and neutralize the antigen, limiting 
its effects on the host organism. Several techniques have been developed to produce vaccines, 
including weakening or inactivating the infectious agent, using just a part of the antigen, or 
genetically engineering a version of the antigen.  
In the case of Cimavax, the vaccine is given to a person already diagnosed with the 
corresponding illness, cancer. It is most widely used for lung cancer, but also seems to have 
some efficacy for head and neck and possibly other cancers as well. It induces an antibody 
response not to a foreign antigen, but to a protein found circulating in the body called epidermal 
growth factor (EGF). EGF stimulates a number of effects on the body under usual circumstances, 
when cancer is not present. EGF receptors (EGFR) are overexpressed in 40-80% of people with 
non-small cell lung cancer (NSCLC) (Rodriguez et al 2016). EGF provokes cell growth and 
proliferation. In a person with cancer it contributes to uncontrolled growth and proliferation of 
malignant cells. Cimavax is a vaccine made from human recombinant EGF2 conjugated to a 
carrier protein and an adjuvant called Montanide, which helps to induce a response to what 
would normally be recognized as a self, or naturally occurring, protein.  It is called a therapeutic 
vaccine because it induces the production of antibodies to EGF which bind to, neutralize and 
 
2 Recombinant DNA manufacturing  uses enzymes to cut out specific genes which make specific 
proteins and insert them into bacteria fragments called plasmids. This biotechnology allows for 
the mass production of proteins using the “machinery” of DNA replication.    
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clear EGF from circulation, effectively diminishing its impact on tumor growth and 
development. This unusual Cuban vaccine is aspirational, even utopian, in ways which are 
explored in detail in the chapters to follow. I will argue throughout this text that this vaccine is 
intimately entwined with socialism.  
In contrast to the highly specialized terms and concepts in Cimavax, offering a succinct 
explanation of socialism is more complicated. Socialism is a term which is broadly used and 
given vastly different, even conflicting meanings. It is, at once, a system of governance, a 
political economy, a political affiliation, a set of ethical commitments and an ideology.  It has 
come to be associated with one party rule, authoritarianism, even totalitarianism.  In the case of 
Cuba, there is often a conflation between what is referred to in shorthand as “El Triunfo,” 
meaning the Cuban 1959 Revolution, and the socialist government. Yet, the Cuban Revolution 
was not a socialist revolution. Socialism was not adopted as an official platform of the 
Revolution until 1962. Just as Cuban socialism cannot be conflated with socialist systems in the 
former Soviet bloc, Scandinavia, China, North Korea or Vietnam, neither has it resembled 
anything like a hegemonic presence even within Cuba over the years. Instead, it has changed and 
adapted for close to fifty years so far. In this dissertation, the term socialism appears frequently. 
In each case, I have attempted to convey the specific aspect of socialism relevant to the situation 
in which the word is used, while simultaneously recognizing this to be fraught, contested, partial 
and inadequate.  
 
The There There: Or, What is the Point of Studying Cuban Biopharmaceutical Expansion?   
 In the second month of the longest of my five trips for fieldwork in Cuba, in January 
2018, I entered into conversations with officials from the Cuban Ministry of Public Health, in a 
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(naive) attempt to find a workable affiliation for myself as an anthropologist of science and 
medicine from the US. I had prepared a two-page Spanish proposal for the project, summarized 
as an ethnographic examination of the social, cultural and political context of Cuban 
biopharmaceutical innovation, emphasizing the novel situation of the counter-current technology 
transfer behind the CIM-RPCI collaboration.3 As we sat in armchairs in the lobby of the 
imposing mid-century Ministry of Public Health (MINSAP) headquarters in the Vedado 
neighborhood of Havana, the official with whom I spoke closed my folder of materials, leaned 
back, and responded, “I don’t really think this project is necessary.”  While his response might 
be interpreted along several lines, my sense was that he meant the project was so self-evident as 
to not be worth examining. My other thought, based on many conversations with other Cuban 
anthropologists as well as and non-Cuban anthropologists of Cuba, was that my project was not 
only not “necessary,” but also likely unwelcome. As the following chapters describe, the Cuban 
health system closely controls its messaging. While cultural anthropology has a robust presence, 
medical anthropology is poorly developed in Cuba. Perhaps he could be indicating that the 
conditions for developing and expanding Cuban biopharmaceuticals are no different than 
anywhere else, and therefore not worth studying? In the end, I was left to my own speculations, 
never discovering what he meant.   
 In many of my conversations with and observations of Cuban biotech researchers, I found 
them expressing their feeling of kinship, as well as collaboration, with a broader international 
community of researchers. They spoke to me of their collaborations with prestigious European, 
Canadian and US institutions. Many completed at least part of their training abroad. Cuban 
 
3 Counter-current here refers to the idea that technology is generally moving unidirectionally, 
from resource-rich toward resource poor environments. 
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medical and scientific conferences I observed included a focus on how to improve national 
scientific journals, how to better engage with the prestigious scientific publications of North 
America, disseminate their findings and work on cutting edge projects.  True, some Cuban 
researchers would lament the difficulties in obtaining particular supplies to conduct experiments, 
the delays and stagnation of projects which elsewhere could be done quickly and easily.  Yet, 
their overall sentiment was that their science was the same, not different from that being 
practiced anywhere else. In this project, I will explore this claim and the evidence to the 
contrary.   
 For a biotechnology sector from a relatively poor country, aspiring toward sameness and 
inclusion in the international community is perhaps not surprising.  Up against the juggernaut of 
highly capitalized public-private or all private national and multinational research centers of the 
Global North, what else should Cuban biotech aspire to?  Not only is the health of a nation, but 
also recognition, respect and potential for financial benefit are at stake. Underlying this 
aspiration toward sameness and standardization of scientific procedures are the actual conditions 
of possibility not only for what type of research gets done, but also, who does it and what types 
of results are considered acceptable.   
 Medical anthropologists and science studies scholars have taken granular approaches to 
interrogating the fault lines and heterogeneity behind claims to sameness and difference in 
science, including questions of whether science itself is universal or local (Hayden, 2013; 
Rabinow, 1999; Haraway, 1988; Latour, 1990). Arguably, an important subtext of my research 
engages the question of whether and to what extent Cuban science is the same or different from 
the science produced in the Global North.  As I will show in the chapters that follow, Cuban 
science is simply “western science” as practiced in major research centers around the world; and, 
   9 
it is also a radically distinct endeavor shaped by the political and economic context of life in the 
ever changing iterations of Cuban socialism and also by the particular circumstances fueling 
specific lineages of research on the island.   
 
Exceptional Numbers: Cuban Healthcare and Cuban Medical Solidarity 
 This dissertation focuses on the social, political and economic context of Cuba’s 
biopharmaceutical sector and its expanding global footprint, shaped by socialism. My research is 
not centrally concerned with the Cuban healthcare system, yet chapters that follow cannot be 
read without some basic knowledge of that system.  The Cuban doctor and nurse program has 
been studied, documented and lauded by hundreds of scholars, politicians and international 
entities, including the Pan American Health Organization (PAHO) and the World Health 
Organization (WHO).  Indeed, the study of this system has transformed into a virtual industry for 
both foreign businesses and nonprofits in leading tours and hosting conferences, as well as an 
economic resource for the Cuban government. Here, my intention is not to list the achievements 
of the Cuban medical system, as hundreds of existing publications can and have already 
accomplished this goal.  Rather than re-detailing statistics on doctor training, on improvements 
in morbidity and mortality in Cuba, on numbers of medical missions including disaster response 
efforts, what is important to highlight, for my purposes, is the way in which Revolutionary 
Cuban biomedical achievements are shaped as exceptional, buoyed by numbers and circulated as 
narrative. These achievements are often spoken about as unique, unexpected and difficult to 
explain. In particular, since the collapse of the Soviet Union, the achievements are juxtaposed to 
the conditions of deprivation and struggle and received as contradictory (Burke, 2013). 
Frequently, the complex state of affairs, alongside the accompanying narrative, are referred to as 
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Cuban biomedical “exceptionalism” (Briggs, 2011).  The narrative of Cuban exceptionalism is 
forged from the combination of an affective morality, expressed in the idioms of socialism, as 
well as the production of globally legible, quantitative metrics of health and illness.    
 While the Cuban biomedical phenomenon, in its most frequently circulated form, is 
linked to Revolutionary Cuban socialist science and medicine, in fact Cuban notability in 
scientific achievement dates back about one hundred years earlier. Colonial-era Cuban science 
made early inroads into infectious disease through the pioneering research of nineteenth century 
epidemiologist Carlos Finlay, whose research led to the discovery of the Aedes egyptii mosquito 
as the vector for the transmission of Yellow Fever (in the US, credit for this discovery goes to 
Walter Reed. Chapter One addresses this history and controversy in greater detail).  This 
discovery, stuff of legend and many statues in Cuba, cemented this island as an early site of 
advanced research on infectious disease and subsequently laid the foundation for a robust 
program of vaccine development central to the eventual birth of the biopharmaceutical sector in 
the 1980s.  
 At the height of the so-called Special Period in Cuba, in the early years following the 
collapse of the Soviet Block and subsequent loss of its financial support, a period of extreme 
economic insecurity and privation, Julie Feinsilver, policy consultant and one-time visiting 
scholar of International Service at American University, wrote a book which has become 
foundational for medical anthropologists of Cuba.  Healing the Masses (1993) was, for its time, a 
fairly comprehensive treatise on Cuban medicine and Cuban health diplomacy.  Feinsilver writes, 
“[s]ince 1978 Castro has made a number of declarations about the direction of Cuban medicine, 
indicating that Cuba would become "the bulwark of Third World Medicine," put a doctor on 
every block, become a "world medical power," and equal or surpass the United States on certain 
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health indices (1993:1).  Backed by extensive secondary source research and interviews with top 
Cuban and international health figures, Feinsilver not only offered an overview of the state of 
health achievements at the time, but she also accurately forecasted some of the achievements to 
come in the years following its publication. Yet, her greatest impact was not in documenting of 
the history of specific campaigns and progress in Cuban biomedicine. Her most enduring 
contribution was her analysis of the goals and intentions of Cuban biomedical achievement: the 
significant investment in medicine, science and technology and their endeavors in dozens of 
countries of the Global South since the first years of the Revolution, even throughout the period 
of dire economic circumstances on the island.  
Cuba's focus on health care projects an image of progress that other developing nations do 
not have. To gain international influence and prestige, Castro has chosen to represent Cuba 
as a country of increasing social development and scientific sophistication. The 
improvement of the population's health initially required more political commitment than 
hard currency and scientific expertise. Once the obvious public health, health education, 
and sanitation measures were taken, however, further progress depended on other factors, 
such as the expenditure of considerable hard currency on a system of well-equipped 
medical institutions and the rapid incorporation of scientific advances (1993, 4-5). 
 
 The thrust of Feinsilver’s argument contends that, for Fidel, Cuban healthcare and 
medical internationalism were not primarily about delivering care.  Instead, the symbolic power 
of not only offering universal healthcare, but sending doctors and other technoscientific support 
to other countries was a revolutionary act. She quotes Fidel Castro in a broadcast delivered in 
1990: "What is Cuba today? Cuba is the symbol of resistance; Cuba is the symbol of the firm and 
intransigent defense of revolutionary ideas; Cuba is the symbol of the defense of revolutionary 
principles; Cuba is the symbol of the defense of socialism (22).”  
 Latin American Studies Professor John Kirk and Cuban policy and diplomacy scholar 
Daniel Erisman have authored many publications documenting Cuba’s medical and scientific 
achievements (2011, 2017, 2018).  Kirk’s 2016 volume, published in Cuba, updates and expands 
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on Feinsilver’s work and offers a longitudinal analysis of Cuban biomedical endeavors. Kirk 
divides Cuban medical internationalism into four periods, beginning in 1960 after the Chilean 
earthquake. The first period, spurred by the earthquake’s devastation, was propelled by what 
Kirk refers to as  the “revolutionary fervor” of the 1960s. Phase two began at the end of the 
1970s, with multiple interventions in Africa in support of decolonization, particularly including 
major military intervention in Angola. The third phase began at the end of 1990s after the Central 
American and Caribbean hurricanes; the fourth phase began in 2008 with Raul Castro’s 
economic reforms (lineamentos) (27).  Kirk further divides phase one into two sub-phases: a first 
sub-phase of proletariat internationalism, effectively ending with Che Guevarra’s assassination in 
Bolivia in 1967, and a second sub-phase, fortifying Cuba’s position with the Soviet Union and 
improving relations in Latin America. Despite Cuba’s efforts and desire to solidify its position 
within the socialist camp and gain Soviet support, the country nevertheless pursued its own 
independent foreign policy, in terms of both medical internationalism and military intervention, 
as in its involvement in Angola, in this case, directly against the expressed advice of the USSR 
(Gleisjes, 2002).  As noted by both Kirk (2016) and Gleisjes, even when the Soviet Union 
recommended Cuba reduce its military and international humanitarianism to concentrate on 
fortifying its own economy, Cuba actively ignored the advice, pursuing campaigns in medical 
and military solidarity throughout the Global South.   
 Describing the full extent of Cuba’s medical interventions across the Global South is 
beyond the scope of this dissertation. And yet, the act of listing some of the other notable 
campaigns is important, if only to better convey the duration and level of commitment and 
investment made by the Cuban Communist Party, as well as by thousands of individuals who 
volunteered for these campaigns, toward these ends.  Since the 1990s, following the collapse of 
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the Soviet Union, Cuba has continued sending healthcare providers, scientists and technicians to 
areas hit by natural and man-made disasters. In 1998, triggered by the devastation inflicted in 
Central America by Hurricane Mitch, Cuba dramatically augmented its global doctors program, 
sending thousands throughout Central America both for initial disaster relief but also for ongoing 
support. Cuba founded the Escuela Latinoamerica de Medicina (ELAM), a medical school 
initially intended to train doctors from Latin America, the Caribbean and Africa. Today, ELAM 
also trains doctors from the US who come from underrepresented and disadvantaged 
backgrounds and who commit to returning to their communities to provide primary care.  
Operation Milagro has provided thousands of free eye surgeries to people from Cuba, Africa, 
Latin America and Caribbean; Cuban doctors and nurses provided medical care to thousands of 
children affected by radiation exposure in the years following the Chernobyl disaster.  A new 
team of doctors specially trained in disaster management was assembled to deploy assistance to 
the US after Hurricane Katrina in 2005. The offer was declined by President G.W. Bush, but the 
effort took the shape of a permanent team called “The Henry Reeve Brigade,” named after a US 
citizen turned Cuban hero in the war for independence from Spain. Most recently, Cuba has sent 
thousands of doctors overseas to aid in the 2020 COVID-19 pandemic, while simultaneously 
quelling the outbreak at home.  
 In the chapters that follow, as I mine the phenomenon of global expansion of Cuban 
cancer vaccines, considering the extent to which this new direction is consistent with, and 
departs from, Cuba’s history of international efforts is a crucial element of the project.  These 
international endeavors project an idealism, a utopic inclination.  Yet, they are not simply 
altruistic. As Feinsilver pointed out, Cuba’s medical interventions are also about the symbolic 
impact of a relatively poor, socialist country sending its doctors to help around the globe.  In 
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addition to this geopolitical or soft-power side of the equation, and in particular over the past 
thirty years, doctors have grown to be a considerable source of income for the country. Per Kirk 
as of 2016, doctors bring in 8.2 million USD annually to the Cuban government (this figure 
decreased significantly in 2018 due to Venezuela’s economic collapse and the election of right-
wing President Bolsanaro in Brazil, detailed later in this chapter) (2016:51).  
  In the remainder of the dissertation, I will use the phrase medical solidarity to describe 
Cuba’s interventions and endeavors in the Global South.4  With roots in both anthropological 
theory (Durkheim, 1893) and Marxist discourse, the phrase might appear overdetermined by 
history and ideology.5 Yet, it conveys the ways in which Cuba’s version of global health and 
globalizing pharmaceuticals departs from efforts initiated from the Global North. Solidarity 
implies an act to demonstrate alliance based on a mutual respect, shared interests and values. 
Importantly, it also entails a material commitment. In using the term medical solidarity, my 
intention is to render visible that which is usually obscured but implied both within global health 
 
4 Recently, this solidarity is extending to marginalized communities in the Global North, as Cuba 
has made efforts to bring their novel treatment for diabetic foot ulcers to First Nations peoples 
of the US.  
5 In the shadow of a persistent Cold War, certain words become unwieldy to work with, yet 
impossible to avoid. I find the term, “ideology,” has taken on some of that character in the early 
21st century, with regard to talking about Cuba.  While some US-based scholars of Cuba like 
Gordy (2015) have mined the term to examine the how it gets taken up in a range of 
governmental and nongovernmental organizations across the left political spectrum in Cuba, the 
weight of the word and its associated baggage is, for me, an unwelcome distraction from the 
elements of Cuban science I find useful and interesting.  An interesting alternative is Yurchak’s 
(2006) use of the Russian term, svoi, which means something like “normal.” Through his 
analyses of diaries as well as interviews with people of their recollections of the final years of the 
Soviet Union, Yurchak develops a rich analysis of the ways in which people identified neither as 
supporters of the state/party nor as dissidents but rather as svoi, incorporating ways of thinking 
and acting including elements which could be described under the rubric of state Soviet 
ideology, for multiple, variable and changing reasons. Some reasons included what they 
described as a belief or agreement with the particular principles, others were adopted to facilitate 
ease of social life, as in, saying what is necessary so as to be able to move through a system 
where neighbors and friends might be informants. 
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and globalizing pharmaceutical expansion originating from the economic superpowers of the 
world. That is, medical solidarity stands in contrast to a global health characterized, in both its 
philanthropic and militaristic branches, by its roots in liberal democratic ideals and capitalism.  
As explored in greater detail in Chapter Four, Cuban pharmaceutical expansion grows out of 
relationships forged through acts of solidarity. This does not mean it is not connected to an intent 
to generate income. Rather, it is not fundamentally shaped by the directive to be profitable. This 
is not a semantic difference. It changes what types of drugs can get made and who will have 
access to them. These distinctions are explored in greater detail in the chapters that follow.  
  The so-called exceptionalism of Cuban healthcare and medical solidarity does share a key 
component of most biomedical interventions: it is conveyed through metrics.  Understanding the 
different valences these numbers represent, as well as the ways they have been and continue to 
be contested, is equally relevant. While quantitative measurement is often received as objective 
fact, the circulation of health statistics involves much more than simple number crunching.  In 
her recent edited volume interrogating the primacy of the quantitative and the tyranny of the 
randomized controlled trial (RCT) in global health, Vincanne Adams notes, “In fact we might see 
number crunching and metrics work as, in their own way, forms of storytelling. They tell stories 
about what those who produce them and what those who rely on them care about most. These 
cares are coded into the naming of some variables as important and the exclusion of others… 
(2016:9).”  
  Adams’s volume is largely addressed toward a critique of large-scale, vertical global 
health endeavors. Yet, the concerns addressed in the introduction and first chapter of her volume 
both offer insight, as well as complicate, a question raised to me during my fieldwork by 
multiple proponents and detractors of Cuban bioscientific achievements and medical solidarity: 
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the believability of Cuban numbers. This controversy could also be rephrased: who gets to 
produce numbers?  Adams contends, “[t]he dominant discourses in global health today also 
imagine a world in which neoliberal economic strategies will seamlessly work toward the 
achievement of health as a right of, and therefore achievable for, all. What enables all this to 
happen today, of course, is metrics (6).” The chapters in the metrics volume point out the 
hegemony of neoliberal thought underwriting the vast majority of contemporary endeavors in 
global health.  The neoliberal logic is communicated through the seemingly objective medium of 
numbers which are interpreted as if they speak for themselves and are neutral.  This carefully-
argued insight dovetails with the related concept known in medical anthropology as 
pharmaceuticalization (Biehl, 2007, see below).  Adams and her co-authors reveal how the 
hegemony of quantitative metrics, in this case undergirding global health efforts in the form of 
RCTs, normalizes a particular configuration of health and economy.  She argues, “[g]lobal health 
today has become a platform that binds the sense of neoliberalism in a novel form, inheriting the 
common sense of neoliberalism and increasingly mobilizing the private sector and its market-
based, profit-driven solutions for all health problems (2016:25).”6  Cuban metrics don’t fit this 
mold. Instead, they perform a different kind of labor.   
  In Cuba, metrics are exquisitely important to the state and the party: they offer tangible 
support for the success of the Revolutionary program of healthcare; evidence in favor of  party 
continuity; and a materiality through which to stake a claim for an ethically grounded state 
apparatus. The generation and circulation of globally recognized metrics like infant and maternal 
mortality, HIV transmission, life expectancy or incidence of infectious diseases like dengue and 
 
6 Adams does observe that the use of RCTs in public health did not begin with a neoliberal 
agenda. Instead, endeavors like the Cochrane collaboration aimed to provide national health 
programs with fair ways of distributing scarce resources.  
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zika confers an authority otherwise unavailable to a poor country in the Global South. Many of 
these figures are certified by international bodies like the WHO and the PAHO: they are facts in 
circulation. The high ratio of doctors and nurses to the general population behind the 
internationally acclaimed neighborhood doctor and nurse program gets a good deal of credit for 
the labor behind the generation of these statistics. The doctors and nurses staffing neighborhood 
consultorios do not content themselves with waiting for the local patients to come by, although 
many, if not most patients, do come by with great frequency. House-calls are regular, and 
periodic cadres of health professional students can be seen in droves on the streets in their white 
coats, reaching out to those patients who do not frequent their local clinics and may be in need of 
assessment and assistance.  
 And yet, as with many statistics and big data in general, anecdotes creep in, some 
intended to function as a form of exposé, others seemingly casual. Some of these anecdotes tell 
of physicians who might knowingly misdiagnose a patient in the service of maintaining 
favorable statistics. A friend with a small child spoke of this experience, when her child had a 
fever but was otherwise healthy, and she was advised to be admitted to a remote hospital, but not 
told exactly what diagnosis her daughter either had or was suspected to have. Dengue was named 
by some as the possible culprit for suppressed statistical counting. The diagnosis was, in the 
mother’s view, purposefully vague. Anecdotes abound in the form of disgruntled blogging about 
shortages of medicines and inadequate treatment. Even state-sanctioned journalism, like the 
Cuban Communist Party’s (PCC) principal newspaper Granma, tells of such shortages, although 
these may be effectively blamed on the embargo and therefore do not necessarily reflect 
negatively on the state-run system of pharmaceutical distribution.  Anthropologist-activist 
Scheper-Hughes famously wrote somewhat critically of the mandatory residential HIV/AIDS 
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treatment in Cuba (1993), a program designed to reduce transmission and related to the relatively 
low rates of infection in comparison to the rest of the Caribbean.  This publication resulted in 
Scheper-Hughes effectively being banished from returning to Cuba.   
  Anecdotes like the ones described tell a well-worn tale: numbers are often made to serve 
political demands. This is just as true in capitalistic societies as it is in socialist ones like Cuba. 
Yet, the circulation and interpretation of Cuban health statistics, as well as scientific results, as 
will be explored in greater detail in this dissertation, are frequently subject to greater scrutiny and 
skepticism than those produced in or by entities from the Global North. The production, 
reproduction and circulation of these Cuban statistics are not always readily accepted as 
“objective” or as “fact” to the same degree enjoyed by metrics produced by national or 
international entities of the Global North. Once again, while any statistics may be subject to 
critique, doubt or scrutiny, Cuban health statistics do not enjoy the privilege of health statistics 
produced elsewhere.  Instead, they are politicized in distinctive ways tracking along ideological 
lines and reflecting geopolitical conflict.   
 
Qualitative Antecedents: Texture, Subjectivity, Local Meanings, Local Reason  
 As an anthropologist, as one might expect, Adams’s volume critiquing metrics in global 
health calls for greater emphasis and attention to non-metrical modes of inquiry, such as those 
available to qualitative social scientists. Over the past decade, medical anthropologists have 
offered examinations of some of those aspects of the Cuban healthcare system not accessible 
through the types of narratives spawned by metrics. Burke’s (2013) edited volume offers a 
collection of both local, intimate ethnographies and larger scale analyses. The volume examines 
themes related to healthcare, food insecurity and medical diplomacy, each chapter adding texture 
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and troubling many of the dominant narratives of Cuban health and healthcare. Brotherton’s 
(2012) ethnography focuses on changes to the Cuban healthcare system in the post-Soviet era, 
where he traces the emergence of what he describes as “medicalized subjectivities” amidst a 
disintegrating health system in the decade following the collapse of the Soviet Union and 
subsequent loss of subsidies to Cuba. Brotherton finds a system in which people navigate their 
health needs through negotiation between socialism and social ties (‘sociolismo’). As 
Brotherton’s work reveals, more than 30 years after the fall of the Soviet Union, Cuba’s 
socialism continues unfolding and adapting, albeit now alongside a parallel private sector.   
 Anthropologist Sahra Gibbons (2010; 2016) has conducted research over the past decade 
on how genetic screening for breast cancer is reinterpreted in Cuba as a public health 
intervention through family history collection, using available resources and logics. Sociologist 
Nils Graber (2018) has examined the integration of state-run clinical trials for Cuban cancer 
vaccines into public health via neighborhood health centers.  Like Gibbons, my research 
considers local difference in cancer research. Like Graber, my research most closely concerns 
Cuban cancer vaccines.   
  Simon Reid-Henry’s The Cuban Cure (2010) examined the birth and rise of the Cuban 
biopharmaceutical industry. His work is foundational to my research, and the questions pursued 
here both build on and depart from his work. The crux of Reid-Henry’s argument rests on two 
questions: “[f]irst, to what extent are forms of scientific reason and rationality geographically 
bound? And, second, what happens when different forms of scientific reason collide.” He 
concludes,  
[t]the conditioning of life-science research under social and moral obligation of public 
interest has resulted in a very different life-science industry on that island. It is not one that 
all those scientists involved have agreed on, nor is it one free of certain restrictions or 
political enforcement which run contrary to its ethic and which have at times threatened to 
   20 
undermine it. Cuban biotechnology does not offer a model that other countries might 
unproblematically emulate, therefore. But as with the not entirely dissimilar experiences in 
Brazil and in India, among other places, there is a good deal to learn from their experience 
(169). 
 
 Reid-Henry described and analyzed many of the founding figures and moments leading 
to the development of a biotech sector in Cuba. The situation Reid-Henry analyzes has developed 
and changed, and now, with the trial of Cimavax at RPCI, a new dimension of counter-current 
technology transfer is taking shape. My research engages not only with Cuban researchers, but 
also with general oncologists, former patients, workers in the Cuban regulatory and 
commercialization sectors, tobacco workers, and, with collaborating researchers in the US. This 
dissertation offers a new direction in medical anthropology: examining counter-current 
technology transfer and a socialist form of global (bio)pharmaceutical expansion.   
 
An Anthropology Around (not of) Cancer 
 This dissertation engages, but is not focused on, cancer.  A growing number of 
anthropologists are examining cancer across the globe, analyzing the ways in which the 
experience of cancer intervenes on subjectivity and is shaped by local resources, histories and 
traditions, corporate interests, national discourses, patriarchy and racism (Bell, 2012; Dyer, 2015; 
Jain, 2013; Livingston, 2012; Manderson, 2011, 2015; Mathews, Burke, and Kampriani, 2015; 
McMullin, 2016).  While my interlocutors included several people with personal histories of 
cancer as well as family members who had lost a loved one to cancer, these interviews informed 
my primary focus: the social, political and economic context of  Cuban cancer vaccines.  Chapter 
Two does engage cancer as subjective experience through an analysis of new ways of thinking 
about terminal cancer through therapeutic vaccines.  Yet, fundamentally, my research is not like 
the rich and robust anthropologies of cancer documenting the inequities of the experience of 
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cancer across the globe. Mathews, Burke and Kampriani’s edited volume (2016) brings together 
scholars working across a range of settings examining the interface of the local and the global in 
an approach simultaneously intimate and systemic. As the editors stress: 
[C]ancer is an economic disorder rooted in material practices, which vary among nations 
arrayed along a continuum from resource rich to resource poor. Cancer is a profoundly 
social disease that requires a reexamination of the boundaries of patienthood in an era of 
biosocial identity making. Cancer today is a transnational condition involving the 
unprecedented flow of health information and technologies as well as people across 
national borders, raising issues about the nature of therapeutic citizenship, about how and 
where structurally vulnerable populations obtain care, and about the political geography of 
blame associated with this disease (1-2). 
 
 While I do not consider this work an ethnography of cancer, I have attempted to hold the 
experience of having advanced cancer close to the center of most of the questions guiding this 
research.  Therapeutic cancer vaccines are, by design, not intended to cure. Instead, they are 
intended to hold advanced cancer at bay, buying more time (although Dr. Mary Reid at RPCI 
hopes to one day use them as preventative vaccines in high-risk smokers). Having introduced 
key elements of background in Cuban bioscience and healthcare useful for approaching the 
following chapters, in what follows I situate my work in the literature I consider most relevant to 
my own scholarship. 
 
The Unbearable Between-ness of (Science in) the Caribbean  
  As examined in the preceding pages, the biomedical domain represents one way in which 
Cuba is received as exceptional. Exceptionality is also posited in relation to a given 
circumscribed geographic or ideological space. Cuba is posited as exceptional within the Global 
South; within the socialist camp; within Latin America; and within Caribbean in general.  The 
Cuba I examine here, in my exploration of the expansion of its biopharmaceutical sector, is 
shaped through its liminal position across several domains. Cuban science, as is the case with 
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Cuba in general, is shaped by its position as both of and yet distinct from: the Global South writ 
large; the Caribbean, Latin America, and the socialist and post-socialist camp.  
 The betwixt and between-ness of Cuba underwriting the claims of or for exceptionality 
shares kinship with broader linguistic, cultural, and religious syncretism, as is often asserted 
about the Caribbean in general.  Cuban science in general and the biopharmaceutical sector in 
particular owes something to its place on the map and its irrevocable connection to a history 
shaped by slavery, colonialism and syncretism, before taking the Revolutionary socialist form. 
Yet, even if Cuban science might have some relation to syncretism, the basic processes and steps 
of their experimental science are not radically different than what one would find in any major 
site of biomedical research. Generations of Cuban scientists have spent at least part of their 
training or careers in European or Soviet universities and Cuban science is published across 
global platforms aligned with the norms established by the major centers of research.  
 For anthropologists of the Caribbean in particular, syncretism has historically offered a 
way in to analyzing a topic of interest.  Stephan Palmie’s work (2002), for example, represents 
an interesting attempt to think Afro-Cuban religion as its own form of science.  Palmie argues 
that Afro-Cuban practices and beliefs are both modern, rational and valid as a scientific approach 
based on knowledge, scholarship and testing.  Palmie draws on Stanley Tambiah (1990 cf 
Palmie) to consider how “as scientific rationality spills over from its proper domain into other 
areas of life, it suffuses them with a sense of vulnerability to external control and transparency to 
power that most of us find, if not frightening, at least morally vexing (2002:203).”  Palmie 
revisits Shakespeare’s The Tempest, an important and recurrent text frequently analyzed in Cuban 
and Caribbean literature, inverting the usual tropes by positing Prospero as the magician and 
Caliban as the scientist.    
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 My own research efforts were occasionally redirected by my Cuban interlocutors away 
from science toward traditional healing and religious practice. During my 2018 six month stay in 
Havana, I made the rounds of various centers of social science research in an attempt to build 
bridges with Cuban social scientists and also in the service of trying to find an institute through 
which to establish an academic visa. These endeavors afforded me the pleasure of learning about 
different types of anthropological and historic research as well as building relationships with 
social scientists in Havana.  I had many fascinating conversations with these scholars, several of 
whom insisted on gifting me books so I could learn more about Cuban anthropological research 
areas and traditions. Ultimately, none of the anthropologists I spoke with felt their institute could 
support a US-based anthropologist who wanted to study Cuban biotech. There is no significant 
tradition of medical anthropology as it has taken shape in the academe of the West over the past 
forty years; neither is there a tradition of science and technology studies in Cuba. (In March 
2020, the American Society for Medical Anthropology had their meeting in Havana, and the 
majority of the Cuban participants worked in public health.)  Indeed, several of these scholars 
discouraged my project and encouraged me to consider another line of research more aligned 
with the established domains of anthropology in Cuba: in particular Afro-Cuban religion. One 
physician-researcher, Ernesto (a pseudonym), advised me that my project would never be 
accepted within the social science community in Cuba. Instead, he encouraged me to consider 
another direction and invited me to work with him on a research project involving observing and 
interviewing alternative and Afro-Cuban spiritual healers as part of his larger project to 
document the history of what is known in Cuba as MNT, “medicina natural y tradicional.” MNT 
is, in fact, quite prominent and important, accepted within the MINSAP.    
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 Attempting to convey the complex and heterogeneous influences on Cuban science is a 
risky endeavor, raising two important concerns.  As discussed above, one concern relates to the 
ways in which Cuban data does not always enjoy the same automatic acceptance as data 
produced in the Global North. That is, Cuban science may be subjected to extra scrutiny. The 
other concern is the risk of exoticizing Cuban science in some way by rendering it an “other.” 
Yet, as I will elaborate in detail in the chapters to follow, considering both the conditions through 
which the biopharmaceutical sector has developed as well as the significance of its global 
expansion entails close attention to what makes it distinctive: socialism, postcolonialism, 
syncretism are all part of this story. Whether Cimavax ends up getting approved for use in the US 
or not (which is not clear at the time of this writing), understanding how it got to this point and 
why it available as a novel form of advanced cancer treatment in a growing number of countries 
contributes significantly to our understanding of the relationship between political economy and 
biomedical innovation; it simultaneously renders more visible, and unsettles, the dominant global 
model for drug development and expansion grounded in the market.    
 In some ways, an anthropological inquiry into Cuban science shares some kinship with 
broader Caribbean social science scholarship. Michel-Rolph Trouillot, considering the place of 
the Caribbean in the social sciences, noted that, “with a predominantly nonwhite population, it 
was not ‘Western’ enough for sociologists. Yet it was not ‘native’ enough for anthropologists 
(1992:20).”  He goes on to argue for a consideration of place of primacy for the Caribbean in any 
analysis of modernity, capitalism, and the rise of the West as the dominant global force, at least 
in the 20th century.  This is, of course, because it is the origin of slavery and the colonial project.  
Trouillot offers:  
Each in its own way pointed to a third feature of the sociocultural landscape, the fact that 
Caribbean societies are inherently colonial. It is not only that all Caribbean territories have 
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been conquered by one or another Western power. It is not only that they are the oldest 
colonies of the West and that their very colonization was part of the material and symbolic 
process that gave rise to the West as we know it. Rather, their social and cultural 
characteristics- and, some would say, individual idiosyncrasies of their inhabitants cannot 
be accounted for, or even described, without reference to colonialism (22).   
 
 While the hazards of taking a broad and unorthodox approach to examining Cuban 
science are real and the stakes high, I have proceeded, cautiously, offering my analysis back to 
key interlocutors and incorporating their feedback. In the chapters to follow, I invite the reader to 
consider, alongside me, the intersecting, overlapping influences, histories, and ontologies 
through which this geographic space and diaspora are continually made and remade, through the 
lens of Cuban biopharmaceutical expansion.  
 
Toward an Anthropology of the Socialist Pharmaceutical? 
 This dissertation examines the global expansion of a socialist pharmaceutical sector, a 
novel terrain within the anthropology of pharmaceuticals. As anthropologists have shown, 
pharmaceuticals play social, cultural, political and economic roles far beyond treating, managing, 
or curing, disease. They have prestige, symbolic power and the capacity to transform local and 
global markets (Nichter and Vuckovic, 1994; Reynolds-Whyte, van der Geest, and Hardon, 
2002; Petryna, 2006; Biehl, 2006, 2007; Sunder-Rajan, 2017; Dumit, 2012; Peterson, 2014). 
Cuban cancer vaccines move against the grain of knowledge and technology transfer, suggesting 
a new conceptual terrain not previously analyzed by this anthropological work.  
 From the earliest formulations of my research question, I have been drawn to 
anthropological approaches to the interface between humans, as bodies and social beings, and 
those state-sanctioned substances, organic and inorganic, designed to stimulate, change, or cure 
the mind and body: pharmaceuticals. The domain, therefore, preceded the field site. From 
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ethnobotany to traditional medicine, placebo effect to pharmaceuticalization, anthropologists 
have found, within the category of licit drugs, worlds of meaning, forms of suffering and 
enactments of power.  The structuralist anthropology of Levi-Strauss (1963) and the symbolic 
anthropology of Turner (1970) are important precursors to a line of inquiry in the mid-twentieth 
century which opened the door to the birth of the anthropology of pharmaceuticals.  Laying the 
intellectual foundation for the next generation of anthropologists who would describe themselves 
as members of the sub-discipline, Levi-Strauss legitimated inquiry into the intersection of 
culture, belief, and the body, a project embraced by the first generation of self-described medical 
anthropologists like Arthur Kleinman and Byron Good, among many others.7  
The early anthropologists of pharmaceuticals extended Arjun Appadurai’s (1986) “the 
social life of things” framework to examine the “the social life of medicines,” examining the 
ways that pharmaceuticals enter ‘traditional’ societies and are remade and enfolded into a 
symbolic terrain of healing, value and sociality (van der Geest and Reynolds-Whyte, 1996; 
Nichter and Vuckovic 1994). Starting in the early to mid-2000s, a robust body of scholarship 
within this subfield began to interrogate the penetration and spread of capitalism through 
pharmaceutical means. Most of these works intervene in the theoretical terrain of 
pharmaceuticalization, an extension of medicalization. Pharmaceuticalization (Biehl, 2007) 
focuses on the identification of phenomena amenable to prescribable intervention that previously 
 
7 Anthropologists Andrew Lakoff (2002) and Kalman Applbaum (2009) explicitly draw on Levi-
Strauss in their examinations of psychoanalysis, psychotropic medications and the placebo effect.  
Applbaum ties Levi-Strauss’s work to the production of evidence for the efficacy of mental 
health treatment.  Lakoff (2002) focused on the importance of the community of belief behind 
psychotropic drug research, drawing from the symbolic anthropology of biomedicine in 
establishing the importance of a shared sense of scientific authority (Moermann, 1997, cf Lakoff, 
2002). Lakoff turns this perspective on its head by focusing on the ‘community’ of drug 
developers who, he argues, have something akin to faith in the efficacy of their drug.  
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did not call for pharmaceutical solutions, such as behaviors, modes of living, difference, and 
other ‘symptoms,’ which interfere with a ‘productive’ life (e.g. Vuckovik 1999 and Wolf-Meyer, 
2009), as well as transformation of public health toward pharmaceutical solutions (Biehl, 2006, 
2007). These scholars focus on the ever-expanding reach of capitalism’s tentacles. They have 
examined the ways in which the industry has reconfigured its relationship to the nation-state and 
the NGO sector and advanced its own interests under the guise of humanitarianism and crisis 
intervention (Biehl, 2006; Ecks, 2010; Lakoff, 2006; Nguyen, 2010); and how shifting regulatory 
terrains enable the proliferation of new categories of local, generic, similar, counterfeit and other 
stratified medications, fostering new categories with competing definitions of quality and value, 
spinning-off their own set of market seductions (Hayden, 2013; Lakoff, 2006; Peterson, 2014). 
Joe Dumit (2012) extends pharmaceuticalization theory most broadly in his ethnography of the 
industry. Interrogating the means by which the pharmaceutical industry has shaped a set of logics 
through which any living being is constituted as inherently at risk, Dumit reveals the roadmap 
through which entire populations could theoretically be enveloped in the pharmaceutical project. 
The novel biopharmaceuticals developed in Cuba, emerging from its socialist healthcare 
system, are expanding into continually changing political and economic terrains. While the 
nature of the island’s economy has changed significantly, with an ever-expanding private sector, 
increasing public-private partnerships and collaborations with foreign corporations, there is a 
fundamental difference in the history of the establishment of the research and development 
pipeline: it was not primarily designed to be profitable. As Dumit (2012) reminds us, 
multinational pharmaceutical corporations make no secret about what interests they advance: 
their shareholders. Turning Dumit’s conclusions around, we might ask: if Lipitor exists within 
the pharmaceutical expansion model as part of a system enfolding all persons into the gradations 
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of risk to be managed for profit, what might be the role of Cimavax, the Cuban cancer vaccine, 
designed in a system not significantly organized around profit? My enduring fascination with 
pharmaceuticals and the political, relational and chemical connections they can both build and 
destroy was the catalyst propelling my research. Yet, as innovative pharmaceuticals developed in 
a low resource country, Cuban cancer vaccines must also be considered within that body of 
scholarship aimed at science in the Global South. 
 
Scientific Innovation from the South 
My work is also situated in what has at times been called STS of the Global South, post-
colonial STS or STS from the periphery. A growing body of scholarship examines science and 
biomedicine in regions now most frequently called the Global South, including Latin America 
and the Caribbean and Africa (e.g. Medina, da Costa Marques and Holmes, 2014; Palmarola and 
Alonso, 2014; Pollack, 2019).  In Beyond Imported Medicine, the editors of this volume assert: 
there is a widely held perception that science and technology necessarily come to Latin 
America from elsewhere, a notion fostered by ideas of modernization and development 
that originated outside Latin America and encouraged the transfer and diffusion of 
machinery and knowledge from more industrialized nations to less industrialized ones 
(Basalla 1967; Rostow 1991, cf Medina, da costa Marques, and Holmes 2014). Such ideas 
held considerable sway, shaped understandings of how science and technology should 
move, and guided decades of development polices. They have also propagated value 
systems that relegate Latin American nations to secondary or peripheral status…Framing 
science and technology as forms of imported magic overlooks processes of reinvention, 
adaptation, and use. It may also suggest that innovations such as a scientific way of thinking 
or an industrial technology should be adopted uniformly, rapidly, and unmediated, without 
considering the potentially negative or mixed effects of epistemic and technological 
change. All the essays in this volume contest this simplistic notion of unidirectional 
movement of science and technology from the supposed center in the North to the assumed 
periphery in the South (Medina, da Costa Marques and Holmes, 2014: 2).  
 
STS and anthropology scholars of the Global South have examined: how traditional 
knowledge is taken up by market-driven biomedical research regimes (e.g. Hayden, 2000; Kloos, 
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2016); how the architecture of western, biomedical clinical trials adapts to (or was designed for) 
an ‘other’ constituted through race and poverty as an ‘available’ subject (e.g. Petryna, 2006; 
Sunder-Rajan, 2006; Whitmarsh, 2008); the legacy of colonialism on technoscientific endeavors 
(e.g. Anderson, 2002; Anderson and Adams, 2007); and the specific ways in which scientifically 
marginalized regions such as Latin America have developed inclusive scientific environments to 
facilitate research and knowledge production in resource-poor regions (Fressoli, Dias, & 
Thomas, 2014). Da Costa Marques (2014) explores what he calls “the ontological politics” of 
scientific knowledge production in Brazil, in which the “reality,” of the “periphery” in rural 
Brazil is in conflict with that of the scientific “centers.” The majority of anthropological 
literature described here analyzes a scientific center comprised of Europe, the US, Japan, and 
possibly China, with postcolonial countries as the site of that center’s expansion.   
Cuba both is and is not part of the Global South. The term Global South, invented by the 
World Bank, is problematic at best. It emerged as a substitution for the earlier “three worlds” 
schema used during the Cold War.  Indeed, in relation to this schema, Cuba’s history as a 
socialist state, with health indicators on par with the Global North, was technically part of the so-
called “Second World.” Cuba’s pharmaceutical research environment and the treatments it has 
spawned remain relatively understudied within the anthropological and STS literature. To date, 
only Reid-Henry’s geography research (2010) has focused on Cuba as a biotechnology 
center, examining its history as shaped by place and what happens when different forms of 
reason collide. STS and medical anthropology scholars of the Global South have explored other 
concerns, and, to date, few have focused on technoscientific innovation originating by scientists 
from, and working within, the so-called periphery.   
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Anne Pollack (2019) offers a noteworthy exception in her examination of a South African 
pharmaceutical start-up company.  Her analysis of the creation and, ultimately, demise of 
iThemba, a company attempting a novel environmentally friendly or “green” mode of 
production, is one of the only studies of innovation outside of the Global North, as phenomena 
distinct from reverse engineering or re-purposing. Combining her ethnography of iThemba with 
analysis of philanthropic documents from the Gates’ Foundation, Pollock finds broad evidence 
for the assumptions of unidirectionality of global knowledge flows. My research overlaps with 
Reid-Henry’s in terms of content but shares a kinship with Pollock in terms of examining 
innovation from the Global South. My ethnographic examination of the political, social and 
economic context of Cuban biotech sector shows specific ways in which both the counter-current 
technology transfer behind the RPCI-CIM collaboration and the expanding global footprint of its 
innovative pharmaceuticals are shaped by a continually adapting form of socialism.    
 
Temporally Ambiguous Socialisms  
 In the chapters that follow, my examination of Cuba as an emerging center of 
pharmaceutical innovation is centered within the terrain of post-socialist anthropology. The 
medical anthropological scholarship of post-socialism has explored the ways in which health 
care exposes contradictions between past structures and practices of socialism and reforms 
marked as neoliberal or market-oriented in women’s health, addiction and mental health in the 
former Soviet Union (Rivkin-Fisch, 2005; Matza, 2009; Zigon, 2011; Raikhel, 2010). Priscilla 
Song (2011) examines the enterprising and sometimes ethically dubious tactics of the stem cell 
medical tourist industry under “socialism with Chinese characteristics.” Other than Brotherton’s 
work, described above, very little scholarship has considered Cuban healthcare and biomedical 
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research system within the larger body of post-socialist anthropology. As Brotherton’s work 
reveals, Cuba’s socialism continues unfolding and adapting, albeit now alongside a parallel 
private sector.  
 In his examination of the last Soviet generation, anthropologist Alexei Yurchak (2006) 
demonstrated how the collapse of the Soviet Union was paradoxically characterized as both 
predictable and surprising. Yurchak traces changes in which authoritative discourse began to 
loosen from its constative meaning (Austin, 1962), creating enough of an opening in the control 
of the socialist state that Gorbachev’s perestroika was simply the final straw pushing the system 
toward collapse. The concept of the un/surprising paradox as developed by Yurchak in the 
context of the Soviet socialist collapse affords a useful perspective in examining the relationship 
between the discourse around Cuban biopharmaceuticals and the context of Cuba's late hybrid 
socialism. 
 In a field already self-identified by the pre-determined temporal moniker, “post,” many 
scholars of post-socialism have considered the intersection of time with space: how lingering 
socialist structures continue to shape the conditions of living and working long after countries 
have been declared as “post” socialist in Eastern Europe (Verdery, 1996; Collier, 2011); how 
notions of subjectivity respond to ideas about modernity and consumption in China (Rofel, 1999; 
Farquar, 2002); and how time is conditionally transformed as the past becomes reconstructed 
through nostalgia (Verdery, 1996; Nadkarny and Schevechenko, 2014). This scholarship of post-
socialism is largely self-defined as post event.  While scholars of Cuba have used similar 
temporal prefixes including post-Soviet, post-socialist or late socialist, instead I follow Felix 
Ringel (2016) in proposing an alternate lens on socialism. Rather than assume or attribute a 
temporal characteristic to my object of study, I focus on the emerging present, analyzing and 
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contextualizing what is actually occurring in light of the specific conditions of history including 
socialism and colonialism, among others. As anthropologists of Cuba like Paul Ryer (2018), 
Stout (2014), Humphreys (2019) and Garth (2020) have pointed out in their recent 
ethnographies, Cuba, still governed by the Communist Party, is not exactly post-socialist. As I 
alluded to in the opening section of this introduction, part of examining the global expansion of a 
cancer vaccine developed under Cuban socialism entails a reconsideration of the role of 
socialism in a supposedly post-socialist world. 
 
Five Years of Continuity and Change 
 Fieldwork happens at particular moments in history which can leave indelible marks on 
the structure of a study, the type of questions asked, the results, analysis and how the work is 
received. My project was conducted over a five-year period marked by five major events which 
both inspired and shaped my research, particularly as a US-based anthropologist. In 
chronological order (as opposed to level of importance or impact), the first event was the 2014 
Raul Castro-Barak Obama rapprochement, a seismic shift in geopolitical relations with attendant 
policy changes on both sides, stopping short of making the real change needed on the island: the 
lifting of the US embargo of Cuba. The second event was the November 2016 election of Donald 
Trump, with the near-immediate reversal of many elements of the rapprochement beginning in 
early 2017, followed by an expanding set of restrictions. The third event was the death of Fidel 
Castro, also in November 2016. The fourth event was the loss of political and economic support 
from the Bolivarian governments of Venezuela and Brazil, beginning in 2017. In late 2017, the 
fifth event was the so-called “acoustic sabotage” or “sonic attacks,” where a number of US 
Embassy workers developed a series of vague neurological symptoms, leading to the closure of 
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the newly re-established embassy and withdrawal of staff, generating significant obstacles for 
Cubans seeking to travel to the US.  All of these shifts directly impacted my fieldwork, and this 
dissertation, in some capacity.    
 
First Event: Rapprochement 
 The first major shift, rapprochement, was seen as generating massive economic potential 
across a spectrum of interests on both sides of the Florida Straits. Practically speaking, it led to a 
major boost in US-Cuba collaborative efforts across a host of areas: business, film and television, 
tourism and science.  It was an auspicious year to begin a research project in Cuba. Indeed, the 
overall climate of optimism colored the experience of my first summer of fieldwork in 2015 in 
ways which would later highlight my own naïveté at the long history of tension and climate of 
surveillance perpetuated by both Cuba and the US in this still quite active iteration of what might 
otherwise seem a relic of the Cold War.  
 While I identify myself as a political progressive and make my home in the historic seat 
of both counterculture and radical politics, San Francisco, I had not previously identified myself 
among those in my social circles who you might describe as Cuba-philes.  From friends and 
colleagues who came of age in the 1970s and proudly participated in the venceremos brigades8 
or participated in Global Exchange tours, to the younger generations traveling equally out of 
curiosity and vague political allegiance, I mentally filed away stories and interests.  My exposure 
to ideas about Cuban biomedicine increased as I continued my work in an academic medical 
 
8 The venceremos brigades were founded in 1969 by the US organization Students for a 
Democratic Society to show solidarity with Cuba. The still active organization initially sent 
young, ideologically motivated Americans to cut sugar cane as part of Castro’s (ultimately 
failed) effort to rescue the Cuban economy through the show of extraordinary effort of workers 
to harvest ten million tons of sugar. 
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center, where numerous colleagues took structured tours of the Cuban health system. In 2014, 
then, like many Americans plugged into the New York Times and NPR and similar mainstream 
liberal media outlets, I was captivated by the outpouring of stories related to the rapprochement.  
I decided to shift away from an earlier project I’d conceived following work I’d done previously 
in Ecuador and began in the summer following my first year of the doctoral program to pursue a 
project in Cuba focused on mental health screening.   
As the escalating news cycle on Cuban biotech reached its peak in the spring of 2015 
(Googletrends, 2015), I abandoned interviews on depression, turning toward this exciting new 
development, scouring the internet for any and all media related to Cuban biotech in general and 
Cimavax in particular. In May 2015, US media coverage of Cuba reached its apogee with 100 
articles that month (Schoenfeld, 2016), most focused on the “therapeutic vaccine,” Cimavax.  I 
began to consider whether and how, as a medical anthropologist-in-training but also as a 
healthcare provider with experience in clinical trials, I could research these developments on the 
ground as they were unfolding.    
In 2015, the Roswell Park Cancer Research Institute (RPCI), availing themselves of 
newly negotiated openings in Cuba-US relations, moved forward a relationship which had begun 
originally by chance a few years earlier. According to Dr. Kelvin Lee, lead immuno-oncology 
researcher at RPCI, a connection between RPCI and the Cuban Center for Molecular 
Immunology (CIM) had begun to develop several years in advance of the political changes 
instituted by Raul Castro and Barack Obama in 2014.  Like many stories I was to hear about the 
growth and development of science in Cuba, the relationship began with a chance meeting.  Dr. 
Lee recounted the tale of a Cuban scientist who was visiting nearby in 2011 and looking for an 
opportunity to share her research with colleagues.  Per Dr. Lee, she first reached out to someone 
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at an East Coast university with a strong immunology research program, but, when this failed to 
materialize, she moved on to RPCI.    
 I returned to Cuba in the summer of 2016, new project in hand, very preliminarily 
formed.  I wanted to understand the context of the seeming and much touted contradiction 
between the cultural and historic importance of tobacco in Cuba with the advanced medical care 
and biopharmaceutical innovation for cancer treatment, in particular, the lung cancer vaccine, 
Cimavax. I began interviewing smokers and nonsmokers alike, including people working in 
tobacco farming, cigar factories and illicit cigar sales.  In addition to my fieldwork in Cuba, I had 
the opportunity to connect with an applied medical anthropologist at Roswell Park Cancer 
Institute (RPCI) in Buffalo, New York, the site of the US-based clinical trial of Cimavax, who 
introduced me to the two leading researchers involved in the Cuba collaboration, Drs. Kelvin Lee 
and Mary Reid.9  
 
Second Event: Trump Election 
 My first conversation with Drs. Lee and Reid took place on November 9th, 2016, the 
morning after the presidential election of Donald Trump. An excruciating silence permeated the 
first minute of our conference call, until Dr. Reid broke the ice with a sigh which served to 
communicate enough for the three of us to reach consensus that we were all on the same page 
about our feelings regarding the outcome of this election. This conversation marked, for me, the 
beginning of an affective shift around the US-Cuban science collaboration: a pivot from the first 
year of overwhelming optimism and promise to a more careful and guarded approach. RPCI 
 
9 Drs. Lee and Reid agreed to be named, rather than given pseudonyms. Given the publicity 
around their involvement in the RPCI-CIM collaboration, anonymity was not feasible.   
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continued the collaboration and regular meetings with the CIM scientists, with certain changes, 
such as meeting across the border from Buffalo, NY, in Canada, where Cubans could travel with 
greater ease.  Of greater significance, however, were the everyday impacts felt through the 
rolling policy changes diminishing both tourist dollars and remittances.   
 
Third Event: Fidel Dies 
 The death of Fidel Castro was simultaneously momentous and unremarkable.  Having left 
the office of the president eleven years prior, his death created no crisis of leadership or 
uncertainty in direction for the country in which the Communist Party still maintained near 
complete control of the government. Similarly, in 2018, when Raul Castro stepped down to make 
way for new elections, despite significant international media presence and attention describing 
this as a historic shift, my experience being on the ground in Havana during the elections was 
that most people, in general, did not see this change as especially momentous. The newly elected 
parliament selected the favored candidate, Diaz-Canel, a party insider groomed for several years, 
to the office of president while Raul Castro occupied a position nearly equal in power and 
influence as head of the Communist Party. And yet, symbolically, Fidel’s death marked a 
definitive rupture with the continuity of “El Triunfo” (of the Revolution).  
 
Fourth Event: Venezuelan Economic Collapse and Brazil Elects a Right-Wing President 
 The increasingly dire economic conditions in Venezuela led to a scaling down of the 
Cuban physician presence as well as an end to the oil for physician exchange (Brotherton, 2013).  
This shift had massive economic consequences for Cuba, resulting in significant fuel shortages 
which reverberated throughout other economic sectors beyond transportation, exacerbating 
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already vulnerable stores of food and other products of modern living like toilet paper or pencils. 
A parallel pivot in relations and subsequent economic downturn occurred for vastly different 
reasons between Cuba and Brazil, with the election of right-wing candidate Jair Bolsanaro as 
president. One of his first acts was the expulsion of Cuban doctors in Brazil. The expulsion, 
along with reductions in other collaborations, similarly exacerbated already difficult 
circumstances for average Cubans, as well as undercutting the health system for poor indigenous 
communities in Brazil who suddenly had no access to medical care.  
 
Fifth Event: Acoustic Sabotage 
 In the Fall of 2017, reports began to emerge of a series of US diplomats experiencing 
bizarre neurologic symptoms, and the reporting on these diplomats began taking the shape of a 
phenomenon. The symptoms were vague, including reports of hearing buzzing or humming, 
headaches, nausea and fatigue. The Trump administration characterized these symptoms as 
‘sonic attacks’ or ‘acoustic sabotage’ and reacted by withdrawing the majority of the staff at the 
US embassy and asking Cuba to reduce its embassy in Washington reciprocally, effectively 
shutting both down.  To date, numerous explanations have surfaced across the political spectrum, 
each seeking to make sense of what the US diplomats experienced through a particular lens.  
Some of these hypothetical explanations were inspired by the history of the many wild but true 
accounts of espionage and assassination attempts, mostly directed at Cuba from the US in the 
1960s. Among these theories circulated about the so-called ‘sonic attacks’ were: the Miami- 
Cuban theory, where conservative Cuban Americans, a lobby concentrated in Miami, would be 
trying to sabotage the slight improvements in relations heralded by the rapprochement; the deep 
state theory, on either the US or Cuban side, which imagined a shadowy network of government 
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actors intent on closing the embassies for their own purposes; Russian interference theory, where 
Putin undermines any progress in US-Cuban negotiations in the service of his/Russian interest; a 
virus; a fungus; a hysteria.  The closure of the US embassy in Cuba has had a massive negative 
impact, most notably, on average Cuban citizens who need to travel to the US. The process now 
entails expensive journeys to third countries, blocking thousands of would-be travelers due to the 
untenable costs of such a journey.   
 The inauguration of the longest of my fieldwork trips to Cuba coinciding with the so-
called sonic attack/acoustic sabotage episode cast yet another layer of suspicion over a project 
which was already subject to significant scrutiny.  A project which, according to a few US-based 
scholars of Cuba, would be difficult and perhaps, as expressed in the earlier vignette by the 
official at the Cuban Ministry of Health, “was not necessary.” Finding myself thrust into and 
moving between multiple modes of surveillance engendered a greater sensitivity to the 
possibilities enabled not only around but also within the zone of surveillance.  Not only do Cold 
War regimes of surveillance persist, or recur in new forms, but mutual recognition of 
surveillance generates novel relationships and subjectivities.  Suspicion of surveillance remains 
ubiquitously visible, through the embodied responses of whispering, mouthing words, pointing, 
writing and hand-gestures (Mauss, 1934; Bourdieu, 1984).  My positionality as an unaffiliated 
American researcher embarking on sensitive research at a time of escalating tensions in relations 
between Cuba and the US may reveal as much about my own ambivalence and naïveté as it does 
about the situation on the ground. Nevertheless, the conditions of surveillance that I and my 
family experienced, and those of some of my Cuban interlocutors, influenced the direction and 
scope of the research project which ultimately took shape. I continue to wrestle with my 
ambivalence about surveillance, albeit, and not unimportantly, from the privileged position of 
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one not (yet?) facing any consequences of said surveillance. Furthermore, my experience of 
security, particularly as a woman (often roaming the streets of Havana, unbothered, late at night 
after fieldwork), and a foreign woman with some (relative) money at that, was the direct result of 
a surveillance society established during the height of the Cold War under Cuban socialism.  
 These five events shaped the context, conditions, access and experience of my fieldwork. 
Ultimately, they structured the form and content of this dissertation. A recurrent refrain I heard 
from interlocutors and friends in Cuba throughout my fieldwork was a tension between 
perceived change and perceived sameness, or, perhaps, stuck-ness. The common narrative of 
Cuba on the cusp of change has shaped a sizeable portion of writing about Cuba by non-Cubans 
since the collapse of the Soviet Union. Yet, these externally produced narratives of change were 
countered by the narratives of sameness from both many Cubans I spoke with as well as official 
state messaging. That is, friends and interlocutors, when asked about their experience of the so-
called changes (things like internet connectivity or party leadership change), were more likely to 
say something like, “nada cambia…todo lo mismo…(nothing changes, everything stays the 
same).”  State billboards and signs offered another valence of sameness. The signs declaring the 
persistence of the Revolution, the counting of the years since 1959, the messaging about 
continuity following the election of Diaz-Canel peppering the landscape throughout the country 
offered official reassurance that, while some things might be changing, political change, at least, 
was not afoot. The striking story I found through my research bears this tension of continuity and 
change, shaped by specific events over these five years. Accepting the tension of dual (or 
dueling) realities like this turned out to be key to understanding how and why Cuban science has 
been as successful as it has been to date.  
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Seeing and Unseeing 
 After returning from the field, as I began my first efforts to turn my data into a 
dissertation, I struggled with how to think and write about this sense of the dual/dueling realities. 
As I read and experimented with different approaches, I recalled a science fiction novel I read 
while in Cuba, where the principle conceptual feature of the novel turned out to be more 
interesting than the plot of the book.   
In The City in the City, China Mieville (2009) creates a fictional Eastern European region 
where a long history of ethnic conflict resulted in a political solution in which two cities occupy 
the exact same geographic territory, and each one is, by law, invisible to the other. The citizens of 
Besźel live and work next to the citizens of Ul Qoma but they cannot see one another, on penalty 
of disappearance by a pervasive cadre of surveilling secret police.  That is, they are not literally 
invisible to each other, but they are juridically invisible. The term Mieville uses to describe what 
is demanded of each respected nationality is “unseeing.”  That is, citizens of each city are 
mandated to “unsee” whatever or whomever might cross their path or enter their field of vision, 
lest they be abducted and disappeared by the omnipresent surveilling secret international police 
designed to enforce the juridical arrangement. Yet, in certain zones within these two overlapping 
but mutually juridically invisible cities, zones of mutual apprehension exist. Mieville refers to 
the type of perception in these zones as crosshatching. Crosshatching, as developed by Mieville, 
is permissible within certain circumscribed zones of the city, where the two realities are legally 
“seeable” simultaneously, even as each one seems to simultaneously negate the other. 
Increasingly, the protagonists of the book find themselves crosshatching, seeing the previously 
unseeable, apprehending two realities simultaneously.  
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Mieville’s work in The City in the City realistically depicts an imaginary mode of seeing 
in which two co-existing realities are apprehended, where both are simultaneously seen, in all 
their complexity.  Crosshatching, as depicted by Mieville, occupies the realm of the everyday 
and demands the conceptual task of holding two contrasting ideas together without synthesizing 
or erasing one.  Mieville is also well-known within Science Fiction circles as an ardent socialist. 
He has edited a volume entitled Red Planets (2009), as well as written a novelized history of the 
Russian Revolution called October (2017). I have repurposed Mieville’s concept of 
crosshatching as an analytic device in several places in this dissertation. Crosshatching allows us 
to see how Cuba is like the rest of the Caribbean and not; it is a poor country with rich country 
health problems and solutions; it prides itself as much on its tobacco production as it does on its 
cancer treatments; it is socialist and capitalist. In my experience exploring 21st century Cuban 
biotechnology, crosshatching expanded my field of vision and comprehension. Moreover, it 
reflects the perspectives I’ve encountered across the social and political spectrum during my 
fieldwork in Cuba. 
 
 
Chapter Summaries  
The following chapters offer an ethnographic engagement with Cuban biopharmaceutical 
science, in a broad and fairly unorthodox manner. Chapter One takes vaccine as concept, 
material and medium through which to examine Cimavax. I trace the particular history of 
vaccine development and use in Cuba, drawing on primary and secondary sources as well as 
interviews with researchers in vaccine development, regulation and marketing. This chapter 
shows how success in Cuban biotech, including the counter-current technology transfer 
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underway between CIM and RPCI, emerges from both the materiality of vaccines as well as the 
conceptual architecture of immune modulation and population health. 
Chapter Two elaborates an idea promoted by CIM leadership and disseminated 
throughout the biomedical sector in Cuba called cronicidad. Cronicidad, in the context of Cuban 
oncology, considers how metastatic, terminal cancer can become chronic, through therapeutic 
vaccines like Cimavax.  I push the concept of cronididad further, expanding it through interviews 
with a range of interlocutors broadly connected with the Cimavax project, including tobacco 
factory workers and drug marketers. I approach the landscape of Cimavax through the lens of 
chronic. Chronic is at once an object, a metric and a relation. I introduce and develop a new term, 
biocompanion, through which to consider how cronicidad reimagines the relationship between 
humans, tumors and tobacco.   
 Chapter Three considers three vignettes engaging with science and technology outside of 
the Cuban biotech sector.  This chapter introduces Cuban Science Fiction author Yoss: a trained 
biologist, iconoclastic public intellectual in Cuba and a well-versed writer and social theorist. 
Drawing on both interviews with Yoss and analysis of his writings, I bring the theoretical 
insights from Science Fiction theory to the specific, local situation in Cuba.  
Chapter Four considers what forms of value are produced by the global circulation of 
Cimavax. Drawing on interviews with Cuban drug regulators and state pharmaceutical 
marketers, I examine how innovative pharmaceuticals developed in Cuba (innovadoras), such as 
Cimavax, develop value and expand globally in new ways, following a path initially carved out 
by medical solidarity. I consider how this new model for expansion differs from existing 
anthropological analyses of globalizing pharmaceuticals focused on profit maximization (Dumit 
2012, 2018; Peterson, 2014; Rajan, 2017).   
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 The endeavor to carve out a terrain in which to intervene, the public to whom I address 
this work (Warner, 2002), or maybe even a hole in which to be pigeoned, is particularly fraught 
for scholars of but not from Cuba, where works are received as politicized, at least in the US, to a 
greater degree than other regional scholarship. In contextualizing the moment of my fieldwork, 
offering background on Cuban biomedical science, examining the ways in which this history 
circulates as narrative and situating my scholarship in the relevant literature, this introduction 
prepares the reader for the chapters that follow. While the subsequent chapters could be read on 
their own by a reader with some prior background in Cuban studies, together they depict and 
analyze the situation of socialist Cuban bioscience and its global pharmaceutical expansion.  
Through the remainder of these chapters, I offer a window into how these unique cancer 
treatments emerged; their relationship to socialism; how their circulation and expansion 
reimagines the conditions for scientific innovation and global health; and the relations between 
humans, tumors and tobacco.  
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Chapter One: Vaccine Therapy 
Vaccines are pharmaceuticals that don’t cost much…the help they bring, especially to children. 
Really the institute has a social mission. I think it’s really significant that our institute keeps 
working on this line, each time with a better selection of vaccine candidates that can resolve the 
biggest problems in our country, and worldwide, in terms of vaccination (Mykel, Cuban vaccine 
researcher 6/28/17).   
  As both a researcher, as well as an elected official in the state socialist congress for 
vaccines in Cuba, Mykel succinctly captures something important about the medium of vaccines 
to the story of Cuban biotech: they are pragmatic, social and they can carry a moral charge.  
Vaccines are generally a low-cost technology with a broad social impact. For Cuban bioscience, 
vaccines afforded a productive avenue to grow and develop expertise. This chapter examines the 
connection between prophylactic or usual vaccines, and the therapeutic vaccines at the heart of 
the Cuban biopharmaceutical industry. I explore vaccines as uniquely entangled political, 
semiotic and material forms. Thinking through vaccines, I analyze Cimavax as a technoscientific 
and political expression of state-sponsored socialist research, pharmaceutical development and 
disease management. I will argue that the therapeutic vaccine as form renders visible the 
possibilities of a biotechnical adaptation of socialism in 21st century Cuba.    
As I will show in the pages to follow, novel Cuban drugs emerge from a line of research 
related to both the broader global field of immunology and a technical expertise developed in 
vaccine production since the 1990s. The therapeutic vaccines at the heart of this dissertation, in 
the form developed in Cuba, afford special insight into the conditions of socialist science and 
pharmaceutical innovation. This insight comes through examining the zone between public 
health, socialist pharmaceuticals and the immune system.  
Interrogating the Cuban biopharmaceutical sector through the lens of vaccines affords a 
multidimensional view of the conditions, and stakes, of its expansion. It is not an exercise in 
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demonstrating an origin story or explanation. As sociologists of cancer Keating and Cambrosio 
have pointed out,  
Accounts of innovation should similarly avoid privileging, a priori, single factors or 
structures, whether social, technical, cultural or economic. As in our previous work on 
biomedical platforms (Keating & Cambrosio, 2003), we consider technological 
determinism—the explanation of history through technical or scientific breakthroughs—
and sociological reductionism—positing social or political or cultural factors as the 
ultimate explanation of medical and techno-scientific developments—as mirror images of 
the same mistake. In short, we look for singularities rather than regularities, and we do so 
by recognizing that “there are no fundamental phenomena. There are only reciprocal 
relations, and perpetual gaps between them” (Foucault, 1994b: 277, cf Keating and 
Cambrosio, 2011:11-12). 
 
Cimavax is a treatment for advanced lung cancer. It neither prevents nor cures cancer. 
Instead, it allows people to live longer with their tumors. It could be seen as either treatment 
failure or success, depending on the criteria of judgment. This treatment is seen as having 
extraordinary political and medical potential, and, as I will show, this potential lies in its form as 
vaccine. As I will show in this chapter, the vaccine form, a biomedical regime built on the 
paradigm of population health, afforded an ideal concept and material through which to 
showcase Cuban socialist biopharmaceutical innovation.  
In this chapter, I draw on ethnographic material primarily from interviews with and 
observations of vaccine researchers at conferences and in social gatherings, but also with several 
others connected, in different ways, to Cuban expertise in vaccine therapies. This data is 
contextualized in relation to the relevant history and anthropology of vaccines in general, and 
specifically, their capacities as instruments uniting science and politics. I connect this history to 
the current context of vaccines in Cuba, from prophylactic vaccines to the therapeutic vaccine of 
interest to this project: Cimavax. I relate the vaccine expertise and affinity developed in Cuban 
socialist bioscience to the relevant histories of socialist science from the Soviet Union. Finally, I 
situate therapeutic vaccines, as a technology of cancer immunotherapy, within the domain of 
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immunological thinking, as both biomedical discipline and political philosophy.  What I will 
examine and argue in this chapter is how and why Cuban socialist science took the form of these 
therapeutic vaccines, why they emerge as a unique expression of Cuban socialist biotechnology 
and how they relate to anthropological considerations of public health and pharmaceutical 
expansion more broadly. My claim is that Cuban cancer vaccines emerged and are expanding 
through a therapeutic charismatic technopolitics achieved through socialism. 
 
Vaccine Thinking 
 Vaccines do a lot of work. Conceptually, they can convey protection. Semiotically, they 
can signal technoscientific knowledge, hygiene, medical authority. Vaccines are generally used 
for prophylaxis, but they can also be therapeutic. They are a tool of population or public health 
management, politics, privilege, and even, coercion. Vaccines are and are not like other 
pharmaceuticals. Like pharmaceuticals generally, they are complex molecules, biomedical 
technologies introduced into the body to elicit specific reactions for a medical, as opposed to 
recreational or ritualistic, purpose.  Yet, vaccines are specific types of treatments. They mimic, 
rather than kill, the disease. Their activity acts as a form of insurance against a potential (or in 
the case of a tumor, a known) hazard, characterized by a temporal delay. They are not given to 
exact an immediate response. Instead, vaccination is a type of investment and, like all 
investments, has no guaranteed return. Yet, this vaccine form of investment exerts large-scale 
changes on populations, in economic, political, social and immunological terms.  
The promise of a cancer vaccine has long captured public imagination, emerging briefly 
in the late 19th century (Hall, 1997), only to quickly die out, then rising from the ashes again in 
the 1990s, then again dying out.  The most well-known and broadly used vaccines that could be 
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considered cancer vaccines are the prophylactic Hepatitis B and the Human Papilloma Virus 
vaccines, offering protection against cancer associated with viral infections: hepatocellular (liver) 
carcinoma and cervical cancer, respectively. One of the earliest cancer vaccine treatments was 
the repurposing of the Bacillus Calmette Guérin or BCG vaccine, a vaccine originally developed 
to prevent tuberculosis. BCG, a live but weakened bacterial vaccine, is infused into the bladder, 
introducing enough bacteria into to stimulate an immune response which can be active against 
malignant cells (cancer.org, 2020).    
The initial progress in the use of cancer vaccination was slow and over a hundred years’ 
work in the laboratory yielded little success in actual cancer treatment. Thus, the early 
history of cancer vaccines is a history of failure. Yet the idea of creating vaccines that teach 
the body to prevent or destroy tumors by the activation of the immune system is so elegant 
and so fundamental that generations of scientists have continued to endeavor in pursuit of 
this goal, albeit without success (Mohammed et al, 2016: para 8). 
 
Aside from Cimavax and Vaxira, the therapeutic vaccines developed by Cuba’s Center for 
Molecular Immunology, or CIM, the only other example of a therapeutic cancer vaccine in use is 
Provenge, or its generic, Sipuleucel-T, used for prostate cancer (Anassi and Ndefo, 2011; 
Vijayaraghavan, Binaya, 2017), discovered initially by Stanford scientists, then purchased and 
developed by Dendreon Corporation, a California based biotech company (Dendreon was 
purchased by Valeant, which was then purchased by the Chinese company Sanpower Group).  
Therapeutic cancer vaccines are among the most commercially viable Cuban 
pharmaceutical therapies developed to date. The pioneering work in infectious disease in 
colonial-era Cuba, combined with early success in immunotherapies and vaccine development, 
afforded the fertile terrain for the innovative biopharmaceutical sector Cuba boasts today. Yet, 
part of the story of the success hinges on the country’s relative scientific isolation in the first 
decade of post-Soviet collapse, when immunotherapies and cancer vaccines fell out of favor in 
the cancer research sector. Cuban biomedical innovation hinges on the vaccine as political and 
   48 
moral entity: as a preeminently communal medical technology, the vaccine captures the socialist 
shape of biotech on the island, devoted to continuous mass training of scientists and doctors, 
where public health, research and development are all part of the closed, state-run system and 
funding is sheltered from whims of the market.  
 
Vaccine as History: Political Prophylaxis  
 
 By some measures, vaccines, in their fourth century of use, are one of the earliest and 
most enduring technologies of population health.  Observations about immunity to smallpox date 
back to the 429 BC, when Thucydides observed that smallpox survivors were immune for life.   
The technique of variolation, or inoculation of a healthy person with the material of the smallpox 
lesion of an infected person, began in China, possibly as early as the 10th century, with use more 
widespread in both China and India in the 14th to 17th centuries (Mohammed, Bakshi, Chaudri, 
Akhter & Akhtar, M., 2016).10 Over centuries, a range of techniques for variolation developed 
across East and South Asia, the Middle East and into Europe. Edward Jenner, in his discovery 
that cowpox immunity conferred protection against smallpox, coined the term vaccine, forever 
linking the cow or vacca to this technology of public health. Building on the centuries of work 
on variolation, Jenner’s intervention in the late 18th century paved the way for the development 
of vaccines as they are generally known today. 
 
10 Margolin (1990) describes the complex history of smallpox vaccination in India in the context 
of the violence of colonialism, a project met with local resistance. She describes the forced 
replacement of smallpox variolation with vaccination in India as an example of knowledge 
erasure. In the case of variolation, this medical technique was accompanied by the worship of the 
goddess of smallpox. Thus, forcible erasure of the practice resulted in an entwined loss of 
scientific and cultural heritage.  
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Historian of vaccines Stanley Plotkin (2014) locates the birth of modern vaccine 
development in the mid-20th century, when scientists began to distinguish between antibody-
mediated, as opposed to lymphocyte-mediated, protection. Technological advances in vaccine 
development moved from rendering infective agents less virulent through attenuation and 
inactivation, and development of approaches which mimicked the outer coating of infective 
agents, rather than the agents themselves. A critical moment in vaccine technology development 
emerged in the 1970s with the development of genetic engineering. Originating with the 
production of the sequence for the hepatitis B surface antigen in plasmid yeast, this technology 
changed the course of vaccine development and the nature of mass vaccination in two important 
ways: 1) it enabled a significant scaling up of vaccine production, and 2) it heralded the era of 
patented technologies concentrated in the hands of a few large multi-nationals, undermining, to 
some extent, a system of national vaccine development across many parts of the globe.  
 An edited volume by Holmerg, Blume and Greenough (2017) analyzes the relationship 
between vaccines and the state. Specifically, these authors explore how vaccines have served, at 
different times and places, to both strengthen and weaken social cohesion. Their argument rests 
on two claims: 1) that the capacity of a government to manufacture its own vaccines sustains 
national sovereignty and 2) that the success or failure of national vaccine manufacturing impacts 
the sense of community and citizenship. Put another way, vaccines can act as a powerful force 
toward national identity.  They argue, for example, that early experience with smallpox 
vaccination campaigns in newly formed German states conveyed the sense of the state caring for 
its citizens.  From the early 19th century up through the 1970s, vaccine campaigns figured 
prominently as a tool of nation building. One contributor to the volume, Dora Vargha, describes 
the role of vaccination and the communist state in Eastern Europe through the lens of polio 
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vaccination. She argues, “[p]olio, primarily a disease of children, raised the stakes for the state’s 
provider role in public health… the ideological stance in public health objectives which framed 
themes of health and disease on dialectical materialist ideas, was based on the post war Soviet 
model of public health…preventative and prophylactic interventions against external 
threats…free access to health care for workers. (2017:80).”  
 
“We Persevered and We Managed to Be Successful”  
 Dania, Vladimir and their adolescent daughter AnaPaola are a tight-knit Afro-Cuban 
family living in Havana. Dania and Vladimir, biochemist and pharmacist, respectively, are mid-
career scientists in their late 40s, with twenty-plus years of experience working in the biotech 
sector. Their intertwined careers engage both of them in cutting edge research. They are both 
well-published, but are not top researchers or official spokespeople, not the people quoted in 
newspapers, like Drs. Lage and Crombet Ramos (see Introduction, Chapter Two, Chapter Four). 
The family lives on their state salaries paid in moneda nacional without any connections to the 
hard “convertible” currency (many in Cuba rely on remittances from family off the island or 
contributions from family members working in tourism).11 They have a small house inherited 
from Dania’s father in El Cero, a neighborhood between the aesthetically dilapidated but trendy 
music and art hub of El Vedado and the gritty, worn, urban bustle of Centro Habana.  While state 
rations provide very basic food provisions, they struggle, like many subsisting on state salaries 
alone, in the quest to obtain what anthropologist Garth (2019) calls “a decent meal,” especially 
occasional meat, a major expenditure, but considered by most Cubans I met to be a necessity, 
 
11 The Cuban socialist state still provides basic food through what is called the bolsa or purse. All 
of my interlocutors described this as inadequate to meet their needs. Further, items like laundry 
detergent, soap and deodorant are generally only available with hard “convertible” currency.  
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especially for their daughter. This family of established and budding scientists had much to say 
about the history, and current state, of biopharmaceutical research in Cuba.   
 I first met Dania at a dinner for Cuban cancer vaccine researchers, US and Canadian 
immuno-oncologists, science diplomats and other notables from the Cuban scientific community 
in  2017.  I came at the invitation of Dr. Kelvin Lee, an immuno-oncologist and principle 
investigator of the Cimavax trial in the US. Kelvin graciously walked me around the event and 
introduced me as an anthropologist of science studying the collaboration between CIM and 
RPCI. The introduction sparked great interest amongst the North American oncologists, who 
asked about my research, about medical anthropology in general, then told me what they felt that 
“the public” didn’t understand about their work.12 
 After the first hour of circulating conversations and rum, we sat around a large outdoor 
table for dinner. By chance, I sat next to Dania. Soft-spoken with bright eyes and an easy smile, 
Dania was a good conversationalist, and we covered a wide range of topics, ending with the topic 
of money: specifically, the different environments for research funding between Cuba and the 
US. She wanted me to know that in Cuba, unlike in the US, they never had to worry about grants 
or funding cycles or keeping up with what was trendy to fund. In a country where shortages and 
economic insecurity are a well-known part of everyday life for most people, even the relatively 
well-off and well-connected, this was an example of a notable economic advantage. As the 
immune-oncology researchers from North America talked about the uncertainty inherent in 
 
12 Medical anthropology and science studies seemed an unknown and exotic topic to the North 
American “hard” scientists at the dinner, generating both puzzlement and enthusiasm. The Cuban 
researchers, on the other hand, seemed less perplexed or surprised at my presence. My 
experience in Cuba, as described also in Chapter Three with SF writer Yoss, was that most 
people in Cuba had a far greater working knowledge of cultural anthropology than average 
people in the US.   
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funding cycles, Dania shook her head, pitying them. How can you focus on the science when you 
have to worry about your research being funded?  She expressed gratitude for her own ability to 
carry out her research without focusing on whether or not she would get funding. Her experience 
as a scientist working in socialist Cuba, where the government funds all basic and most clinical 
research, rendered more visible, by contrast, the system in place in North America, where most 
scientists work on grant funding cycles, often needing to peg their work to what is considered 
“fundable” at a particular moment. Her observation highlighted the relative impoverishment and 
precarity of North American scientists relative to the stability of guaranteed state funding she and 
her colleagues enjoyed. The feature of guaranteed state funding for basic research is a hallmark 
of Cuba’s socialist program of science and medicine, a model borrowed from the Soviet Union, 
as we shall see later in this chapter.   
 Several weeks later, Dania and Vladimir and I met for a formal interview. Dania shared 
how she came to her current position, beginning with her work as a biochemist during the 
Special Period. She described the conditions at the time as unusual and “isolated.” In those days, 
she says, the most direct path to working in science was more like an apprenticeship. After 
graduating with a bachelor’s degree, “you went to work in someone’s lab and through that 
process, you might work toward a master’s or doctorate.” Dania graduated from university in 
1993 and went to work for one of the first state biotech companies in Havana’s scientific center, 
the Polo Cientifico. At that time of economic crisis in the wake of the evaporation of Soviet 
subsidies, working in biotech, in Dania’s recounting, was one of the best possible jobs. Her early 
scientific work involved the production of anti-bacterial vaccines. Dania worked in the industry 
for almost fifteen years before beginning her doctoral work on cancer vaccines, a logical 
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extension of the research she was already involved in, receiving her PhD only after many years 
of research.   
 Dania and Vladimir spoke of the challenges they faced in the day to day work in the lab: 
in particular, the challenges in obtaining materials like reagents and equipment featured 
prominently. “Between the young investigators, there’s always a kind of joke they make that is 
real. That one can spend an entire year working on an experimental trial that will either work or 
not, but the same experiment can be done in 15 days in a lab in the exterior.” The punchline of 
his joke was: “With much security you will stay here (Vladimir, July 2017).”  I turned the 
punchline over in my head after reading the transcript, realizing I wasn’t getting the joke.  This 
type of play on words invoking scenes of mild daily suffering, are comic gold in Cuba, 
guaranteed to elicit a big laugh. On further reflection, I speculated it was the double valence of 
security, and the punchline hit, in my mind, with a wry and bittersweet landing. Dania and 
Vladimir explained that over the past decade in Cuba’s scientific/biotech sector, collaborations 
have become the norm, in part, to compensate for the difficulties obtaining materials. Dania 
explains, “98% of these are with European institutions. You look for who has what you are trying 
to do…The equipment you lack, etc… to do a certain line of research, where can you go to work 
on that?”   
 Dania and Vladimir talked about the experience of working on anti-bacterial vaccines 
early in their careers, and Dania’s eventual move into cancer vaccines.  Dania mused,  
Perhaps it’s something a little particular about Cuba…Maybe it’s something 
good, that we got out of our isolation or fog…Because in science in general 
there was a boom in vaccines in cancer. The idea was, I don’t know, maybe 
twenty years back. But [then] the world abandoned it because they failed, 
etc…Here, I don’t know why…There had been a tremendous experience in 
vaccines in general, in the Center, in a large part of the country…It was part 
of the community of investigators, they were used to vaccines, although they 
were bacterial vaccines. And perhaps also they weren’t obligated to compete 
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and put themselves in the popular current…[In countries] where they give 
financing for new projects, there are authorities which evaluate the project, 
they compare it with the general research, with the fashion. But we don’t have 
this, so perhaps the investigators [here] that were in front of these [cancer 
vaccine] projects could maintain the idea, because they didn’t have to defend 
it against the state of the art, the fashion, as we say…Eventually they were 
successful. They said, we persevered, and we managed to be successful 
(Dania, 7/15/17).  
 
 
 Dania points to a moment where Cuba continued along a line of inquiry abandoned by 
major research centers. The persistence, in her recollection, had something to do with Cuba’s 
experience with prophylactic vaccines. Dania’s professional journey from preventative 
antimicrobial vaccines to cancer vaccines maps onto a national narrative in the Cuban 
development of cancer vaccines. The Cuban cancer vaccines entering the international 
pharmaceutical arena, like Cimavax and Vaxira, are immunotherapy drugs with similar 
mechanisms of action to therapies developed by the multinational pharmaceutical not in vaccine 
form. Genentech’s cancer drug Tarceva, for instance, also targets EGF but is taken in pill form. 
Cuba’s mark of biopharmaceutical innovation is, in no small part, related to the vaccine 
formulation of their most successful treatments to date. A form rife with both political and 
medical potential.  
 
Biotech is Fidel 
Dania and Vladimir give Fidel Castro the credit for Cuba’s biotech industry. Their general 
summary echoed the sentiments of dozens of others I’d heard both formally and informally over 
several years of researching Cuban biotech, equating the sector with the Revolutionary leader. 
When Vladimir summarized the history, saying, “the biotechnology enterprise was managed 
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directly through the council of the state;” Dania chimed in, adding, “yes, by Fidel Castro 
personally.”  
On the one hand, Cuba’s expertise in vaccines shares a history with other countries in the 
Global South, characterized by efforts in the first part of the 20th century to develop a national 
vaccine program (Holmberg, Blume, and Greenough, 2015). Yet, the expertise that would lead to 
innovation in, and dedication to, vaccines is thoroughly entwined with the socialist structure of 
society, governance and economy.  Specifically, Revolutionary Cuban investment in education, 
science and public health.   
 In Dania’s view, a confluence of circumstances at odds with the pace and process of 
biomedical research in the major scientific centers set the stage for Cuba to develop cancer 
vaccines. Cuba entered the biotech industry at the beginning of a boom, a line of research then, 
in her terms, “fashionable,” but also playing to Cuba’s strengths. But although for the global 
oncology research community the fashion passed, circumstances in Cuba meant the work 
persisted. The question of why Cuba continued this line of research when the rest of the global 
scientific community essentially abandoned it relates to geopolitics and Cuba’s relative isolation; 
its model tethering research to local concerns and providing guaranteed annual funding; and a 
concentration of researchers working on drugs related to the immune system. 
Vladimir chimed in: 
I think that the big global funders of [cancer] vaccines behind the boom arrived at a certain 
level and then declined because they had a different concept of [the vaccine’s] function. The 
important thing is that now they know to listen to Cuba in technology, to have a new form of 
obtaining and utilizing it. [Cuba] kept working on vaccines because this was more or less what 
they had at hand. In any event, the idea and the norm of Cuban investigators had them say, 
“yes this could work.” It gave its fruits…but a lot of time has passed since they got to what 
they arrived at that people now believe will work.   
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 Vladimir emphasizes the role of the confluence in expertise in and commitment to 
vaccines, a relative lack of other materials and projects and stability in state funding to the 
eventual success in creating a novel therapeutic vaccine like Cimavax. This expertise, in fact, 
predates the Cuban Revolution. Instead, it dates back to the colonial era, and Cuba’s unique 
history as a site for the scientific discovery of yellow fever as a vector-borne illness.   
 
Vectors to Vaccines: Finlay’s Legacy 
 In some ways, Dania’s career maps onto the trajectory for Cuban bioscientific innovation: 
investigative work on infectious disease led to research in therapeutic vaccines. This, too, has its 
counterpart in the history of public health in general. Discovering the link between mosquitos 
and infectious disease marked a watershed moment in public health and sanitation across the 
globe, one which continues to shape interactions between humans and arthropods. Mosquitos 
transmit yellow fever when infected with an RNA virus in the Flavivirus genus, the same genus 
responsible for dengue and zika which continue shaping population health and sanitary responses 
in Cuba.  
Cuban health statistics are frequently touted as evidence of the success of the 
Revolutionary government. The narrative of the transition from a country with morbidity and 
mortality statistics comparable to the Global South to that of the Global North undergirds the 
country’s status as exceptional,13 as a rightful regional leader in public health and medicine.  If 
the discovery of mosquitos as vectors of yellow fever set the stage for infectious disease research 
in Cuba, the successful deployment of the first Cuban-made biotech product to stem an outbreak 
 
13 See Introduction for a discussion of Cuban metrics and the phenomenon of Cuban 
“exceptionalism.” 
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of an infectious disease set the stage for an integrated approach to biotech and public health, 
from infectious diseases to cancer treatment. The successful synthesizing and use of interferon 
(see next section) was the first step in an integrated research lineage which ultimately led to the 
development and use of Cimavax (Reid-Henry, 2010). 
 Most histories of pioneering Cuban medical research begin with yellow fever and the 
national hero, Dr. Carlos Finlay: legendary as much for his discovery as he is for not having 
received the proper credit, according to the typical narrative. Finlay is the subject of dozens of 
books and countless articles; his face is chiseled into marble on dozens of statues across the 
island; his name graces a major biotech institute in the Polo Cientifico and the largest medical 
brigade dispatched to fight the Ebola epidemic in Western Africa bore his name.   
Yellow fever shaped the colonization of the Americas, decimating hundreds of thousands 
in the Caribbean and Latin America, changing the course of military and civilian interventions 
over centuries. The impact of the illness on indigenous populations is not well documented, but 
the historical records suggest that the disease was far more pervasive and deadly among 
newcomers to the area. Finlay took an early interest in yellow fever and set about a series of 
experiments and observations culminating in the discovery of the mechanism of yellow fever 
transmission via the mosquito vector: the Aedes agyptei.  Finlay’s discovery marked Cuba as a 
center of research on infectious disease, starting a scientific tradition that bridged the colonial 
and revolutionary eras. Yet it was the American Dr. Walter Reed who received the major 
international recognition for the discovery. Where the Cuban narrative and timeline firmly places 
Finlay as the pioneering scientist and discoverer of the vector mode of transmission of yellow 
fever, in North America, on the other hand, Finlay’s contribution is erased, replaced by the work 
of Walter Reed who, per the Cuban narrative, built his work directly from Finlay’s discovery.  
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Thus, Cuba’s first major contribution to global health is enveloped in resistance against historical 
erasure and marginalization. Many books and articles published in Cuba have mined the work, 
the debates and the historical record, attempting to recuperate Finlay as the true genius whose 
years of research laid the foundation for Reed’s subsequent work (Lopez Sanchez, 1999). The 
story of Carlos Finlay also serves as an allegory for Cuba, another example of injustice, robbery 
and marginalization perpetrated by the hegemonic giant to the north.  
 
From Vaccines to Biotech  
 The early 19th century saw the dawn of public vaccination in Cuba, beginning with Dr. 
Tomás Romay Chacon’s introduction of the smallpox vaccine in 1804 and created the Central 
Vaccine Board for the production, preservation and dissemination of the vaccine (Gonzalez, 
2018). A “Royal Vaccine Expedition” was launched that same year, sponsored by King Charles 
the IV of Spain (Galindo, 1999). In 1927, the Finlay Institute was founded to train physicians for 
health service management. The institute began producing vaccines in 1934, beginning with the 
smallpox, then typhoid, tuberculosis, rabies and tetanus vaccine (WHO, 2015).  
 Vaccine production changed significantly with the birth of biotech in the 1970s. 
Biotechnology revolutionized production of vaccines globally, enabling the production of 
recombinant vaccines, facilitating mass production. Like many stories I heard in Cuba, the story 
of how biotech came to Cuba, and how that related to vaccines, was a story of a chance meeting.   
In 1980, Dr. Randolph Clark, an oncologist from Texas and former cancer policy advisor 
to Richard Nixon, visited Cuba. Clark impressed Fidel Castro with two ideas: 1) the vision of a 
cure for cancer and 2) the significance of the work of Kari Cantell, who had successfully 
discovered how to produce and purify interferon from human leukocytes without patenting the 
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process. Interferon is a human immunological molecule with antiviral and anticancer activity.   
Two Cuban scientists spent a week in Clark’s lab in Houston, and six were invited to Cantell’s 
lab in Finland for twelve days. Castro outfitted a former luxury house in Havana as a lab, and the 
team successfully produced and purified interferon within six days (Feinsilver, 1993; Reid-
Henry, 2010).  
 Local production of interferon, coupled with an early success in its use for population 
health, marked the beginning of a national story of scientific achievements linked to public 
health outcomes, a hallmark of the Cuban Revolutionary government’s success story.  Shortly 
after the purification of interferon, a dengue outbreak that resulted in the hospitalization of 
116,000 patients spurred the first linkage of Cuban biotechnology with public health. 
Researchers working on interferon approached the Ministry of Public Health (MINSAP) with the 
idea of using the still largely untested treatment to mitigate the severity of the infection.14 
Preliminary positive results spawned a mass campaign of prophylactic interferon administration. 
Reid-Henry (ibid) points to a simultaneous effort which successfully nearly eliminated Aedes 
aegypti mosquitos, the dengue vector, in thirteen of Cuba’s fourteen provinces. The epidemic 
was halted, most likely due to vector elimination, but the end result allowed the interferon 
campaign to be judged a success.  This first campaign merging basic clinical research with public 
health priorities would prove the hallmark of the Cuban model from here on. Interferon 
generated the stepping-stone on which Cuba’s biopharmaceutical industry has grown, based on 
immune-modulating molecules, paving the way for the generation of over a thousand patented 
molecules, called innovadoras, including Cimavax.    
 
14 The life-threatening response to infection with dengue occurs, in part, due to its ability to 
block certain key immune responses, including interferon (Castillo Ramiriz, J and Urcuqui-
Inchima, S, 2015).   
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 Innovadora is the general term used in Cuba to denote the novel medicines developed on 
the island. This is in contrast with the other class of medicines produced, the bioequivalents, 
which are reverse-engineered from existing patented medicines developed off the island. Cuba 
has two streams of innovadoras: biopharmaceutical and natural medicines. These innovadoras 
include both homeopathic remedies as well as biotech-derived cancer treatments.  Innovadoras 
mark Cuban science as distinct within the Global South.   
Cuba’s Center for Genetic Engineering and Biotechnology (CIBG), inaugurated in 1986, 
was the country’s first biotech entity. The US embargo, limiting access to many basic 
medications, created the major impetus for the early investment in biotech. CIBG began 
developing the technology to produce both pharmaceuticals and vaccines in in the 1980s, using 
techniques developed during their early work manufacturing interferon in the 1980s.  
CIBG’s first products included a recombinant vaccine against hepatitis B, natural and 
recombinant interferons (alfa and beta) and recombinant epidermal growth factor (EGF) in the 
1980s. The Finlay Institute developed the first vaccine against Neisseria miningiditis type B in 
1980, providing the vaccine to Brazil, Argentina, Colombia and Uruguay, helping control a 
major regional outbreak. CIBG, together with the Finlay Institute, developed EGF into 
Heberprot-P, a treatment for diabetic foot ulcers. CIGB also developed the pentavalent vaccine 
Heberpenta, which protects against diphtheria, tetanus, pertussis (whole inactivated Bordetella 
pertussis cells) and hepatitis B, as well as a novel, synthetically-developed Haemophilus 
influenzae type b (Hib) infection (WHO, 2015).   
CIM, the newest biotechnology center, began with a group of researchers from 
the Institute of Oncology and Radiobiology (INOR, picture) working on developing  
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monoclonal antibodies and tumor markers, particularly EGF. CIM developed the therapeutic 
vaccines, Cimavax and Vaxira, for lung and central nervous system tumors, respectively. 
Cimavax generates antibodies to EGF, a circulating factor which causes tumors to grow. Vaxira 
induces an antibody response against Neu glycolyl GM3 ganglioside (NGcGM3), a circulating 
antigen overexpressed in CNS tumors (Gajdosik, 2014). CIM has also developed 
nimotuzumab, a monoclonal antibody to treat central nervous system tumors. CIM’s other major 
products include erythropoietin and granulocyte colony stimulating factor (WHO, 2015).  
Revolutionary Cuba’s biopharmaceutical innovations emerged, in part, as a response to 
the US embargo, to foster independence from US markets. Other innovadoras include a vaccine 
treatment for chronic hepatitis B, HeberNavasc (CIBG), sold to a Paris-based biotech company 
called Abivaxx. The National Center for Scientific Research (CNIC) developed Polyconasol 
Ateromixol (PPG), a natural product derived from sugar-cane used to lower cholesterol and 
Abexol, an antioxidant obtained from beeswax. Other well-known products with significant 
circulation off the island include Melanginina, a medicine derived from human placenta, 
effective for skin conditions like vitiligo, and Vidatox, a homeopathic remedy, derived from blue 
scorpion venom, which, I was advised by many pharmacists in Cuba, was very popular in China 
and could sell for up to $200 for 2 ounces. 
 In 2012, BioCubaFarma was created as a state-run umbrella company coordinating the 
production and marketing of all of Cuba’s biotech research institutions. BioCubaFarma has 
negotiated preferential agreements with multiple regional associations, including the Latin 
American Integration Association; MERCOSUR (Common Market of the South); CARICOM 
(Caribbean Community); the Association of Caribbean States (CARICOM);15  as well as 
 
15 Colombia, Costa Rica, the Dominican Republic, El Salvador, Guatemala, Honduras, Mexico, 
   62 
numerous countries in Africa16 and the Middle East.17 Several other countries granted a 
generalized system of preferences for trade including Canada, Japan and the European Union 
countries, which usually provides most favored nation (MFN) rates of 3.5% ad valorem. 
Between 1985 and 2013, Cuba’s export revenues increased from 11 million to 686 million  
(WHO, 2015). Cuba also exports to Serbia, Slovakia and Spain (Cubaheal, 2020).  
Cuba’s south-south collaborations continue expanding, in particular over the past seven 
years. Cuba has developed collaborations with companies in India, China and Thailand. Since 
2003, Biocon India, built with support of Cuban researchers, produces monoclonal antibodies, in 
particular, nimotuzumab. Collaborative efforts have progressively scaled up nimotuzamab 
production in China, used there for head and neck cancers, a common type of cancer in the 
Chinese population.  As of 2016, Cuba has signed agreements with 32 countries of the Global 
South: 13 in Latin America and the Caribbean, 12 in Asia and 7 in Africa.   
 
Vector Epilogue  
 The Cuban narrative of biomedical achievement often points out that Cubans are now 
“lucky” enough to die of the same causes as people in the Global North, namely cancer and heart 
disease. Therapeutic vaccines redeploy the pragmatic, social and moral charge of the 
prophylactic vaccine to this newer terrain threatening the health of the population. Yet, since 
infectious diseases are endemic in Cuba’s tropical climate, basic strategies like vector mitigation 
 
Nicaragua, and Bolivarian Republic of Venezuela 
16 Algeria, Angola, Botswana, Burkina Faso, Cape Verde, the Congo, Egypt, Ethiopia, Gambia, 
Ghana, Guinea, Guinea-Bissau, Mali, Mozambique, Namibia, Niger, Nigeria, Seychelles, South 
Africa, Tunisia, Uganda, United Republic of Tanzania, Zambia and Zimbabwe 
17 Iraq, the Islamic Republic of Iran, Lebanon, Qatar, Saudi Arabia, the Syrian Arab Republic and 
Yemen 
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remains a cornerstone of the MINSAP.  These are very visible, tangible, smellable efforts which 
make regular rounds to homes and businesses around the country via fumigation teams and 
trucks. These state-run services are a key factor in why Cuba’s rates of vector-borne illnesses are 
much lower than other countries in the region with similar climates: and they are not exactly 
optional. Yet, as is the case throughout Cuba today, most state-run services provide very low 
wages at all levels, and oversight is not as robust as it once was, engendering less-than-complete 
dedication to the job at all levels. In this case, some wiggle room for compliance with the vector-
control program can and does emerge. Inez, a Mexican American living in Cuba for the past 
decade, is married to Marco, a Cuban from Havana. They have a two-year-old son, Ramon and 
live next door to the neighborhood consultorio, the residence/clinic of the local doctor on the 
block. Inez recounted her experience with fumigation over the past three years, specifically, her 
wariness of exposure to potentially harmful chemicals once she became pregnant and later as the 
parent of a small child. On the one hand, Inez feared infectious disease. On the other, she feared 
the potential of harm from the chemicals in the fumigation. She believed the biggest risk for 
mosquitos was a standing pool of water in the neighboring unit, which happened to be the 
doctor’s residence and consultorio. Whereas she repeatedly asked the young doctor next door to 
fix the leak resulting in the pool of standing water which attracted mosquitos, and she herself 
made calls and visits to the MINSAP to attend to the standing water, for over a year the problem 
remained unrepaired. Yet the fumigators continued coming frequently according to their regular 
schedule. Inez concluded she was more fearful of the fumigation chemicals than the mosquitos 
and refused to let them into her apartment to fumigate. The fumigators did not pressure her, they 
just filled out their paperwork and instructed her to sign it as if the work had been done, leaving 
her alone until the next round.   
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Inez’s small tale highlights some of the tensions in the contemporary situation of Cuba’s 
public health sector and its relationship to technology. Here, the responsibility for both 
fumigating and attending to standing water in a clinic both fall under the auspices of public 
health. Her story highlights how a robust approach to population health through vector control 
via mandatory fumigation can fail when not accompanied by very basic interventions like 
removing standing water. They may fail further in the context of low state salaries which might 
sap incentives from already low wage workers conducting said fumigations, if bureaucratic 
demand for paperwork completion takes precedence over the intervention itself (or perhaps the 
fumigator agreed with Inez, and was willing to look the other way).    
Cuba’s geographic susceptibility to vector borne disease, early pioneering work of Carlos 
Finlay and the robust socialist public health response to this vulnerability (even if marked by 
difficulties like those described by Inez above) paved the way for the emergence of a Cuban 
socialist biopharmaceutical industry. The US embargo, cruel and crippling, fueled the urgency 
for a Cuban pharmaceutical sector. Cuban socialist investment in education, science and 
medicine, significantly inspired (and trained) by the Soviet system, laid a foundation on which 
the interferon technology shared by Kari Cantell could combine with experience in vaccine 
production, leading to the development of a cancer vaccine like Cimavax. Yet, the story turns 
another, extraordinarily important, element: the rise of cancer immunotherapy.  
 
Cancer Immunotherapy 
 Cuban cancer vaccines are considered a form of cancer immunotherapy. That is, a 
treatment which mobilizes the patient’s own immune system to fight against cancer.  While 
therapeutic vaccines are still relatively new, they are part of a lineage of treatments dating back 
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almost 130 years. Over the years, these types of treatments have waxed and waned in popularity. 
Taken together, for many scholars, the ratio of success to failure has not been seen as promising. 
Today, cancer immunotherapy is back in the mainstream in places with access to the latest 
therapeutics. At the time Cimavax was developed, however, cancer immunotherapy was more 
fantasy than reality.   
 Understanding something of the roller coaster ride of cancer immunology is important to 
contextualizing the slow, steady Cuban project resulting in Cimavax, alongside its counter-
current technology transfer to the Roswell Park Cancer Institute. Written in the 1990s, during a 
period of “fashion” for cancer immunotherapy, Stephen Hall’s Commotion in the Blood (1997) 
captured a high point in hopes for these types of treatments. Hall’s superbly researched book 
charts a lineage of physicians and basic researchers beginning with Dr. William B. Coley, an 
American physician practicing in New York in the late-19th century, one the first clinicians to 
experiment with using what he came to call a “therapeutic vaccine” in 1892.  His research was 
inspired by his patient, Fred Stein, a man with unremitting round-cell sarcoma erupting from his 
ear to his cheek then neck. Four surgeries failed to remove the cancer, and as he remained 
hospitalized for surgical recovery, he developed a fever and rash, diagnosed as erysipelas, a 
streptococcus pyeogenes infection, which, after two weeks, seemed to have cured his cancer.   
Dr. Coley spent several years collecting and growing cultures and injecting them into 
patients, resulting in just a few responses but generating enough enthusiasm to propel his 
continued efforts along this line of treatment for the next three decades, using a formula that 
would long be known as “Coley’s toxins.” In this pre-antibiotic era, Dr. Coley’s repeated 
experimentation yielded as many deaths by infection as responses by tumors, prompting him to 
abandon live bacteria and search for some less pathogenic factor related to the bacteria which 
   66 
might similarly be exploited. Parke Davis & Co. manufactured a version of Coley’s therapeutic 
vaccine in 1899, although some believed that they didn’t follow his instructions and produced a 
markedly weaker and, subsequently, inferior product. In 1953, Dr. Coley’s daughter Helen Coley 
Nauts founded the Cancer Research Institute (CRI) which remains a leader in funding and 
support of cancer immunology research, including the development of cancer vaccines.  
 Hall’s book also closely follows the relationship between the scientific and popular press, 
and the impact of this relationship on the development of certain branches of cancer 
immunotherapy. The Journal of the American Medical Association (JAMA), for instance, 
covered Coley’s toxins three times over forty years, first in 1899 in optimistic tones, then two 
years later reversing tone, then, finally, forty years later, publishing an op ed recognizing that 
Coley’s toxins did, indeed, appear effective for a percentage of patients. What Hall demonstrates 
so clearly is how, as in so much of medicine, the “whys” of when treatment does or does not 
work remain so elusive. Speaking at a 1993 symposium, one of the twentieth century’s leading 
cancer immunologists, Lloyd Old, who directed CRI from 1971 through his death in 2011, 
offered the following interpretation: “The best reason, however, is that science had to catch up 
with the Coley phenomenon and that the cellular and molecular language of inflammation and 
immunity had to be understood before the forces that Coley unleashed could be predictably 
translated into tumor cell destruction (1997: 123).” Generations of researchers have 
demonstrated remarkable cases of responses, yet responders still represent a minority of those 
treated with immunotherapies, and complication rates remain very high with many treatments. 
The past decade has seen a new resurgence of interest in cancer immunotherapy across the major 
cancer research centers worldwide. Today it is considered, in Dania’s term, “the fasion.”  Cuban 
researchers, however, started in the 1980s and never stopped.   
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Vaccifarma 
 The 2017 Vaccifarma Cuba conference took over the Melia Marina Hotel in Varadero.  
Conveniently held at one of Cuba’s premier beaches and vacation spots, this conference boasted 
300 attendees, including a large number of foreign researchers and clinicians, although the 
attendees were majority Cuban. Visitors hailed mostly from the Global South including Latin 
America and Africa, as well as the economic powerhouses in Europe and Asia, yet at least twenty 
or so were North American. Some were frequent flyers, having made multiple trips previously, 
with histories of institutional collaborations. Others came out of curiosity, to mix business with 
pleasure, out of ideological conviction, or all three.   
 I met researchers from Belgium, India, Japan, South Africa, Argentina, Canada and the 
US.  Cuban medical conferences have taken on an almost industrial form, generating an 
important source of income for the island, as hundreds of international medical, public health and 
nursing conferences spur their own microeconomies, bringing with them significant tourist 
income. Since 2007, the island has hosted an annual conference called Immunopharmacology. In 
2015 and 2017, the conference changed its name to Vaccifarma and Immunopharmacology.  The 
conference is a showcase for some of the most successful biopharmaceutical products and 
research lines emerging from the Polo Cientifico to date. As such it is a hub of social networking.  
These conferences afford a specific mode of sociality. As Brotherton (2012) and others have 
written, particularly in the post Soviet context of a weakened state, many sectors in Cuba operate 
through a form of networking known as social-ismo (social-ism, as opposed to socialism). 
Social-ismo indicates a means of establishing business networks through socios, a term 
encompassing the idea of a trusted person, a specific type of interested and mutually beneficial 
friendship.  
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 This first evening of the Vaccifarma 2017 conference, the opening reception included a 
string trio of three young women in ball gowns, opening the keynote event with the theme from 
“The Phantom of the Opera.”  Following the musical interlude, a South African physician 
addressed the audience. He emphasized the twenty five years of collaboration between South 
Africa and Cuba, starting with the hemophaelous influenza B vaccine, now having turned to 
collaborations in pneumococcal vaccination. He flipped through slide upon slide of data from 
India and Africa, showing graphs of morbidity and mortality from pneumonia and sepsis. “These 
are the problems of poor countries…much poorer than Cuba.”   
 One Cuban vaccine researcher I met at the Vaccifarma conference, Mykel, quoted in the 
opening of this chapter, had twenty years of experience working in Cuban vaccine production. 
Graduating from the University of Havana as a pharmacist, he started his career in a regulatory 
agency, specializing in vaccine regulation for several years. Looking for new opportunities, he 
moved to one of the major vaccine-producing institutes, where he’s been responsible for vaccine 
quality assurance ever since. Warm, professional, with a relaxed demeanor, Mykel seemed, 
nevertheless, an extraordinarily busy man. Our interview, conducted in a hotel lobby during a 
conference, was peppered by phone calls, text messages and in-person interruptions. In the 
intervening minutes between the interruptions, he launched into a history of Cuban vaccine 
development. Like many people I interviewed around themes of medicine and science in Cuba, 
Mykel succinctly conveyed a coherent national story, suggesting the possibility of an official 
narrative. There was a proper order, a logic and a theme. According to his narrative, 1983 was 
the key year spawning Cuba’s foray into vaccine development, when an outbreak of meningitis B 
ravaged the island, a type of meningococcal infection without any effective vaccine.  In Mykel’s 
telling, generating a vaccine for this type of meningitis had eluded other centers of vaccine 
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production, as the bacteria elicited weak immuno-stimulatory effect. It required a unique 
approach to generate antibodies. Researchers at Cuba’s Finlay Institute developed a vaccine 
based on a bacterial membrane protein that turned out to be both novel and efficacious, and they 
began producing en masse, exporting large quantities, especially to Latin America.  
In the Global South, Cuba is a leader in vaccine development and distribution. Mykel’s 
version of the origin story elides the thick, multi-layered history of how and why Cuba is, in the 
words of the US cancer research center collaborating partner Dr. Kelvin Lee, “good at vaccines.” 
The reputation is hard-won, and, in many ways, inseparable from both the legacy of colonialism 
as well as the Cuban revolution. Dr. Lee is a self-described fan of Cuba and Cuban science.  
Cuba has been good at vaccines, mostly infectious disease, it is very much in their mindset, 
even prior to the communist revolution…Fidel Castro had a particular interest and insight into 
the role of biotechnology going forward. Interferon in MLL (mixed lineage leukemia), Fidel 
Castro said, we need to do this, he told this story… Very high up you had the leadership having 
identified this as being an important component. The other aspect is that vaccines are the cost-
effective ways to develop a response. It’s not like you are giving people a monoclonal antibody. 
The vaccine is a living drug, induces your own immune system to induce.  You don’t need to 
get antibodies…That fits in very nicely with their requirements that it be cost-effective. So, I 
think it was that whole set. Pre and post-revolutionary factors… But it really is, our CIM 
colleagues, see it they view the antibody response can block an interaction—whatever you 
want to block—you can generate an immune response---in this case EGFR. They’ve developed 
a vaccine to block cholesterol—phase one studies. They look at the immune system as a tool. 
They look at it as an ability to block. They think of vaccines as keys and locks (Kelvin Lee 
and, November 9, 2016).  
 
  As an outside collaborator, friend and Cuban science enthusiast, Dr. Lee’s gloss on a 
“Cuban” approach to immunology and vaccine development conveys a simple and elegant 
conceptual approach to science, at odds with the often messy and haphazard process of basic 
research.  His comment about keys and locks highlights how a vaccine can be a conceptual 
model for pharmaceutical development which inspires the proliferation of innovative 
pharmaceuticals developed as so-called therapeutic vaccines. That is, the vaccine stimulates the 
production of keys which either turn on or open up a response.   
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 On my first trip to Cuba for fieldwork, before I even had clarity on the Cimavax project, I 
had my first inkling of how important and widespread vaccine development could be as a fertile 
line of research and development.  The adult child of my host/landlord was a pharmacy student 
working on a project to develop a vaccine for urinary tract infections. The goal of the project was 
to create a vaccine to provoke antibodies against the most common cause of these infections: the 
bacterial pathogen E. Coli.  Cuban vaccine therapy seemingly knew no bounds.   
 As expansive as the directions in which Cuban biopharmaceutical products seem, from 
the gel for diabetic foot ulcers to lung cancer vaccines, in fact they are derived from a very 
narrow intellectual lineage. All of the novel treatments are derived from techniques learned from 
the development and purification of interferon, after the techniques were shared by Kari Cantel.  
 
Forgettable Vaccines 
 Sociologist Nils Graber’s (2018) study with Cuban cancer patients in a clinical trial 
emphasizes the integration of cancer care into primary health care (PHC), highlighting the 
treatment of a patient with cancer, receiving her therapeutic vaccine, alongside young mothers 
with their children receiving routine primary care. My interviews with oncologists working with 
Cuban therapeutic vaccine cancer treatments emphasized a related but distinct goal of social 
integration. For these oncologists, cronicidad, the ideal of converting cancer into a chronic 
disease, meant integration into the community. Both Graber’s argument about integration of 
cancer care into PHC as well as the idea of cronicidad gesture toward an ideal future in which 
cancer and its treatment might become banal, maybe even forgettable.  
My informal networks of friends, always curious about my research, often wanted to help 
in some way. Over the course of my fieldwork, I only had the opportunity to interview one 
   71 
person with a personal history of cancer (in remission) who had used Cuban immunotherapy as 
part of her cancer regimen. Adding breadth and perspective to this interview were several other 
interviews with persons who had experienced a loved one going through cancer treatment in 
Cuba in recent years. What stood out from these interviews was that therapeutic vaccines did not 
stand out at all.  
 For Leonora, breast cancer was a transformative experience. Her involvement in a 
clinical trial for therapeutic cancer vaccines, however, was completely forgettable. According to 
Marina, her daughter in law, who introduced us, Leonora doesn’t actually like to refer to or say 
the word, “cancer.”  I was instructed by Marina to refer to it instead as “the problem with the 
breast.”  Like others who describe cancer as a wake-up call in one form or another, Leonora has a 
strong before and after narrative which, for her, centers around her self-care practices. Whereas, 
pre-cancer, Leonora enjoyed a range of fried foods, meats and dairy, now she tries to follow a 
mostly vegan, macrobiotic diet. She notes wryly that while milk is an expensive luxury item for 
most households, “if you have cancer the state gives you milk” (along with the regular food 
rations). Yet, Leonora is also a pragmatist. “Remember, this is Cuba. If a steak falls on you, you 
eat it.” Not only did Leonora transform her diet, she took up meditation and yoga, eventually 
abandoning her career as a music teacher to become a yoga teacher herself.  
 In her third-floor apartment on the outskirts of Nuevo Vedado, while her husband Tomás 
made the coffee, Leonora recounted her history with “the problem with the breast.”  She’d found 
a lump five years ago, brought it to the attention of her local primary doctor, gotten the 
mammogram and biopsy, and received her diagnosis in coded terms alongside her son and 
daughter in law. Leonora had memories of her chemotherapy, that “red devil” doxyrubicin, of the 
side effects. She remembers the regular visits to the oncologico, where sometimes she’d show up 
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for an appointment, but her doctor would not be there. Her doctor, it turned out, was also a 
politician, a member of the national assembly, and frequently called out of clinic for her political 
duties.  
 We’d been talking for an hour about her macrobiotic diet, her yoga teacher, fellow-breast 
cancer survivors friends, and all the changes she had made to her diet and lifestyle routine since 
her diagnosis with cancer.  She goes to the farmer’s market several times per week, eats leafy 
greens.  She frets over finding things she’s been told are healthy, but are difficult to come across 
in Cuba, like oatmeal and whole wheat bread. We sat drinking sweet coffee in her living room, 
talking about her experience with cancer.   
 After talking for over an hour, we meandered into family and personal life, she played me 
recordings of her daughter and grandchildren who live abroad, we looked through photo albums 
together. Then suddenly she recalls a detail previously forgotten.   
Wait, I was in a vaccine protocol. I had forgotten. How they’re promoting many…there are 
many clinical trials about different cancers…prostate, lung cancer is very advanced and 
there’s a very good vaccine. And between this also breast cancer. I entered a protocol for 
patients in stage 2b3a….I was in the trial for 18 months I had to go every 21 days to get a 
vaccine. Of course, we signed a consent and we didn’t know if they were putting placebo 
or vaccine. It hurt a lot. It hurt for days. There were people who, this didn’t happen to me 
because I gave myself vaccines but there were people with these lumps like this. I would 
say, why are you letting them put this?  
 
Imagine every 21 days I had to go on the same exact day. I couldn’t change the day or 
anything. After putting the vaccine, I had to stay there for an hour sitting there to see if I 
would have any reaction. You couldn’t leave right away.  
 
I decided quickly that this would not cure me of anything but that I would help another 
person. 
 
One time they didn’t have enough chemo for the number of patients they had. They told 
us. I don’t know what they did, I don’t know if they divided it up between everyone, I don’t 
know what they did but we were in this situation. But now the pharmaceutical sector is 
progressing and now they can make many things here. This was maybe four or five years 
ago. And maybe, many things now they make here. But they try to make many things here. 
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Although there are components only available in the US and these you can’t use. But, oh 
well (May 22, 2018). 
 
 In the scheme of cancer diagnosis and treatment, Leonora’s involvement in a clinical trial 
for a therapeutic vaccine protocol was entirely forgettable. Of all the physical and emotional ups 
and downs, the lifestyle changes, changes in outlook, the involvement of this treatment barely 
registered. Of course, Leonora falls into that category of person often referred to as a “survivor,” 
having “won” the battle with cancer, at least, in the early rounds, so far. Unlike those with 
metastatic or incurable cancer, toward whom the therapeutic vaccines are most publicly targeted, 
Leonora was “cured.”  Yet, the very forgettability of the vaccines are, in fact, a central point of 
their popularity. When compared to chemotherapy, radiation, surgery, or even other, non-vaccine 
forms of immunotherapies, these vaccines are purported to be easily tolerated, with minimal side 
effects. In short, they should be ideal therapeutics in their very forgettability. Forgettability is, in 
fact, a part of what renders therapeutic vaccines like Cimavax particularly charismatic 
interventions. Their form renders something like advanced cancer into a terrain proximal to 
routine childhood immunizations: a normal, forgettable moment.  
 Innovadoras like Cimavax (or Cimaher, the likely candidate for the clinical trial in which 
Lenora was enrolled) emerged, and took their form, from the history of pioneering infectious 
disease research and the early success in vaccine production, dating back to the colonial era. As 
Dania and Vladimir, along with countless others and the “official” narrative would also say, they 
were made possible by the forceful and shrewd decisions of Fidel. They were made possible also 
by the collaborative efforts of Kari Cantell sharing interferon production technology. Yet, the 
degree to which Cuba has far outstripped any other country of similar economic status in 
developing, producing and distributing novel medicines is rooted in the sector’s socialist design, 
a system modeled originally on the Soviet Union.  
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Soviet Science 
 
A central theme I assert throughout this dissertation holds that the success and expansion 
of the Cuban biopharmaceutical sector are inseparable from the persisting, if adapting, conditions 
of socialism. Cuban science and medicine were significantly influenced by the Soviet system 
during the 1960s-1980s. Historian Loren Graham has written eighteen books, along with 
numerous articles, documenting the failures and successes of Russian and Soviet science, 
analyzing their relation to Marxist theory, the socialist system, geopolitical, ecological and other 
influencing factors. One of Graham’s arguments goes against the grain of other scholars of 
Soviet science in asserting that Marxist ideology had at least as great of a positive impact as a 
negative one on the achievements in Russian science and mathematics. He highlights the ways in 
which Soviet scientists were generously supported financially but repressed politically. Graham 
considers the two great crises impacting Soviet science: 1) the “terror,” when thousands of 
scientists were arrested and assassinated and hundreds forced to work while imprisoned, and 2) 
the years following the collapse of the Soviet Union. He concludes that it was the latter which 
exerted the most devastating impact on Russian science. His controversial conclusion: 
continuous state funding of science turned out to be more important than academic freedom 
(1997). Whereas Graham and other authors like Ings (2016) have described the brutal conditions 
including prolonged imprisonment to which physicists like Andrei Sakharov, nuclear scientist 
and Nobel Laureate, were subjected, they similarly acknowledge the persistence of pioneering 
work produced during the time of repression. Most notable among the Soviet achievements in 
science were those in theoretical physics, a branch which, despite ideologically driven 
government control, was given sufficient independence and latitude, generating eight Nobel 
prize winners from 1958-1978 (Kremenstov, 1996; nobel.prize.org, 2019). 
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What might be learned from considering the history of Russian science, both during and 
after the Soviet period? Graham’s central argument mirrors Dania’s comment to me at the dinner 
gathering between RPCI and CIM researchers. Her experience of financial support and stability, 
guaranteed by the state, reflected a relative state of impoverishment of the researchers from 
North America dependent on financial partnerships, grant cycles and marketability of potential 
products. Capitalist modes of science and technology are marked by constant change. 
Conventional economic wisdom and, indeed, robust evidence, supports the idea that competition 
breeds more choice. That the leading edge of Cuban biotech has taken the shape of a therapeutic 
vaccine for cancer, a mode of treatment largely abandoned elsewhere in the 1990s, highlights a 
potential benefit in also allowing for slower research not pegged to the rapid cycles of funding 
“fashion.”18 In the case of Cuban socialist biopharmaceuticals, vaccines are a perfect medium 
through which to grow science. As shown by scholars like Conis (2016), Homburg et al (2017) 
and Plotkin (2014), vaccines are a unique combination of science and politics. They are material 
and semiotic enactments of the state and biomedicine, operative both on a population and 
individual scale.  
 
Immunitarianism 
 Vaccines as a technology work through the immune system. They introduce an antigen, a 
molecule capable of exerting an immune response. Antigens can be either foreign or “auto,” 
meaning self-generated. Vaccines can be further subdivided into live-attenuated (weakened), 
inactivated, toxoid (weakened bacterial toxins), subunit and conjugate (CDC, 2019). These 
antigen which stimulates two types of white blood cells: B and T lymphocytes.  The T cells or 
 
18 See Adams, Burke and Whitmarsh’s (2014) call for slow research in global health.  
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“memory” cells remember the antigen and are able to subsequently develop a targeted response 
to it.  The B lymphocytes produce antibodies, which bind and neutralize or otherwise impair the 
activity of the antigen. Cuban cancer vaccines work by stimulating a reaction to an auto-antigen 
called Epidermal Growth Factor, a molecule with multiple effects in the body, one of which is 
stimulating tumor growth. Do the physiological responses have any relation to the socialist 
science driving the development of Cimavax and other Cuban innovadoras?   
 Immunology, as a branch of biomedicine, borrows the from the language of political 
philosophy. Immunology is derived from the Latin word, munus: a special form of public 
obligation or duty. The prefix modifier “im” connotes exemption from that duty. Immunity was a 
special political designation before it emerged as a field of biomedical science. Italian political 
theorist Roberto Esposito (2002) considers the conceptual terrain of the entity known as 
immunity from a phenomenological perspective. He proposes, “Immunitas, is an exemption. But 
based on both ancient and modern definitions, it is also a privilege. The most fertile connotation 
of the term lies precisely where these two meanings overlap or intersect; immunity is perceived 
as such when it occurs as an exception to a rule that everybody else must follow (6).” Esposito 
continues,  
The immunitary paradigm does not present itself in terms of action, but rather in terms of 
reaction-rather than a force, it is a repercussion, a counterforce, which hinders another 
force from coming into being. This means that the immunitary mechanism presupposes the 
existence of the ills it is meant to counter…the immune mechanism functions precisely 
through the use of what it opposes (7)… This is where the structurally aporetic character 
of the immunitary process is to be located: unable to directly achieve its objective, it is 
forced to pursue it from the inside out. In so doing, it retains its objective in the horizon of 
meaning of its opposite: it can prolong life, but only by continuously giving it a taste of 
death (2002, 9).   
 
Considering its implications in the social sciences and humanities, in the broadest possible terms, 
immunology has provided ample material for philosophical examination of self versus non-self 
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(Haraway, 1989; Martin, 1994). Anthropologists and science and technology studies (STS) 
scholars have shown how the directionality of the metaphors on which both the science and 
philosophy are built is unstable. That is, the modes of human thought informing both the 
scientific and philosophical praxis shape the questions posed as well as the interpretations of the 
answers to such questions. Esposito’s development of immunitas suggests a way for thinking 
through the medical and political potential in a therapeutic vaccine like Cimavax, how it may 
exert its effects from the inside out, “retaining its objective in the horizon of meaning of its 
opposite (ibid).” Politically, as Cimavax moves into the terrain of global pharmaceutical 
distribution, this socialist vaccine may indeed be most potent in the horizon of its opposite: the 
highly profitable multinational pharmaceutical industry. Esposito’s idea resonates with the 
clinical aspirations for Cimavax in its therapeutic use as well. As we shall see in the next chapter, 
Cimavax has inspired oncology researchers in Cuba to reimagine advanced, incurable cancer as a 
chronic disease. The therapeutic cancer vaccine, administered in a routine, forgettable way, 
reimagines a way of normal living while not denying the persistence of its opposite: normal 
dying.  
 
Conclusion  
 This chapter examined the importance of vaccines as concept and medium to the story of 
Cuban biotech success. Vaccines are a special types of intervention. Cimavax, a therapeutic 
vaccine which does not work like preventative vaccines, exists and expands globally, in part, in 
its configuration as a biotechnical intervention of science, geopolitics and circumstance. Cuban 
cancer vaccines offer a way into thinking about the adapting conditions of socialism in 
contemporary Cuba. These vaccines operate through the immunitary paradigm. The routine 
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suffering of daily life under 21st century Cuban socialism, that fodder for the popular humor 
invoked by scientists like Vladimir, is the price for the universal healthcare, the lack of extreme 
poverty, the (nearly) cutting edge treatments. It is the prophylaxis and the treatment which, 
Esposito proposes, “can prolong life, but only by continuously giving it a taste of death.” Cuban 
therapeutic vaccines could be received as either treatment success or treatment failure, depending 
on the terms of evaluation. They persist and expand because the terms for their reception 
represent realities of the global burden of cancer.  
In this chapter, I explored the vaccine as a material and ideological entity, attending to the 
particularities inherent in its design, in theory, in the imaginary and in the many configurations of 
its applications and effects.  Into the fourth century of their use, vaccines are one of the earliest 
biomedical technologies. Much of the research of this last century has been in the service of 
discovering the hows of why vaccines work in general, uncovering the mechanisms, components 
and interplay of the elements which have come to be considered part of what is commonly 
referred to as “the” immune system. Cimavax, a vaccine and cancer immunotherapy, directs the 
body’s resources against that form of life which is simultaneously part of and distinct from the 
self. Therapeutic vaccines like Cimavax are always already failing, yet in their failure they open 
up a new space for living and dying.  
 Vaccines have and are a politics. As Conis (2016) argues, vaccines afford the enaction of 
a range of political imaginaries: a healthy populace, a caring state, a state of security. By the 
same token, vaccines are taken by some as a politics of violence, representing the intrusion of the 
state. In the case of the therapeutic cancer vaccines at the heart of this dissertation, their overall 
impact is rather marginal, at least at present. Yet, in their existence they afford the persistence of 
an aspiration and an imaginary. Therapeutic cancer vaccines, in their mode of containing growth, 
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signal failure and success. They point toward a new mode for thinking of cancer as part of the 
human condition, living and dying alongside one’s tumors.  
This chapter has shown a relationship between therapeutic vaccines like Cimavax and the 
iteration of socialism adapting through the late 20th to early 21st century.  As both concept and 
material, vaccine is a particularly rich substrate. In the case of Cuban biopharmaceuticals, 
vaccines are especially well-suited as a vehicle through which a socialist pharmaceutical might 
take shape. Cimavax is a real-world example of how a drug produced under Cuban socialism 
looks distinctive. As an inexpensive vaccine for metastatic cancer, it could only be produced 
under state-funded regimes of science. It is easy to administer and has few side effects. It may 
not have a massive effect, but it may have about as much effect as many of its much more 
expensive, and more toxic, alternatives.  
Vaccines are a unique category of pharmaceutical. They act through us, not on us. They 
are active treatments, incapable of working without the active participation of the immune 
system. Indeed, this very active principle fuels some of the fear and resistance which has 
emerged among certain sectors (usually of privilege) in the west. The prophylactic vaccine is 
meant to intervene on our reaction to the outside world. It helps us defend ourselves against 
would-be assaults from pathogens. Therapeutic vaccines render visible the possibilities of a 
biotechnical adaptation of socialism in 21st century Cuba. As Esposito’s immunitary paradigm 
suggests, Cimavax achieves its directives indirectly, an embodied instantiation of socialist 
technoscientific innovation. It draws strength from the moral valence of the politics of 
vaccination, resonant with sacrifice for the greater good. Bringing Esposito’s immunitary 
paradigm closer to the case of Cuban socialist pharmaceuticals might encourage us to ask what 
might be the political impact of inoculation with a socialist therapeutic cancer vaccine? The next 
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chapter explores how Cimavax might reshape the relationship between humans, tumors and 
tobacco through a reconfiguration of the temporality of advanced cancer.  
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Chapter Two| Chronic: Tobacco and Tumors 
 
“We have to throw out the word, ‘terminal’  
— Dr. Agustin Lage-Davila, April 27, 2018. 
 
“A comedian would say the best solution would be to sell boxes of cigarettes with a dose of 
Cimavax. But this would be a campaign without much commercial potential”  
—Yoss, Cuban biologist and science fiction writer, April 2018.  
 
  
The word terminal signals an approaching endpoint, a destination, a sense of the finite. Dr. 
Lage, quoted above, is an oncologist-immunologist and head of BioCubaFarma, the umbrella 
organization for the commercialization of innovative products developed in the Cuban socialist 
biotechnology sector. His quote was delivered to audience of scientists, clinicians and policy 
makers at a public health forum in Havana as a provocation to reject framing advanced cancer as 
a “terminal” illness. Instead, he argued, advanced cancer should be considered a chronic disease. 
Dr. Lage’s aspirational, perhaps utopic, quote was grounded in the materiality of a specific 
intervention. Prior to working for BioCubaFarma, he ran one of Cuba’s most successful state 
biotech companies: The Center for Molecular Immunology (CIM), the entity responsible for 
developing the therapeutic lung cancer vaccine, Cimavax. In a 2014 review article for the journal 
MEDICC,19 Dr. Lage, asked, rhetorically, “The new evidence and conceptual transitions point to 
a future in which the medical challenge will be chronic treatment options for an increasing 
population of patients with tumors that are not curable, but controllable. What do we have in our 
arsenal to address this challenge  (Lage, 2014)?” 
In this chapter, I examine a movement stemming from Cuban oncology researchers’ efforts 
to reframe advanced cancer as a chronic disease. I will argue that this movement demands a 
 
19 MEDICC is both an organization and a medical journal produced by a collaboration of US and 
Cuban-based entities to promote Cuban science and improve US-Cuban relations. 
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reframing of the relationship between humans, tumors, tobacco and time. The idea, referred to as 
cronicidad, is connected to treatment with Cuban therapeutic cancer vaccines designed to slow 
the growth of tumors by generating antibodies to Epidermal Growth Factor (EGF), a protein 
normally circulating in the blood of humans (among other organisms). The anti-EGF antibodies 
bind to the EGF receptor, blocking the proliferative effects of EGF. For some people with 
cancer, this effect holds their tumors in check for variable periods of time. It does not shrink or 
destroy the tumors. It allows the tumors to continue living alongside their host.  
Lung cancer is the sixth leading cause of death worldwide (WHO, 2018) and the fourth 
leading cause of death in Cuba (IHME, 2018). These mortality figures have a dual valence in 
Cuba. On the one hand, they represent serious problems facing the population; on the other, they 
signify that a country like Cuba that is resource-poor and economically isolated (because of the 
US economic blockade) can achieve leading causes of death that are similar to wealthy parts of 
the world such as North America and Europe. Medical Anthropologists and other scholars have 
examined aspects of the Revolutionary Cuban universal health program behind these statistics. 
Their research offers insight into both the unique context of healthcare delivery in Cuba, as well 
as the nuances of local, community responses to the socialist state-run system (Brotherton, 2012; 
Burke, 2013; Andaya, 2009). They have also examined the shape of cancer screening and care, 
such as genetic screening for breast cancer (Gibbon, 2016) and the distinct approach of 
integrating clinical trials for cancer into community primary care (Graber, 2018). Given Cuba’s 
long-standing cultural and economic connection to tobacco, one might reasonably predict a 
unique approach to lung cancer as well. This is why, as we shall see, cronicidad is a potent idea 
in Cuba.   
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A 2016 newspaper article in Granma, the official newspaper of Cuba’s communist party, 
describes how the use of therapeutic lung cancer vaccines links to the aspiration of cronicidad:20   
Luis, Pedro Pablo, Eugenio, Olga and Ramona receive their lung cancer vaccine treatment 
cycle at the Benéfico Jurídico Pneumological Hospital in Havana. Each states that they 
have an active social life, with a survival rate of over three years since being diagnosed 
with the disease… None of these patients know the price of the drug, nor have they asked. 
They note the conscientious care they receive from doctors, nurses and hospital workers. 
Before the vaccine is applied, they wait in an air conditioned room with TV, armchairs and 
varied literature, where they talk about anything but the disease. 
“It is not a curative medicine, but stabilizes the tumor and makes the illness a chronic non-
communicable disease,” the pulmonologist (Dr. Toledo) explains, adding, “It is a treatment 
with durability over time and is administered to the patient as long as the body allows. At 
the end of the first cycle a good general condition is observed, with greater participation in 
social activities without significant adverse reactions (Leon, 2016). 
Several months later, The New York Times ran an article on Cimvax similarly highlighting the 
aspiration of cronicidad.   
“There’s no doubt that without this medicine, I would be dead,” said Mick Phillips, 69, of 
Appleton, Wis., who first went to Cuba in 2012 and has been returning annually ever since. 
“When we were children, we were taught that Cubans didn’t know what they were doing. 
Turns out they do”… Mr. Phillips, a lifelong smoker who was given a lung cancer diagnosis 
in 2009, said it was worth every penny. After chemotherapy and radiation, his cancer 
returned in 2010….“Since I have been taking Cimavax, it hasn’t come back,” said Mr. 
Phillips, who travels to Cuba via Toronto (Jacobs, 2016). 
  
 These passages, one from Cuba and one from the US, are samples from dozens of media 
articles gesturing toward cronicidad. As Cimavax has been in use for almost 25 years in Cuba, 
numerous anecdotal tales circulate of people living as long as ten years, or “indefinitely,” as I 
heard from a doctor at a conference, with advanced lung cancer, purportedly due to this vaccine.  
The peer-reviewed evidence, on the other hand, is more modest, suggesting an average of three 
to six months of what is known as “survival benefit” (Rodriguez, et al, 2016; Zhou, et al 2016).   
 
20 Granma the newspaper is named after the yacht on which Fidel and Raul Castro, Che Guevarra and Camilo 
Cienfuegos, along 76 of their compatriots, launched an assault against the dictatorship of Fulgencio Batista in 1956. 
   84 
Dr. Lage’s provocation emphasizes that while cancer represents a leading cause of death, 
before death, people coexist, together with the cells which have taken on a growth pattern at odds 
with the dominant mode of cell division, sometimes growing together into something we call a 
tumor(s), in this state known as having cancer. What is the nature of this time from cancer 
detection to death?  How should this span of time be approached: as living, as dying or 
something else?   
The program of cancer immunotherapy of the Center for Molecular Immunology 
(including various monoclonal antibodies and therapeutic vaccines) can illustrate the 
problems to resolve, at the biological and social level, along the route to transform 
advanced cancer into a chronic disease, not transmissible, compatible with years of quality 
of life (Lage and Crombet-Ramos, 2011).    
 
CIM boasts close to fifteen hundred employees, over 1000 of them hold master’s degrees 
and about 250 are doctorally- prepared researchers (Lage, field note, June 2017). While hundreds 
of low-profile researchers work on cancer immunotherapies and cancer vaccine-related research 
in Cuba, the two authors of the preceding quote, Dr. Agustin Lage and Dra. Tania Crombet-
Ramos, represent the public face of Cuban cancer immunotherapy research, both in Cuba and to 
the outside world. Together, they have published hundreds of articles in the national and 
international scientific literature, in popular science magazines and mainstream media. They 
have been the subjects of numerous interviews in print, online and televised media.  
Over the last decade, Drs. Lage and Crombet-Ramos have published, along with a 
number of co-authors, dozens of articles describing advanced cancer as a chronic disease.  Over 
the past three years I’ve heard them give numerous talks at conferences for oncologists and 
immunology researchers, and cronicidad is mentioned at each one. In Cuba, Dr. Lage receives 
credit for the development and rise of the concept of cronicidad, one which does not distinguish 
between types of cancer and refers not to survivorship but rather to people living with incurable 
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cancers. Dr. Lage is one of the pioneering figures of Cuban biotech, personally tapped by Fidel 
in the late 1980’s (Reid-Henry, 2010). Drs. Lage and Crombet-Ramos are both well-connected to 
the upper echelons of the Cuban communist party.  Dr. Lage is the older brother of Cuba’s 
former Vice President, Carlos Lage, and Dra. Crombet-Ramos is daughter of revolutionary leader 
and former communist party secretary, Jaime Crombet. Together, Drs. Lage and Crombet 
represent the main public voice of Cimavax, Cuban cancer vaccines, immunotherapy and 
cronicidad.   
 Drs. Lage and Crombet speak and write about cronicidad in relation to the specific 
treatments developed at their center: monoclonal antibodies and therapeutic vaccines. These 
treatments were developed to slow the growth of tumors, to extend the lives of patients with 
advanced cancer, allowing them to live longer alongside their tumors. Unlike the drugs produced 
by the multinational pharmaceutical industry, the innovative biopharmaceuticals developed in 
Cuba’s Polo Cientifico were developed in coordination with the Ministry of Public Health 
(MINSAP) to address the country’s most pressing problems. Cuba’s biopharmaceutical industry 
began in the 1980s with the production of traditional vaccinations and moved, along with the 
demographic trends, toward chronic diseases like diabetes and cancer. The Cuban biotechnology 
sector’s development of cancer immunotherapy departs from the trajectories in most other 
regions in emerging from state planning for public health and chronic disease. The country’s 
most successful drugs so far are Hebereprot-P, a gel to heal diabetic foot ulcers, and Cimavax, 
for lung cancer. The model, as described by representatives of the state, is for profits derived 
from the sales of these medications to non-Cubans to be reinvested in the MINSAP. Thus, while 
the industry is not devoid of profit incentive, neither is it is fundamentally structured around it. 
As we will see, the state-controlled structure of the biopharmaceutical industry in Cuba is 
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influenced, yet not defined by, the market. Instead, another dynamic is taking shape here, 
reconfiguring the relationship between time and living and dying.21 
Dr. Lage’s provocation is more than a theoretical justification for the promotion of a 
treatment like Cimavax. Critics, following the anthropological insights developed around 
pharmaceuticalization and the turn to chronic disease management (Biehl, 2007; Dumit; 2012; 
Whitmarsh, 2008; 2013), might cynically discard his statement as a typical pharmaceutical 
industry ploy to grow a market for a treatment. After all, a recent meta-analysis of the clinical 
studies of Cimavax has shown only about a six-month survival benefit (Zhou, Wang, Wing-
Long, Deng, Du, and Zhao, 2016). Yet, while profit is absolutely somewhere in the calculus of 
Cuba’s biotech venture, the design of the system cannot be mapped onto the multinational 
pharmaceutical industry in terms of its premium on maximizing profitability (see the 
Introduction and Chapters One and Four for more details of the system). Instead, as I will show 
in this chapter, taking Dr. Lage’s provocation seriously opens up a new space for thinking 
advanced cancer as subjective and objective entity: humans and their tumors coexisting.  
The idea of reframing cancer as a chronic disease has emerged sporadically in medical and 
advocacy settings (American Cancer Association, 2019; CDC 2018; NHS, 2018; WHO, 2015). 
However, these discussions peg cancer to chronic disease through the idiom of survivorship (or, 
less frequently, to chronic myeloid leukemia, a slow-growing blood cancer notable for its 
 
21 My analysis of Dr. Lage’s elaboration of cronicidad draws on my observation of his speeches 
at six different scientific professional conferences and textual analysis of twelve publications, 
five interviews and two of his single-authored books. Over the course of three years and 
numerous interactions with varying levels of researchers at CIM, I had multiple interviews with 
four researchers working closely with Drs. Lage and Crombet-Ramos.  I place Dr. Lage’s 
published and presented ideas around cancer cronicidad in conversation with an interview 
multiple interviews I conducted with a junior researcher seeking ways to extend the efficacy of 
Cimavax to broaden the population of patients who can achieve cronicidad. 
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susceptibility to suppression by targeted therapies like Gleevac22). That is, they do not focus on 
advanced, “terminal” cancer.  Anthropologists have examined the heterogeneity in experiences 
of survivorship across national, racial, ethnic and cultural divides (Burke, Villero and Guerra, 
2013; Dyer, 2015); they have critiqued the notion of survivor as victor over one’s potential death 
(Jain, 2013); they have examined how narratives of cancer survivorship map onto larger cultural 
shifts valorizing “trauma-induced disruption” as key to both personal psychological development 
and national development discourses in post-disaster zones (Bell, 2013). Cronicidad differs from 
survivorship in specifically seeking to reframe advanced or “terminal” cancer as chronic. As I 
will show in this chapter, this reimagining of advanced, incurable cancer is determined as much 
by social integration as by specific duration of life. Cronicidad opens up a space for reimagining 
the relations between humans, tumors and time. It it softens the line between living (with) and 
dying (from) cancer. In Cuba, these relations, and this (softened) line, also share an enduring 
connection to tobacco.  
The relationship between advanced cancer and tobacco is not controversial. Decades of 
established research have now incontrovertibly established the carcinogenicity of tobacco. 
Tobacco use is globally accepted as an important risk factor for many forms of cancer. Anti-
tobacco scholars and advocates, drawing on resources made available through the pioneering 
research of Dr. Stan Glanz, among others, succeeded in exposing decades of industry-suppressed 
research detailing the links between tobacco and cancer. These efforts have finally begun making 
inroads with global public health measures in support of anti-tobacco and smoking cessation 
 
22 Kaushik Sunder-Rajan’s Pharmocracy (2017) details the legal battle waged in India over 
Novartis’s patent protection laws, tracing the remarkable case as it proceeded through the 
Supreme Court where the right to maintain the reverse engineered copies was upheld in the 
service of protecting the public health. 
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efforts, including raising awareness of the links between tobacco and cancer. Big tobacco 
companies responded to the increasing regulations in the US by shifting their advertising towards 
growing markets in the Global South, especially in Asia where smoking rates remain high. 
Today, vaping is emerging as a new frontier for public health organizations in the campaign 
against smoking.     
In Cuba, by contrast, tobacco remains perhaps the most beloved and celebrated plant for 
centuries. Tobacco’s central role persists in Cuba today alongside the state’s identity as sender of 
doctors and producer of novel cancer treatments like Cimavax. Both biopharmaceuticals (like 
Cimavax) and tobacco occupy shifting spots within Cuba’s top ten in income-generating 
exported goods (Workman, 2018). Extranjeros, or specifically, la Yuma, foreigners with 
money,23 continue flocking to cigar shops even as they grow increasingly curious about the 
expanding possibilities of health tourism, these days especially for Cuba’s cancer vaccines. 
Cuba’s smoking rates are by far the highest in Latin America, while life expectancy and access 
to full-scope, even high-tech, medical care is also among the best in the region. In short, 21st 
century socialist Cuba’s biopharmaceutical and tobacco sectors are flourishing. The insights I 
developed from my ethnographic fieldwork challenge the standard public health prohibitionist 
approach to tobacco. Instead, cronicidad, via Cimavax, suggests a new way for living and dying, 
reframing the relationship between humans, tumors and tobacco into a new term I introduce in 
this chapter: biocompanions. 
In 2015, a barrage of US news media coverage of Cimavax emphasized the supposedly ironic 
juxtaposition of the association of Cuba and its cigars with this new domain of biotech 
innovation. A typical lede ran something like this: “How did Cuba end up with a cutting-edge 
 
23 The term, la Yuma has a rich history and remains an important, if changing term. See Paul Ryer’s 
(2018) most recent book for some of the changing significations of the term. 
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immuno-oncology drug? Though the country is justifiably famous for cigars, rum, and baseball, 
it also has some of the best and most inventive biotech and medical research in the world (Patel, 
2015). Cuba, producer of cigars; Cuba the poor country succeeding at biotech; Cuba where 
scientists make $30-$60 USD per month (yet goods not subsidized by the state, like deodorant or 
toilet paper, are priced at or above US prices); Cuba, with one of the highest incidences of 
smokers and lung cancer, produces a lung cancer vaccine. The Cuban (state) media, by contrast, 
did not portray any contradiction or paradox. A typical story in state media like Cubadebate, an 
online news media website, quoted Dr. Lage, offering an enthusiastic take on immunotherapy in 
general, and Cimavax in particular:    
 He stated that globally, of all patients with malignant tumors, about three percent are 
receiving some form of immunotherapy, and the prediction is that in the coming decade 
this kind of therapy reaches 60 percent. “The question is not today whether immunotherapy 
is or is not effective, but how long and in which patients,” the scientist noted. In statements 
to Prensa Latina, Lage explained that Cimavax-EGF is making its way worldwide. Several 
clinical trials are ongoing in European and Latin American countries, and the interest for 
the product is growing, as that showed by U.S. scientists who recently visited the island 
(Cubadebate, May 12, 2015).  
 
As I elaborated in the Introduction, one analytic throughline in this dissertation draws from 
the socialist science fiction writer China Mieville’s concept of crosshatching. This term, 
developed in his book The City in the City (2009), imagines a mode of seeing in which two co-
existing ontologies/realities are apprehended, where both entities are simultaneously seen, in all 
their complexity. The mental task demanded by crosshatching my argument centers around (at 
least) two central contradictions. These are, roughly: 1) reimagining terminal cancer as chronic 
disease (to be treated with vaccines) and 2) the enduring/chronic importance of tobacco in Cuba, 
in spite of its position as global public health leader. My intention is not to dissolve the tension 
within and between these two ideas. Rather, crosshatching demands that both ontological 
possibilities can and do simultaneously coexist and there is a tension that is not resolved.  
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 I draw the novel approaches to conceiving of cancer as a chronic disease and treating it 
with vaccines together alongside the historical and ongoing importance of tobacco to the island: 
as crop, commodity and, more recently, a key component of biotechnology research. This move 
demands the reader journey along with me in this move of crosshatching: apprehending tobacco 
as a fellow biocompanion, while simultaneously acknowledging the grievous harm and 
tremendous threat to public health caused by tobacco consumption. This chapter draws on both 
ethnographic and textual research with workers involved in tobacco production in Havana and 
Pinar del Rio, Cuba’s principle tobacco region, Cuban cancer vaccine researchers working in 
biotechnology and regional oncologists. In Cuba, tobacco, cancer and the biopharmaceutical 
sector are shaped by the context of socialism, in both its sixty-year tenure, as well as how it 
stands in the twenty-first century.24   
 
The Chronicity of Cuban Tobacco  
 As a healthcare provider from a country that long-ago inculcated a strong sense of the 
idea that one should not smoke, it was hard to be in a country that so relished smoking. As I 
continued following the threads of this vaccine, Cimavax, I found myself constantly enveloped 
in smoke. Cigarettes were the quotidian, profane combustion; cigars the special-occasion, sacred 
smolder. In some circles, Cuba is synonymous with tobacco: the guajiro of Pinar del Rio 
 
24 My use of the term tumor in this chapter requires some elaboration. Tumor, after all, is simply 
a solid mass of abnormal cells, and may be benign or malignant. The term cancer is similarly a 
notoriously imprecise term, and yet, incredibly evocative and communicative. Yet I am choosing 
tumor as my shorthand here, in part, due to the focus of this dissertation on the cancer vaccines 
developed at CIM which are treatments for solid tumor cancers. In this chapter, I use tumor as a 
synecdoche for cancerous cells in general. Tumor, imperfect though it may be, more clearly 
evokes the matter of interest here: a collective of abnormal cells dividing abnormally within a 
particular organism, in this case, the human. 
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harvesting tobacco, the torcedor rolling cigars. Images of Che Guevarra with his Montecristo, 
Fidel with his Cohiba and Camilo Cienfuegos with his Upmann are found on buildings, 
billboards, books, posters and t-shirts throughout Cuba. These are the quintessential images 
cultivated first by tobacco companies, then by the Cuban socialist state, for decades. The scent of 
tobacco pervades Cuban history, religious practice, music, dance, art and literature.   
My early fieldwork experiences forced me to grapple with my relationship with this 
plant. Does Cuban tobacco have anything to do with the evils of the Phillip Morris Company? 
How does one hold the decades of profit making based on intentional suppression of negative 
health effects, the hundreds of patients I’ve cared for who have suffered the effects of their 
addiction to tobacco products, alongside the experience of watching the process of harvesting, 
drying, curing, rolling, burning, consuming and enjoying this plant in the form of a cigar?  Can 
one form of tobacco be so qualitatively different from the other? For many, especially those in 
medicine and public health, or those who have lost a loved one to complications of tobacco (I 
count myself among both groups), anything other than complete condemnation of tobacco is 
considered at best misguided and at worst, complicit. Yet, despite these caveats, my research on 
the biopharmaceutical industry in Cuba continually challenged my antagonism toward this plant.  
Following the scent of tobacco alongside that of Cimavax turned out to be a key element to 
developing my understanding of how Cimavax came into existence, and what it means in the 
context of reframing advanced cancer as a chronic disease. Tobacco also afforded an attunement 
to how many of my Cuban friends and interlocutors coped with their everyday living experiences 
in 21st century Cuban socialism in terms of stress management, celebration, food and pleasure. 
 Cuba’s history is defined, to a large degree, by its relation to tobacco. It is the birthplace 
of global tobacco: the site where the indigenous practice met the European colonizers, according 
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to records from Columbus and his crew (Gilman and Xun, 2004).  Fernando Ortiz, student of 
Bronislaw Malinowski, produced Cuba’s most well-known anthropological book: Cuban 
Counterpoint: Tobacco and Sugar (1940). This herculean tome juxtaposed the artisanal 
cultivation of tobacco with the massive, industrial slave labor production of sugar, inseparable 
from the brutal conditions of slavery responsible for the death of millions of Africans and their 
descendants. Ortiz delves into tobacco lore, exploring ritual use among the indigenous peoples of 
the Caribbean, early spread to slaves on the island, then to the Europeans and, finally, to the 
African continent. He reminds us that the life cycle of tobacco and humans has long been 
intertwined.    
As in any other invention, there had to be certain natural and certain social factors that were 
closely linked. The natural factors that gave rise to the use of tobacco by man were the 
unique physiochemical properties of the plant and intense physiological effects on the 
human organism…These effects can be reduced to two: the sensual pleasure derived from 
it, and its medicinal utility (Ortiz, 1947: 184).  
 
Cigarettes and cigars form the poles of tobacco consumption on the island. Historian Jean 
Stubbs traced five hundred years of tobacco cultivation, focusing particularly on the labor 
conditions of tobacco workers in the colonial era (Stubbs, 1985). To argue for the importance of 
tobacco to Cuba is neither necessary nor important; it is obvious. Instead, what I propose in 
crosshatching tobacco and biotech is a reordering, or perhaps, reimagining, of the relations 
between humans, tumors and tobacco. To think tobacco and tumors as elements of quotidian life 
in Cuba is to destabilize an attachment to a particular imaginary of the human, one widely 
championed even in public and environmental health, as the ultimate protagonist against an 
onslaught of earthly foes.  
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Chronic Economic: Formal and Informal Encounters Between Tobacco and Tourists 
 In Cuba, tobacco endures, it is pervasive, insinuating its way not only into bodies, but 
also throughout everyday social and economic relations. Pinar del Rio is the prime tobacco 
producing region in Cuba. The lush countryside with valleys of farmland sloping into enormous 
mogotes, strangely uniform verdant plateau-formations, is a popular tourist draw. Viñales is the 
regional tourist hub. The area maintains traditional, non-mechanized agricultural methods, 
thought to produce the highest quality tobacco, affording the Valle de Viñales UNESCO cultural 
heritage recognition for the twinned preservation of land and tradition. The Valle de Viñales 
indexes an idea of a timeless Cuba: the iconic image of the guajiro working the fields is legible 
from the colonial through the Revolutionary era.  
In recent years, Viñales has become so flooded with cigar tourism as to become almost 
suffocating for locals and tourists alike. On arriving by bus, I was greeted by about fifty women 
holding laminated signs advertising their rooms for rent who greeted me immediately by saying, 
“maybe later?” a clear reference to the pat declination they receive from the bulk of tourists who 
have likely booked their rooms in advance. In Viñales, hundreds of small, tidy homes line the 
narrow dirt roads bearing a sign: Arrendedor Divisa, indicating they rent to foreigners. Each 
home was almost an exact copy of the others: two rocking chairs on a porch, surrounded by a 
white picket fence. Some homes were freshly painted, others stood in varying stages of 
construction or decay. Usually, someone was sweeping a cement porch. In short, this was a town 
built around, and flourishing from, tobacco tourism.   
In 2016 I arranged a guided tobacco farm tour in Viñales. My guide was Armando, a 
skinny young man with a college degree in engineering. Like many young, educated men in 
Cuba, Armando said he could not afford to use his education to advance a career in engineering. 
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Instead, he contributed financially to his extended family by working in tobacco tourism. 
Armando led me on a typical tobacco plantation tour: a four-hour ride on a painfully bony horse 
through the gorgeous, green valley. As we rode through the farmland, we made stops along the 
tour where we would connect with one of his socios. A socio, which is very is a widely used term 
in Cuba, is a trusted, usually informal, business-type relationship. It connotes a hybrid social-
economic relationship of mutual benefit in the informal sector. Each stop with a socio provided 
an opportunity for economic activity around this tobacco tour. 
 En route to the tobacco plantation, Armando led me to what looked like an abandoned, 
dilapidated two story building in the middle of the forest. As we dismounted our horses and 
walked inside, Armando introduced me to his socio, Jorge. Jorge was a handsome twenty-ish 
year-old man with perfectly coiffed hair, who donned a leather jacket in the sweltering heat of 
summer and wore sunglasses during the day alone in the shack. Jorge, like Armando, was highly 
educated, with a master’s degree in computer science. His carefully crafted urbane appearance, 
jarring in the jungle shack, lent an air of sophistication to an otherwise haphazard and rustic 
scene. Jorge handed me a wrinkled piece of paper serving as a menu advertising a cocktail 
fashioned from local aguardiente. Naturally, as the only customer in the shack, I paid the 
(extravagant price of) three dollars for it. As the three of us sat around a small, wooden table, 
Jorge and Armando each recounted stories to me about how their grandparents used to own and 
work their relatively large tracts of land in the region. For generations, their families had worked 
the land, growing tobacco. With the revolution, both men’s families lost the vast majority of their 
land to the state, which repurposed it for the nationalization of tobacco production. Also, with the 
revolution both families achieved new educational milestones. With universal free higher 
education, both men had attained master’s degrees. Jorge has a degree in computer 
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programming, but he makes money in this lone shack in the forest, serving three-dollar cocktails 
to people like me. Armando makes his living providing these horseback tours from his family’s 
horses: four in total, none of them healthy looking. Both men could speak extemporaneously on 
the subject of the local land and tobacco cultivation. Neither smoked cigarettes. Both enjoyed the 
occasional cigar.   
After the shack stop, Armando led me to the next socio, a local farmer. Jesus walked me 
up and down the rows of tobacco plants, then took me inside a barn where hundreds of leaves 
were strung up on twine, drying. He took a spray bottle filled with rum and vanilla, misting the 
leaves. Later we sat together at a table, and he taught me how to roll a cigar. Then we sat down 
with Armando and two other farmworkers and had a drink of rum and smoked one of these hand-
rolled, country cigars. My interactions with these three men in Viñales are only notable inasmuch 
as they are common. And yet, they illustrate the enduring importance of the tobacco economy, 
the persistence of its ties to land and labor (now as much through tourism as through agriculture), 
even when higher educational opportunities are abundant and available, given the inverted 
economic structure of the extant iteration of socialism in Cuba today.  
 Tobacco smoke lingers and wafts in uninvited, embedding its scent in everything it 
touches. Likewise, tobacco economics can insinuate themselves into unexpected encounters with 
tourists, blurring the lines between charity and commerce. Whereas a tourist heads to Pinar del 
Rio for the tobacco experience, as an extranjera in Cuba, tobacco emerged in many of my 
informal economic encounters. I experienced these types of interactions relatively frequently in 
my first few trips to Habana Vieja, a tourist-dense section of the city. One Sunday in June 2016, I 
walked through Centro Habana toward Habana Vieja, and a thirty-something, Afro-Cuban 
woman in a skin-tight tank dress began walking closer to me. “Vas a festivar (are you going to 
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party), she asked?” “No se (I don’t know),” I replied. I was mostly wandering, but I suppose I 
could have been convinced. As we walked alongside each other, she told me her name was 
Jenny; she was a teacher and she liked to party.  
Jenny trailed me as I walked toward the tourist zone of Callejon de Hamel. Every Sunday 
at 11:00, this art-installation alley, designed by an artist who maintains his residence and studio 
there, becomes a living mass of human movement and music, as locals and tourists press into 
each other, through alcohol, cigarettes and cigars, to enjoy the weekly rumba music and dance 
performance. This was only my second trip to Cuba and my jineterx25 radar was not particularly 
well-developed, otherwise I might not have continued to walk and banter with her. As we 
continued through the small alleys meandering toward Callejón, she asked me if I wanted to buy 
any cigars. I said I didn’t smoke, but I was an anthropologist interested in talking to people about 
cigars, cigarettes and smoking. “Tengo un amigo que tienes que conocer (I have a friend you 
have to meet),” she said. We pressed through the expanding jostle of the crowd of tourists and 
Cubans toward a few apartments right in the center of all the excitement of the impending rumba 
performance. She yelled in through the iron gate for her friend, Ramon. Jenny introduced us, and 
Ramon agreed to an interview over a meal, which I bought, as the first financial element in what 
turned out to be a tobacco encounter.     
Ramon was Afro-Cuban, married and he had an eight-year old daughter. He was born and 
raised in Havana. He told me, “On the fourth of July, I’ll be 46 years old, the day of 
independence of the United States. I’ve worked for 23 years in the cigar factory. I’ve passed 
 
25 Jinetero/a (or jineterx to use a non-binary form, my preference), originally was a term of 
reference for Cuban sex workers working with tourists. Over the past decade or so, however, use 
of the term has amplified to refer to a broader range of Cuban-tourist interactions in which some 
form of hustle is involved. 
   97 
through all the processes. I was a torcedor (cigar roller), later a supervisor. Now I have a group 
of workers and I teach them the process of tobacco. I’m like a professor of the factory.”  
I asked Jenny and Ramon if they smoke.  
Jenny: No, I don’t smoke.  
Naomi: Why not?  
Jenny:  Well, normally I don’t for health reasons, but I do like Habanos (cigars) 
because they are the most healthy. It’s just the leaf, totally made from nature. Only 
when I go to weddings, parties, anniversaries…that’s when I smoke a cigar. It is 
healthier than cigarettes because cigarettes have a lot of chemicals, but cigars, on 
the other hand, have no chemicals. It’s just from nature without any type of 
chemical.  
Ramon (explaining how he knows cigarettes are not healthy): I used to smoke four 
packs a day. Now I smoke two.  
 
About twenty minutes into the interview, Ramon made me an offer I would get many 
times over my visit: the chance to get the “high quality name brand Cuban cigars” at a fraction of 
the price through a “cooperative,” also known as the black market. He explained how we both 
would benefit if he took me to the cooperative house. “At the cooperative houses its 
cheaper…and you get a commission. They don’t give you money, but they give you extra ration 
tickets for more beans, rice, oil.”  The tickets are part of the libreta, the state rations afforded to 
every Cuban citizen.  He elaborated on the importance of this supplement, “ The amount they 
give you for a month, it’s gone in seven or eight days… At the casa cooperativa, you get extra… 
You need this when you have kids.”   
 Ramon’s scheme- obtaining customers for black market cigar sales in order to earn extra 
tickets for the libreta - was one I encountered a few times during conversations with Cubans 
hanging around tourist areas.  Tobacco fuels the formal and informal economy. He explained: 
If I bring you, for example, they give me a ticket and they give me rice, beans, oil…food. 
Food is really difficult in Cuba. They give you, for one month, seven pounds of rice and 
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half a pound of oil. It’s very little. But with the cooperative houses, if I bring you, I get a 
commission and food… The rations they (the state) give you is very little, and it doesn’t 
last a month. After seven or eight days, you run out, you have to buy things and the cost is 
high. The salary of Cuban workers is really low, it’s 14 or 15 dollars per month, you 
understand me? So, here, the Cuban lives to eat. Everyone lives for eating. And those with 
kids, for three years they give you milk, then after three years, the milk disappears. Milk is 
really important for the child. But in the cooperative house, in the ration they give you, you 
get milk, oil, chicken. To eat is to live. It’s a pity but that is how you live. It makes you 
crazy. 
 
Tobacco encounters like this one (focused on cigars) prop up a socialist economic system 
that no longer meets basic needs. Cigarettes, on the other hand, are easy and cheap and 
subsidized by the state. Cigarettes were part of the libreta, the coupon book of rations, basic 
goods provided for free by the socialist state for many years, ending only within about the last 
decade. The state controls tobacco production and distribution. Yet while they are no longer 
provided for free, the price of cigarettes is still so cheap that the cost is negligible, like riding the 
bus. Ramon explained, “A carton of cigarettes costs seventy cents. Every three months you spend 
seventy cents. This leads to the situation that people will keep smoking, more or less. The Cuban 
lives a very stressed life. Do you understand me?”  
 Ramon and Jenny’s attempt to sell cigars through the casa cooperativa falls within the 
genre of jineterismo, the tourist hustle. It is not a particularly special or rare interaction. Cuban 
cigars fuel the formal and informal economy. They provide pleasure, they provide food. The 
quotidian, processed Cuban tobacco of the cigarette, from Ramon’s perspective, is, unlike food, 
available and accessible. Armando, Jorge and Ramon’s stories show some of the ways that 
tobacco is woven through historic and present-day concerns in Cuba: land, labor, food and 
pleasure, through state-sanctioned and so-called informal, yet clearly state tolerated, channels.  
Valerio Simoni (2007) similarly finds tobacco a familiar participant in the context of tourism and 
informal encounters on the island. Tobacco-human relations pervade so much of everyday life in 
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Cuba: factory work, inclusive of both artisanal and proletariat elements, the hustle with tourists, 
tobacco as appetite suppressant, tobacco as informal provider of supplementary food in these 
days when the socialist state persists but no longer provides enough.  
Tobacco State/ State Tobacco 
 Cuba is one of sixteen countries in which the tobacco industry is state controlled.26 Of 
those sixteen, Cuba is an outlier as the only one in its geographic region and the only country 
known for its impressive national and global public health efforts. While Cuba works closely 
with the WHO on most public health goals, it is the only country with a significant state-owned 
tobacco industry which has not ratified the WHO Framework Convention on Tobacco Control 
(Hogg, Hill and Collin, 2016). More recently, the sector has developed some connections to 
foreign investment for the export of its tobacco. Cubatabaco, the shortened name for Empresa 
Cubana del Tabaco, formed in 1962 (Wikle, 2015), is the state-owned entity which handled all 
tobacco production and distribution until 1994, when Habanos SA was formed to handle the 
export of cigars and cigarettes. Habanos SA is a joint venture, 50/50, co-owned by both the 
Cuban state and a Spanish-owned company called Altadis, itself owned by Imperial Tobacco 
Group PLC, in turn owned by British Tobacco Company.  
The ideal of the socialist state as provider in Cuba continues to have significant currency, 
despite decades of gradual decline in most areas except the health sector. The contrast, then, 
between the expectation that the state provides and the reality of the 21st century economic 
changes of increasing privatization and growing inequality, provoked anger and cynicism in 
many casual conversations in which the subject of the state came up spontaneously.  The libreta, 
 
26 The other countries are: Algeria, Bulgaria, Bosnia-Herzagovinia, China, Egypt, Iran, Iraq, 
Korea, Libya, Republic of Moldova, Syria, Thailand, Tunisia, Vietnam, Yemen (Hogg et al, 
2016). 
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in terms of the content and quantity of food supplied by the state, was a subject of critique across 
many casual conversations I had in Havana. Yet, in spite of the perceived inadequacies, the 
Cuban socialist state continues its role as provider of food, medicine and tobacco. When my 
interviews with Cuban science fiction writer Yoss (a nonsmoker), known for his thinly veiled 
critiques of both socialism and capitalism, turned to the subject of tobacco, he opined, “It’s not a 
secret to anybody that Cuba has one of the highest rates of smoking. The thing is that it’s difficult 
to combat when the export of tobacco is one of the main sources of revenue for the state. I think 
the Cuban government finds itself at a moral crossroads: you can’t make a campaign against 
tobacco and keep selling Habanos.” Yet his characterization of the state’s “moral crossroads” did 
not prevent him from elaborating on some positive qualities of Cuban cigarettes:  
The good part of tobacco here is the black tobacco. This is what is used in the cigar.  Cuba 
is one of the only countries where you find black tobacco in packets of cigarettes, instead 
of red tobacco. [Cuban cigarettes] have a lot fewer chemicals, although this doesn’t mean 
they’re not carcinogenic. They keep causing cancer and also the problem that the tobacco 
is much more pure and therefore more addictive than the commercial cigarettes of many 
other countries. Black tobacco has a much higher concentration of nicotine than red 
tobacco and obviously it is more addictive.  
 
He continued:  
It’s rare for a Cuban to keep smoking up to age fifty without lung problems, not always 
cancer but at least emphysema. Cancer is just the most serious and visible but there are all 
sorts of illnesses associated with tobacco consumption, with a very high incidence in Cuba.  
What can the government do? Obviously, they can’t do anything. It is widely known from 
the time of the Prohibition laws in North America that you can’t prohibit alcohol or tobacco 
without starting a revolution. And the Cuban government is not interested in generating a 
great discontentment.  
 
 Cuban tobacco is prized for purity, for its naturalness. Even the Cuban cigarette, in Yoss’s 
description, with its higher content of black tobacco as opposed to red, is praised for the more 
“natural,” less chemical content, in spite of its acknowledged carcinogenicity.  The Cuban 
socialist state maintains control of production and distribution of tobacco: the agricultural 
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production, the maintenance of Valle de Viñales as a seat of cultural patrimony, the cigarette 
factories, the cigar factories, official cigar tourism, and the pricing and availability of cigarettes 
to its citizens, and more recently, the state is involved in tobacco research in the biotech hub of 
the polo cientifico.  
 The vignettes above illustrate the chronic entanglement between people and tobacco in 
the Cuban context. One particular theme raised by all the interlocutors involved: Armando and 
Jorge; Jenny and Ramon; and Yoss, was an emphasis on Cuban tobacco’s value in terms of its 
“natural” qualities.  As the next section will show, these claims to naturalness and purity are now 
being contested and renegotiated in the domain of biotechnology, where tobacco shapes 
treatments in multiple ways.  
 
Tobacco: The Ur Substrate of Biotech 
At the 2017 Vaccifarma conference in the Meliá Hotel in the beach resort town of 
Varadero, hundreds of Cuban scientists and health professionals mill about, accompanied by a 
smaller number of researchers and professionals from the exterior, mostly Europe, North 
America, a smaller handful from India, Japan and China.  The keynote speaker was the North 
American oncological researcher from RPCI working on the Cimavax trial, Dr. Kelvin Lee, who 
spoke of a new era of immunological cancer treatments. Other presentations highlighted new 
campaigns to eliminate streptococcal infectious in neonates; the head of Cuba’s national vaccine 
program emphasized her nation’s leadership within WHO and PAHO as a standard setter for 
safety and quality of immunizations. On the third day, as dozens of sessions ran concurrently, 
audiences thinned as participants wandered out toward the beach or lingered longer over piña 
coladas and mojitos in the lobby. A session themed around vaccine production ran in one of the 
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smaller conference rooms in the late morning, holding maybe sixty to eighty chairs, about one-
third full. In this session, Rodolfo Valdes Velez from the Cuban Center for Genetic Engineering 
and Biotechnology (CIBG), delivered one of several talks in the panel.  I walked in late, and 
from my read of the crowd, I seemed to be the only extranjerx in the room. Whereas all the other 
talks I observed over the past three days were delivered in English, the first speaker on the panel 
started off asking if anyone in the room didn’t speak Spanish. No hands were raised, and the 
panel proceeded along in Spanish. Dr. Velez’s talk focused on tobacco transgenic plants. He 
described his twenty-eight-year career working on monoclonal antibody production at CIBG. Dr. 
Velez specializes in making antibodies for hepatitis B from tobacco plants: planticuerpos 
(“plantibodies”). His selling point: cost effectiveness. His slide highlighted the cost savings 
compared to the mouse model—half the price! Dr. Velez was just the first of several of the 
interlocutors I encountered over the course of my research, both on the scientific and clinical side 
as well as the regulatory side, to highlight Cuban achievements in manufacturing tobacco 
“planticuerpos.”  
Vaccine researchers Dania and Vladimir (from Chapter One), biochemist and pharmacist, 
respectively, brought up the subject of tobacco in biotech. Both Dania and Vladimir described 
how, as Cuban biotech researchers, they think about some of the issues arising in this new 
direction for tobacco on the island. In Dania’s words:  
The thing to see is that there has been this conflict in Cuba…because in the whole 
world tobacco is the vegetable model for biotechnology.  It’s not that you have to 
change tobacco, it’s that the plant is very easy to genetically modify…It is the 
model they use for vegetable biotechnology.  In Cuba for a long time this meant a 
conflict. They wouldn’t develop vegetable biotechnology because they would not 
modify tobacco…The tobacco industry [here says] “the tobacco is natural.”  So 
here they’ve put the brakes on this. They put the brakes of technological 
development in order to not affect the tobacco market. At times you want to obtain 
a transgenic plant and you would like to try it first in tobacco, because tobacco is 
what you can modify most easily, it is the model. We who research in bacterias have 
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the bacteria model that you use for everything, what is the most easy to manipulate 
in the lab, is E. Coli. Tobacco is like E. Coli, it’s the model.    
 
Vladimir, on planticuerpos: 
 [A]nother thing… That is not to modify the tobacco, but to use the tobacco as a 
factory.  You can make antibodies that can be a therapy for cancer, using the tobacco 
like a factory. Because tobacco is the biotechnology model worldwide…Its the 
vegetable tool for biotechnology, the plant most use to produce things, to try them 
out. If I’m going to try and genetically modify roses, roses are difficult to 
manipulate in vitro, so I will first try it out in the tobacco plant.  
Dania: 
It’s easy to cultivate, it grows in lines, so you can select whatever portion, put it in 
a plaque and cultivate and grow it. Not all plants grow that way. It’s very simple to 
manipulate, it’s the model worldwide.  
Naomi:  
Do you think there’s any connection between this natural resource and the success 
of the biotechnology sector here or that it’s purely coincidental? 
Dania:  
Pure coincidence. This is something everywhere in the world…I don’t know who 
discovered it… In Cuba at first there were conflicts, because one area of work 
develops that says, “we are going to modify tobacco.” “No, tobacco no you can’t 
use.” “Yes, you have to use it because it is the model…” “No, you can’t use it.” 
Until they understood that, yes, they had to use it, it is the model.  
Vladimir:  
Also, at the end public opinion on genetically modified tobacco in Cuba is very 
diverse.  The people don’t understand modifying tobacco.  
Dania:  
Of course, a transgenic tobacco is not going to have a market. You will never sell a 
transgenic Habano.   
 Dr. Yasmin Thanavala is a senior researcher at the RPCI involved in the collaboration 
with CIM.  She, too, has had a longstanding interest in exploring the potential of tobacco in 
biotech research.  We met initially at a dinner co-sponsored by CIM and RPCI in Havana for 
researchers from Cuba, the US and Canada. Several months later I had the opportunity to 
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interview her at Roswell Park in Buffalo, New York. Dr. Thanavala described how, early in her 
career, she collaborated on research into the expression of antigens through tobacco plants. This 
line of research was abandoned, however, as any connection with tobacco was felt to be 
incompatible with the greater aims of RPCI.   
 As Dania, Vladimir and Dr. Thanalavala make clear, Cuba is not unique in working with 
the tobacco plant in biotech research.  Since the early 1990s, a growing number of biotech 
companies have been working on finding new uses for tobacco. Canadian company Medicago set 
up shop in the Triangle, producing recombinant vaccine antigens in tobacco plants, and North 
Carolina also established a partially state financed and controlled biotech center to work with 
tobacco. A new product called Synshark is using tobacco to manufacture omega-2 oil, sparing the 
over-fishing of deep-sea sharks (Creager, 2015). As these planticuerpos continue making their 
way into vaccines and medical therapies, the tobacco plant is entering a new realm of relations 
with and beyond humans.   
 
Tobacco Relations  
  The depth and breadth of tobacco-human relations are particularly visible and legible in 
Cuba. These relations are complex and nuanced: tobacco is plant, crop, material, ceremonial 
object, chemical, drug, commodity, antibody factory, immunotherapeutic substrate.  
Crosshatching enables us to simultaneously apprehend these complexities alongside the other 
face of tobacco increasingly visible over the past thirty years: tobacco as foe, toxin and powerful 
lobby. Decades of excellent research led by dedicated epidemiologists like Dr. Stanton Glantz 
have exposed the malevolence of an industry so consumed by profit-making that it suppressed 
and attacked the research and concern of scientists and health professionals for years, causing 
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hundreds of thousands of untimely and unnecessary deaths.  Decades of thoughtful public health 
scholarship, investigative journalism, intimate ethnographic examinations (Benson, 2011), 
applied anthropological studies (Nichter, Mark 2003; Nichter, Mimi 2015), and even mainstream 
Hollywood cinema (Thank You for Smoking, 2005) reconstruct and elucidate the mechanisms 
through which the tobacco industry has created and manipulated data and even co-opted 
scientific research to advance the spread of a harmful and addictive product responsible for 
millions of deaths. Whereas the critiques of the tobacco industry hinge on its identity as profit-
making entity, in Cuba, by contrast, the population health-minded revolutionary socialist 
government continues to subsidize cigarettes and permit smoking in many public spaces, even as 
it champions a vaccine developed for lung cancer.  In the face of persistent food shortages, a 
reasonable argument could (and has) been made that state subsidization of tobacco staves off 
rampant popular discontent fueled by hunger. This is not wrong. Yet, with crosshatching we can 
see it is just not the only ontological possibility.  
 Tobacco is a carcinogen.  The chronic relations between people and tobacco evident in 
Cuba are intimately involved with the chronic relations between people and tumors. More 
recently, tobacco has become integral to the biotechnology sector writ large. Cuba’s socialist 
biopharmaceutical sector, following the directives of the Communist Party, invested significantly 
in developing treatments to meet the country’s most pressing needs. One of the country’s most 
pressing concerns was lung cancer. Returning now to Dr. Lage’s provocation, that incurable 
cancer be reframed as a chronic condition through cancer vaccines like Cimavax, we will see 
how Cuban socialism enables something like cronicidad.  
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Cronicidad and Integration 
Novel, Cuban-made cancer immunotherapies, including therapeutic vaccines, are 
increasingly included in treatment protocols for Cuban citizens through the MINSAP.  Such 
protocols are not only found in major oncology centers in metropolitan areas like Havana, but in 
the smaller regional medical centers of the provinces as well. Cubans across the island with 
advanced cancer are connected to the appropriate regional facility, and many are invited to 
participate in clinical trials with novel immunotherapeutic agents or new combinations of known 
agents (Graber, 2018). The closed system of both research and care under the auspices of the 
socialist state facilitates a relatively seamless relationship between basic oncology care and 
clinical trials. Conversely, new treatments, once approved by the Cuban regulatory body 
(CECMED), are available as part of the universal health program.  
Drs. Vega and Ortiz staff a small oncology clinic in a mid-size industrial city several 
hours from Havana. Dr. Ortiz, a tall and robust radiotherapy oncologist in his mid-fifties with 
immaculately groomed silver hair, has spent the greater part of the last twenty years working in 
this clinic, apart from a few years on a medical campaign in Zimbabwe. Dr. Vega, by contrast, is 
a relative newcomer to the clinic, having spent just six years in this town, although it is just an 
hour from where she grew up. She is the clinic’s medical oncologist, responsible for ordering and 
supervising chemotherapy as well as the protocols for any therapeutic vaccines or other 
immunotherapeutics given. When I interviewed them at their clinic across the street from the 
regional hospital, they were taking a lunch break upstairs in their small, air-conditioned office, 
enjoying the respite from the brutal heat of Cuban summers. Downstairs in the open-air waiting 
room, a dozen middle-age and elderly patients sat in plastic chairs, fanning themselves, biding 
time until the doctors came back from their break.   
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 Like most people I spoke with involved in Cuban biopharmaceutical research, Dr. Vega 
acknowledged that Cuba, while advanced within the context of the Global South, sometimes 
lacked the latest class of immunotherapeutic treatments for cancer (for example checkpoint 
inhibitors and Car-T therapies). Yet, the range of treatments and experimental protocols available 
to patients in her small clinic facilitated a sense of satisfaction for Dr. Vega, knowing she could 
offer her patients an array of good options.  She explained,  
we are passing into personalized medicine… We can know the molecular biology 
of each tumor and the treatment will be specific for the DNA that this tumor 
expresses. The patient can have control and be stable for a long time. They can be 
like you are when you have a chronic illness. The idea is that the patient, after 
survival with a [good] quality of life, can die with the tumor but not from the tumor.  
 
Dr. Ortiz added, “I remember a case… [t]his man lived with stage four cancer for ten years. He 
was integrated into normal society.   
Dr. Ortiz’s emphasis on integration captures something of the aspiration of cronicidad: 
the ambition to live socially with advanced cancer. In his vision, the patient with advanced 
cancer can live with their tumors, held in check for some unspecified period of time, through 
therapeutic vaccines. In Dr. Ortiz’s example, the notable temporal length of this particular 
patient’s chronicity enabled his social integration. However, the specific duration of a given 
patient’s life alongside her tumor is not the hallmark of cronicidad. Instead, it is the 
reimagination of that unspecified time period as one with the potential to be enfolded into 
“normal society.”   
 The synchronicity of understanding between a national leader in oncology research like 
Dr. Lage and regional clinicians like Drs. Ortiz and Vega speaks to the highly coordinated 
program of state-run healthcare and research. In Cuba, centrally controlled programs and 
messaging are, in-part, hallmarks of success: the program of universal primary and specialty care 
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is credited with generating health statistics that place Cuba among the ranks of much wealthier 
nations. Yet, to dismiss cronicidad as message or propaganda would represent a failure to 
recognize something more interesting at work in the increasing deployment of this term in 
Cuba’s oncology research circles. When leading researchers like Dr. Lage and small-town 
oncologists like Dr. Vega speak of cronicidad, they are participating in an aspirational reframing 
which reimagines the experience of living alongside tumors, within communities. 
 
Cronicidad is Public Health 
  During the course of a week in April 2018, over a thousand healthcare researchers and 
professionals, mostly from Latin America, gathered at the Palacio de Convenciones in Playa, 
Havana for the CubaSalud Conference. The conference featured hundreds of presentations on a 
range of topics of interest to practitioners and scholars of public health, from bioethics to health 
economics and zika. Six of these talks focused on the role of biotech in public health. Dr. Lage 
gave many talks and interviews over the course of the week, connecting Cuba’s 
biopharmaceutical cancer research to public health concerns such as cancer control, followed by 
an elaboration of the specific treatments developed at CIM.  Cimavax and Vaxira, used for lung 
cancer as well as in protocols for head and neck tumors, Cimaher for breast cancer, and the other 
therapeutic cancer vaccines developed at CIM are touted for their contribution not just to 
additional months (as the international peer-reviewed journals attest) or possibly years (cases in 
the national scientific literature portray Cubans who have survived up to 10 years with stage four 
lung cancer using Cimavax). The vaccines are promoted for their safety and lack of side effects: 
their contribution not just to additional time to live, but to quality time of living (Lage-Davila, 
2011; Zhou et al, 2016; Saavedra et al, 2018).   
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 Dr. Lage’s talks began with the reminder of the local “ecology” of Cuban biotech: the 
framework in which biopharmaceutical research and development is linked to public health 
needs and the national health system. Since cancer is a leading cause of morbidity and mortality, 
extending the idea of a public health approach to include high-tech treatment is possible because 
of the still extant socialist system of health care and the state-controlled pharmaceutical industry.   
Cancer screening and treatment are reinterpreted as public health in Cuba according to 
available resources and logics. Gibbons (2011; 2016) explores the reinterpretation of 
individualized, molecular genetic screening and diagnosis from the Global North as an expansion 
of extant family history interviewing practices by public health workers formerly reserved for 
maternal-child health screening in Cuba, enabling a population-based proxy for hereditary breast 
cancer detection. Graber’s (2018) work examines how the integration of state-run clinical trials 
into public health in Cuba brings biotech into neighborhood health centers. These scholars 
highlight the public health infrastructure underlying the “ecology” facilitating the possibility of 
cronicidad as described by Dr. Lage above.  
Cronicidad enlists a population with advanced cancer as a target demographic of public 
health. Such a move reframes terminal as chronic, demanding a shift in the relations between 
temporality and prognosis. Following the logic of the speakers from CIM at CubaSalud, 
including Dr. Lage, could stage four lung cancer be on par with a chronic disease like diabetes? 
Or, perhaps a condition more recently associated with death, HIV? Cronicidad is distinct from 
both the idea of management in diabetes, meaning control of blood sugar and prevention of 
complications, or the control of HIV through the suppression of viral load and prevention of 
transmission.  
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Cronicidad departs from both chronic disease and survivorship. What renders cronicidad 
unique is that it does not deny the ‘dying from’ that continues in the ‘living with.’  Instead, 
cronicidad becomes part of a “normal social:” where we are all living with and dying from this 
life.  By enfolding cronicidad into the language of public health, Drs. Lage and Crombet invite 
the participation of a new, hitherto unformed public: a population both living (with) and dying 
(from) cancer.       
 
Stretching Cronicidad 
 
Conceptually, cronicidad encourages a reinvigoration of the temporal relationship 
between person (host) and tumor or malignancy (unwelcome guest). Part of the work of 
cronicidad within the Cuban biotech sector involves searching out ways to extend cronicidad: 
further into the future, to broader populations.  CIM, with over a thousand researchers, runs 
dozens of clinical trials, many of which involve minor tinkering with existing products approved 
years ago such as Cimavax. Researchers at CIM have identified molecular signals pointing to 
greater possibility for attaining cronicidad in the robustness of anti-EGF antibody response to the 
vaccine. The likelihood that Cimavax will help a particular patient depends on the person’s 
development of antibodies in response to the vaccine, and the best responders are those who 
achieve the highest antibody titer (Saavedra and Crombet, 2017). The non-responders or the low-
responders, typically geriatric patients, remain a challenging population for researchers at CIM, 
as the immune system wanes with age. On an aging island with an inverted demographic 
pyramid, centering the elderly is essential. Where Cimavax was created almost twenty years ago, 
it remains, at least as of 2020, the most promising and popular of the therapeutic cancer vaccines 
developed in Cuba.  
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 Aymara is a junior researcher at CIM, having recently completed her master’s research 
project. When we first met, she was waiting for the official release from her clinical position as a 
physician within the MINSAP to begin her job as a research scientist working with Cimavax.  
Like a majority of the clinicians and scientists I met at conferences and events surrounding the 
Cimavax project, Aymara was a young Afro Cuban woman. When I remarked to her my 
observation that the majority of young researchers in this area seemed to be women, she 
confirmed it also reflected her own experience and that, in her opinion, this was because 
increased financial pressures felt by men led them to pursue work in the tourist (hard currency) 
sector.  Indeed, Aymara’s perspective mirrored others I’d heard casually from female physicians 
and scientists over the course of the five years I spent working on this project. Many shared that 
their careers were premised on another member of the family having access to US dollars or 
Cuban convertible currency or CUCs (linked to the US dollar and considered more stable), either 
from remittances or through working with tourists.  
  Aymara’s research area is one of many lines of investigation at CIM devoted to 
extending the utility of existing patented Cuban therapeutic cancer vaccines and thereby 
facilitating the expansion of cronicidad. Her research aims to improve the response for those 
patients, especially older adults, who do not mount a powerful immune response to the vaccine. 
This problem relates to a phenomenon called immunosenescence, the waning of immune 
responses with age. We agreed not to talk about any specifics of her research, so she could 
remain anonymous and also so as to not enter into the sensitive terrain of intellectual property.  
Like many clinicians and researchers in oncology, Aymara coped with the stressful demands 
of work by holding the idealism that brought her to the field in the forefront of her mind.  She 
explained:  
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[Cancer is] the at the root of my investigations because really it is a very common 
illness worldwide that…takes away family… Really you have to work a lot because 
it generates so much sadness. This is another thing that motivates me. Not just 
families but sick children with cancer. This hits me with so much pain. There are 
few things in this moment that we can do, and the therapy is not always the cure that 
we want. Regression of disease is not what we are hoping for. The evolution [of 
treatments] at times is twisted…For example, when we try a medicine and the 
moment arrives when we analyze the results to see if it worked or not. An experiment 
can give you favorable results but then it doesn’t happen again. Sometimes nothing 
happens. Then there’s this point where there’s a very good result and I think I’m 
really doing what I set out to do.  I’m also doing it when the result is not good 
because at least it’s information that tells us that: ‘down this road you won’t see 
things.’  It’s the information. In this way your work always goes according to what 
you have in mind. 
 
If there were some change or there has been an effect… you analyze all the patients 
in general although there are analyses also of each patient in various moments…you 
have a vision of everything in general in each patient in their moments: before 
initiating treatment, after chemotherapy, after the Cuban product that they are using 
in this moment. And after three months, from the three months to the six months to 
the nine months seeing how the response evolves and how (the patient) has 
maintained during that time. For how long they maintain, how they seem, this order. 
This way.  
 
Aymara conveys the tension between the inspiration and the reality of her career in research 
oncology: her desire to intervene against cancer as foe and killer, in conflict, to some degree, 
with treatments less-than ideal (“not always the cure that we want.”). As a young idealistic 
physician, her pathos pivots, along with her career, toward the orderly, measurable data points of 
the trial. Aymara’s marking of time is rhythmic and expectant, aligned with the ideal type of 
orderly clinical trials. Measuring antibody titers, intervening in immunosenescence, are clinical 
tactics to extend the efficacy of therapeutic vaccines and cronicidad. Three months, six months, 
nine months… temporal markers march out aspiration, results chart iterations written in between 
life and death.  
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The Mutability of Cancer Time 
Operating within the strictures of a clinical trial, Aymara charts the heterogeneous 
response of patients in regular intervals. As points of data for a clinical trial, the length of their 
survival must be specifically and accurately measured. Yet, the cronicidad invoked by leading 
researchers like Drs. Lage and Crombet, and practicing oncologists like Drs. Ortiz and Vega, 
refuses measurement, even measured prognostication in life expectancies and probabilities. 
Instead, it offers a reorientation of the temporal experience of cancer in relation to an indefinite 
and yet finite, future. The biomedical language developed to describe cancer is oriented around 
time and growth. Pre-cancer, pre-malignant. Zones of transformation. Dysplasia. Metaplasia. 
These are some of the terms used to describe the fuzziness of the zones between having and not 
having cancer, zones characterized by growth and time. Yet, as biomedical knowledge of cancer 
accumulates, the idea of a boundary between the condition of having and not having cancer cells 
in our body is increasingly becoming indistinct. Cancerous cells are defined not only by their 
morphology, but by their rapidity of growth. The rate and type of growth does not correspond to 
the living biomatter of the full-fledged biological organism (human) in which they live. Cancer is 
simultaneously part of and, yet, other than, the biological host “with” cancer.27  
 Cancer is often conceptualized as an enemy to be defeated at all costs. The gold standard 
of treatment success is still often defined as the qualitative absence of cancer cells. Lesser 
benchmarks are determined by the quantity of cancerous cells detectable through imaging 
technologies or direct measurement of body fluids and tissues. The dominant biomedical modes 
 
27 The “immortal” HeLa cells are the most famous example of the contested boundary between 
the human and tumor. Derived in 1951 from cancerous cervical cells taken without consent from 
an African American woman named Henrietta Lacks a few months before her death, these cells 
have been used by thousands of researchers working on a wide range of topics (Skloot, 2010).  
HeLa cells continue “living,” approaching sixty years past the death of their original “host.” 
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of contending with cancer unfold along a chronological sequence. First, screening searches for 
pre-cancerous states or early manifestations of malignancies; detection leads to treatment 
decisions, generally aimed at eradication; successful eradication results in the state typically 
called remission; post-remission persons enter into the state of surveillance for disease 
recurrence. Unsuccessful eradication and further spread enters the state of palliation. Yet 
treatment options are expanding, offering more than just the trilogy of surgery, radiation and 
chemotherapy, now with genomic medicine, hormonal therapy and immunotherapies like those 
developed at CIM.  
 Numerous diseases previously closely associated with death are now manageable by 
ongoing medical therapy. Such management is, of course, dependent on access-- no small thing. 
Diabetes, epilepsy, asthma and most recently, post HAARV-era HIV were once highly fatal 
illnesses, closely linked to death. Such conditions today are typically associated with death only 
in the instance of lack of access to therapy, such as in resource-poor regions or within 
marginalized communities. But Dr. Lage’s claim that advanced cancer can be a chronic disease is 
not simply the latest iteration of a new pharmaceutical solution to keep people living with an 
illness longer, thereby enfolding them into a “pharmaceutical nexus” (Petryna and Kleinman, 
2006). Cronicidad represents a substantive change in orientation to the idea of a terminal disease. 
Death, after all, is never stopped. What does it mean to reframe dying from cancer to living with 
cancer (until death)?  In the US, where medical costs dramatically escalate as the end of life 
approaches and cutting-edge therapies cost hundreds of thousands of dollars, the question of 
money and cost-benefit hovers over discussions about whether a particular therapy which may 
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add just a few months of life is worth the expense.28 Under Cuban socialism, the equation is not 
so linear. 
 
Emerging Futures, Charismatic Time 
Conceptually, cronicidad encourages the intensification of a social present and a near 
future as a mode of temporal engagement.29 Anthropologists Jane Guyer and Paul Rabinow have 
highlighted this zone between the present and the near future as a particularly rich ethnographic 
terrain. Drawing from her fieldwork in Nigeria under military rule, Guyer’s (2007) research 
affords insight into the nature of the perception of time and the lived experiences of a “near 
future.” Rabinow’s “anthropology of the contemporary” (2014; 2016) offers another way into 
thinking of how cronicidad demands a reimagination of the temporal experience of advanced 
cancer. He considers present time as both a substrate and an ethos. The important time, he 
argues, is the now, the urgent, the new, the unstable.  Guyer, Strathern, Faubian and others (2016) 
suggest that  Rabinow’s anthropology of the contemporary represents an intensification of the 
temporal, a slowing down and attending to the minutiae, the scarcely perceptible, as it unfolds. If 
 
28 Arteaga et al (2019) discuss how disease stratification of cancer patients both engenders and 
entrenches inequities in healthcare access and delivery. 
29 Anthropologists have grappled with time as a phenomenon particularly subject to manipulation 
and interpretation. Durkheim (1912) includes time along with space and religion as foundational 
categories of thought. Malinowski’s (1922) “primitive time reckoning” presents time as the 
coordinating factor for the practical and sentimental needs of the Trobriand islanders; Evans-
Pritchard’s oecological time charts the differences in divisions of time from his own English 
version, with smaller temporal units organized around the tending of animals and procurement of 
food, and the larger units linked to broad seasonal patterns; Leach (1961) proposes that all time 
can be considered in a binary fashion as either repetition or non-repetition Fabian (1983) argues 
that the concept of linear, progressive time rooted in the Judeo-Christian world has become 
normalized, universalized, and secularized. In short, anthropologists have long examined time as 
a heterogeneous entity and experience, arguing in favor of pluralities of temporality. 
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terminal is to be chronic, yet is still bounded by death, the temporal demands such an 
intensification, the minutiae magnify.   
 If advanced cancer were, through therapeutic vaccines, to become chronic, how would 
this reshape the experience of time? This is the edge of possible, and minutiae matter here. 
Humans and tumors enduring together, negotiating space and time, until death. Cronicidad, in 
Dr. Lage’s terms, may well be utopic. Reframing advanced cancer as a chronic disease amenable 
to treatment through the national health program is perhaps particularly imaginable in the context 
of a system in which both healthcare provision and pharmaceutical treatments are enfolded into a 
state (socialist) system. This is because of the particular ecosystem, with mass education in 
“human resources” produces large numbers of scientists and doctors. This ecosystem involves a 
coordination of national health priorities with state investment in research and development. To 
propose a public health program designed to deliver an affordable cancer treatment to a target 
demographic defined as people living with advanced, non-curable cancers is practically 
unthinkable in a market-based system of healthcare and pharmaceutical development.  
 Scholars of post-socialism have analyzed some of the ways in which the manipulation of 
time was a particular focus of the socialist project. The rise and fall of the Soviet Union was not 
only a grand experiment in social and economic reordering: it was an experiment representing 
the culmination of a particular philosophical lineage grappling with time itself (Buck-Morss, 
2000; Ssorin-Chaikov, 2006; Yurchak, 2006; Ringel, 2016). Hanson (1997) explores time as a 
special domain of socialism, in both the theoretical and political development and actualization 
of Marxism and Leninism in the Soviet context. When workers appropriate their own labor, 
laboring according to social needs, per Marx, there ceases to be a distinction between free time 
and working time, leaving a purely charismatic vision of society, freed from time constraints and 
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economic scarcity.  Such a vision is not unrelated to the ideal of the dedicated research scientist, 
like those thousands of workers at CIM. (Even if, as Aymara explained above, the freedom to 
pursue a career in science in Cuba today is, for the unconnected, facilitated by another family 
member’s employment in the private sector.)  In the Cuban context, we might think of cronicidad 
as charismatic time in two valences. First, emerging from the Marxist vision of charismatic time 
as explicated by Hanson, the socialist health and pharmaceutical system free the time and 
economic constraints to therapy, creating the conditions for cronididad. In the second valence, 
cronicidad as charismatic time envisions the person with incurable cancer nevertheless 
reintegrated into the social, intensifying a present in relation to an indefinite future, lived 
alongside tumors, in community. If terminal is to be chronic, yet is still bounded by death, the 
minutiae magnify.   
 
Living While Dying With Our Biocompanions 
 Cancer is a catch-all term which is increasingly coming under the microscope as 
scientists and nonscientists alike are questioning the lumping together of such heterogeneous 
conditions (Manderson, 2015; Mukerjee, 2010; NCI, 2018). Cancer is characterized by 
unchecked growth and transformation. Cimavax works by blocking a growth-promoting factor, 
checking, to some degree and for a limited time, the wild, untamed growth of malignant tumors. 
Cimavax is an answer to a problem that has yet to be—is likely never to be—solved. It does not 
cure, it stretches time living, its low side effect profile creates more quality time. Dr. Lage’s 
campaign to re-imagine “terminal” cancer as a chronic disease reflects a shifting terrain in which 
cancer is increasingly recognized as a common part of life. Cronicidad reflects a world in which 
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boundaries between sickness, health, toxic substance and organic matter are increasingly 
impossible to disentangle.  
 In Cuba, the state controls both tobacco production and pharmaceutical innovation.  In 
this context, Cimavax is the key to cronicidad, the state-developed, state-provided treatment to 
keep people with lung cancer alive longer. A therapeutic lung cancer vaccine like Cimavax is a 
form of crosshatching, rendering the complex relations between humans, tumors and tobacco 
particularly visible in the 21st century Cuban socialist state. The biomedical rules of engagement 
between human as protagonist on the one hand, and tobacco and tumors as foes to be vanquished 
on the other, constructs a storyline of winners and losers. Who will ultimately prevail: the 
human, the treatment or the tumor?  The public health messaging or the tobacco? Cronicidad 
reframes advanced cancer as a particular form of the dying we are all living.  
 Instead of thinking about cancer as a binary, zero sum game, cronicidad unsettles 
cherished dichotomies like sickness and health, life and death. Such thinking recognizes, even 
embraces, the idea that life and cancer are mutually constitutive, that we die as we live, that we 
are invaded every day. Our bodies are not sacrosanct or pure. Cancer is chronic. Its very 
mechanisms involve a shift in the temporality of cell division. Cell division goes too fast, growth 
exceeds the standard limit. An acceleration of time in a set of cells in which the surrounding 
tissues are living in another temporality. If we accept the porosity of our bodies to chemicals, 
their coexistence with the teeming hordes of biota now commonly accepted as an essential co-
constituent, our coinhabiting microbiome, our gene expression as changeable based on 
environmental and social stressors (epigenetics), could we accept the knowledge that unruly 
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hyperdividing cells are coming in and out of existence throughout our lifetimes, sometimes 
ending them?30  
 While the existing literature on the anthropology of pharmaceuticals has accurately 
exposed the capitalist market maximization model fueling the exponential growth of 
pharmaceutical use globally (Dumit, 2012; Peterson, 2014; Sunder Rajan, 2017), the Cuban 
refashioning of advanced cancer as a chronic disease explored here cannot be dismissed as 
simply another expansion of potentially treatable subjects for growing markets. First, cronicidad 
is rooted in a system distinct from that of the North American and European pharmaceutical 
model: one based, instead, on an inseparable connection to a closed-cycle socialist 
pharmaceutical and biomedical system. Further, Dr. Lage’s concept of cronicidad is based on a 
narrow slice of cancer as it is generally conceptualized within the paradigm of western medicine. 
That is, he is talking about the increasing survival of patients with advanced cancer, those who 
are deemed non-curable. Yet while this may be read by some as a modest claim, in fact this 
reconceptualization requires a sizeable shift in the terms of life itself: to see life in the face of 
terminal diagnosis as still life instead of death. Taking cronicidad seriously requires 
acknowledging that death is the endpoint of noncurable cancer at the same time that a person, 
and by extension, a population, is continuing to live with their tumors.  
 Exploring the enduring importance of tobacco in Cuba alongside this new movement out 
of CIM to reframe advanced cancer as a chronic disease provides texture and dimensionality to 
the entanglements between humans, tobacco and tumors, as they are created, lived, imagined and 
confronted in Cuba today as companions.  My intent with this chapter was to show how, in Cuba, 
 
30 Michelle Murphy (2008) and Vanessa Agard-Jones (2014) are among some of the scholars 
generating critical work our chemical/corporeal entanglements.   
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the enduring importance of tobacco is co-extant with the growing recognition that advanced 
cancer might be a new form of chronic disease, at least in the context of a country with universal 
health care and a nationalized biopharmaceutical industry. My intention in crosshatching tobacco 
and cronicidad is to move beyond the so-called paradox. Instead, apprehending these two 
phenomena, in all their complexity, affords a broader understanding of how the attachments 
between these heterogeneous types of organic matter are continuing to reshape modes of living 
and dying. Crosshatching, seeing the range of social, economic and technological attachments 
between plant, person, market and the state, alongside cronicidad, where a highly stigmatized 
cancer might be visible, livable and normal, might unsettle some of the fixity in cancer 
prevention and treatment. Ideally, such destabilization engenders creative new approaches to 
both advanced cancer treatment and to the vision of public health interventions around smoking 
beyond the enduring tack of prohibitionism. We live in a world where we interact with 
substances which change us daily. Some of these interactions will change us at the cellular level, 
generating mutations in the growth of cells which take on characteristics of interdependent life 
forms. The public health tobacco-free messaging centers a plant instead of the social and 
economic forces at play in the facilitation of nicotine dependence. In the case of Cuba, 
addressing the scarcity of food might be just as effective as regulating the price of tobacco, 
where cigarettes calm nerves and take the edge off of hunger. Our relations with tobacco might 
spur or hinder our companionship with tumors, should we inhale the smoke of its combustion or 
manipulate its cells to produce planticuerpos to fight cancer.  
 As these three entities continue their longstanding engagements, I propose a reframing of 
their relations into the neologism I introduced at the beginning of the chapter: biocompanions.  
Kohn (2013), Viveiro de Castro (2012) and Haraway (2016) have experimented with ways of 
   121 
decentering the human through multi-species, multi-perspective approaches. Haraway (2016) 
explores a heterogeneous sample of multispecies entanglements, even inter-being-ness, as 
experienced and imagined over past, present and future, stressing this relation as rooted in a 
shared connection to this planet, embattled and increasingly toxic as it is, and beyond.  
Biocompanion encompasses some of these same sentiments, albeit, here, the scope is 
comparatively modest, reaching no further than this planet (for now). Like Viveiro de Castro 
(2013), I find the term species limiting, although for different reasons. The standard biological 
definition of the term species is too restrictive for my purposes. Species is a narrow definition 
referring a grouping capable of reproducing under “natural” conditions. I use the prefix bio, 
instead of species, as a broader term indexing “living” matter, which I want to hold quite loosely. 
Bio, here, facilitates the inclusion of the growing awareness of the range of fluidity of genetic 
material and the porosity between living matter including living organisms, and their constant 
susceptibility to genetic mutation and exchange of genetic materials in ways which transcend the 
term, species, but yet still maintain a tether in the domain of what is currently thought of as life.31 
The second part of my neologism, companion, is chosen for its similarly open construction 
which denotes proximity and temporality between living entities.  (I say entity here, as opposed 
to organism or beings, to allow for a broader range of companions like pets, insects, plants, our 
microbiome, etc…). Companion, as opposed to friend, colleague or comrade, is an ambiguous 
term, not predetermined ally or foe. A companion is simply a relationship defined by co-presence 
and time.  
 
31 My use of bio here does not include more recent trends in anthropology and philosophy 
following Agamben to distinguish between the ancient Greek terms of bios and zoe. 
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 In Cuba, tobacco remains an important biocompanion, and it can cause cancer.  Abundant 
scholarship accurately highlights the culpability of the multinational cigarette industry as a major 
factor behind the persistence of cigarette smoking and diseases related to tobacco consumption.  
Yet, that smoking rates and lung cancer remain so high in a highly educated population where 
near daily interaction with local health professionals has engendered what anthropologist Sean P. 
Brotherton has called medicalized subjectivities (2012), a place where the multinational tobacco 
industry does not have a foothold in local cigarette production, highlights some of the other 
important aspects of this biocompanionship of humans and tobacco.  Here, there are structural 
(and political—the US economic blockade, for one) forces resulting in economic hardship, 
including food insecurity, at play which promote cigarette smoking.  Important, also, is the 
national pride in the quality of tobacco, in both its cigar and cigarette form; tobacco farming as 
agricultural tradition and cultural heritage; the artisanal processes of cigar-making. In Cuba, the 
easy availability of cigarettes, coupled with poverty and food insecurity, fuel the level of 
smoking. The role of the socialist state as protector of health and producer of tobacco results in 
an anemic legal and regulatory regime when it comes to enactment and enforcement of smoking 
restrictions and pricing. Before what is now referred to in popular and public health circles as 
“big sugar” crystalized its existence, Sidney Mintz (1985) illuminated the ways in which the 
exploitation of slave labor in the Caribbean transformed sugar from scarce and precious 
commodity available only to the wealthy to the cheap, mass-produced, product available to the 
working-class and poor in England. Sugar, extracted from colonized countries by imported slave 
labor, quelled potential unrest amongst the poor in the in the countries of the colonizers, 
provoked by food scarcity. Sugar became a widespread cheap source of calories for England’s 
poor, especially the women and children, filling their bellies and leaving more of the limited 
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supply of meat and other nutrients to the men. Cigarette smoking, in particular, has a similar 
social tranquilizer effect.  As cigar “professor” Ramon reminds us, cigars fuel the formal and 
informal economy, cigarettes take the edge off stress and hunger.  Per Yoss, cigarettes potentially 
quell an otherwise unrestful citizenry. If tobacco use and its attendant health impacts inflict a 
disproportionate burden on the poor (WHO, 2018; CDC, 2018), the fault does not lie with the 
plant. Corporate greed accounts for a substantial, but not complete part of the blame for tobacco-
related disease. Yet, as tobacco consumption and its health-related consequences in socialist 
Cuba illustrate, capitalism as a system cannot shoulder all the blame. In Cuba, state power faces 
a conflict of interest and the state as provider of health and of tobacco juggles competing 
concerns, including: 1) tobacco-related morbidity and mortality and its attendant costs; 2) the 
economic benefits of tobacco exports and tourism; and 3) mitigating the civic unrest of economic 
hardship, where daily indignities and stressors are blunted by effects of nicotine. Here, as in most 
places around the globe, interventions aimed at reducing poverty might be equally as effective as 
top-down prohibitionist approaches to reducing rates of tobacco consumption. Tobacco in Cuba 
is a persistent biocompanion. One, as Dania and Vladimir suggest, whose role is continuing to 
expand, rather than contract.  
 Biocompanion acknowledges the materiality of an enduring co-presence and the 
entwined nature of our existence with other forms of life which shape our health and impact the 
duration of time we stay living. This term invites a broad array of participants within the 
spectrum of what we understand to be matter that lives, reproduces and dies. It is increasingly 
difficult to imagine, let alone justify, any depiction of the human condition that doesn’t 
acknowledge the porosity and fluidity between living entities. Crosshatching advanced cancer as 
a chronic disease alongside the enduring role of tobacco in Cuba pushes us to think complexity: 
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to recognize the limitations in binary thinking of protagonist and antagonist, in particular as we 
continue struggling to understand the boundaries and limits of illness, life and death, between 
and among the organic matter on the planet.  
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CHAPTER 3 
Towards Impossible: Utopian Visions in Cuban Technoscience  
 
  
The previous chapters of this dissertation have focused on material and concepts close to 
Cuba’s socialist biopharmaceutical expansion: vaccines, tumors and tobacco. This chapter, by 
contrast, steps back to consider the endeavor and the potency of socialist Cuban science and 
technology more broadly, through ethnographic material seemingly far afield from our topic. 
This chapter explores three disparate encounters with Cuban science and innovation: a worker’s 
organization, a television show and a science fiction writer.  I interpret these encounters using an 
analytic approach drawn from the genre of Science Fiction to gain insight into the Revolutionary 
Cuban program of science and medicine, in particular, Cuba’s biopharmaceutical sector.  
Drawing on Science Fiction theory in general and the writings of Cuban science fiction author, 
Yoss, in particular, I draw from these ethnographic engagements to suggest that Cuban socialist 
science and technology serve as a utopian provocation. Specifically, I will argue that the 
potential of Cuban biopharmaceuticals may lie in their ability to provoke utopian thinking, 
disrupting the conceptual boundary between the possible and the impossible.    
In taking genre itself as a form of analytic, I draw inspiration from David Scott’s 
Conscripts of Modernity (2004), in which he reinterprets C.L.R. James’s (1980) The Black 
Jacobins by enlisting genre as a mode of analysis. Drawing in particular on James’s 1963 
appendix, Scott’s intervention demonstrates how shifting from Romance to Tragedy enables a 
deeper understanding of the evolution of James’s thinking about Toussaint L’Overture in the 
context of the disappointments of the Bandung post-colonial movement.32⁠ My approach is also 
 
32 Scott thinks with historian Kosselleck’s (2004) concept of “futures past” and the Hegelian and 
Wittgensteinian philosophy of Collingwood and Skinner, to argue for reimagining the Black 
Jacobins not as Romance but instead as Tragedy. Scott argues that James initial 1938 publication 
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indebted to feminist science studies scholar Donna Haraway, who implores her audience to seek 
out what she calls “‘storytelling otherwise’… to resist and rebel against hegemonic ways of 
thinking and living (Middleton, 2019; Haraway, 2016).” Haraway was one of the first among a 
now growing number of science studies scholars to turn toward Science Fiction (henceforth, SF) 
as form particularly capable of inspiring such “storytelling otherwise.”     
As is often the case in ethnographic research, some of the most fascinating, and illuminating, 
encounters during my fieldwork came to me by chance, alongside, as opposed to in the path, of 
my research. This chapter brings together three chance encounters. The first two encounters were 
brief: interactions with an organization for young Cubans working in the science and technology 
sector and aan analysis of a state television program directed at Cuban youth. The third, and most 
significant, is a much longer and more substantive engagement, spanning almost two years, with 
Cuban SF author, Yoss. In this chapter, these encounters serve as substance and substrate, 
providing detail elucidating important elements of Cuban technoscience as well as material 
through which to introduce theoretical ideas derived from SF studies that offer insight into 
Cuban science more broadly.   
 
The Screw and the Cancer Vaccine 
 
 In the midst of a relatively affluent residential street lined with mid-century modern 
 
portrays is steeped in the aspirational anticolonial movements taking shape around Latin America 
and Africa, and Haitian Revolution as Romance casts Toussaint L’Overture as the hero who 
triumphs against all odds.  Thinking with the 1963 appendix, against the failed liberatory projects 
of both Haiti and many of the post-colonial states, Scott argues, James argues that L’Overture 
was less a Romantic revolutionary hero as a subject “constrained to imagine and make the 
revolution he imagined and made within the conceptual and institutional terrain of modernity 
(2004:129).” Tragedy, Scott argues, assumes a more “respectful position to the contingencies of 
the past in the present (220).”  
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houses, the 1970’s Soviet-style building covered in revolutionary posters stood out.  The two-
story construction of glass and steel looked abandoned, all the windows curtained over, some of 
them with cracked glass.  For several months I passed this building without really noticing it or 
registering its sign. Once in a while someone might be sweeping out front.  On other occasions, 
the front door was propped open and a middle-aged woman could be seen sitting at a desk, 
watching TV, cooling off in front of a rickety old fan.  Eventually, I noticed the acronym of the 
sign on the building: BTJ, the Brigada Técnica Juvenil (Youth Technical Brigade).  
 I would not have given any further thought to the building had I not just begun reading a 
recent book by Fidel Castro Diaz-Balart, or “Fidelito,” the oldest son of Fidel Castro and a 
nuclear physicist with two doctoral degrees from Soviet institutions.  In addition to his own 
original research, Diaz-Balart published several books on Cuban science, innovation and 
philosophy⁠.33  In Science for Innovation: The Cuban Experience (translated title, the book is in 
Spanish) (2015), Diaz-Balart draws on the history and philosophy of science to describe the 
conditions of Cuban scientific innovation up through the early twenty-first century. Over the 
course of this nearly 500- page tome, Diaz-Balart describes not only through text, but also 
through extensive use of diagrams and flow-charts, the coordination of the various national 
entities engaged in the work of generating science and technology in Cuba.  It is the 
“integration,” he argues, of these sectors, aligned with state priorities, which fuel the innovation 
for which Cuba has become so well known.  He lists the scientific poles, the Forum of Science 
and Technology, the Union of Science, the Academy of Science, the Association of Innovators 
and Rationalizers and The Youth Technical Brigade as key groups, the integration of which was 
essential to the development of a science and technology sector.  These groups form one layer of 
 
33 He also suffered from depression—committing suicide in 2018. 
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the interconnectedness of the communist party (PCC) with Cuba’s technoscientific sector, 
influencing priorities for research and development.   
 On discovering this abandoned-looking building represented, in one form or another, a tie 
to BTJ, I spent several weeks walking by hoping to see the doors open. One morning, I stumbled 
across one of the two women who regularly swept the sidewalk in front of the building and 
introduced myself, asking if there might be someone willing to tell me more about the history 
and current state of the organization. The director, said one of the sweeping women, was out at a 
meeting today, but I should return the following afternoon and find her in the office.  Several 
missed meetings eventually culminated in a sit-down with one of the mid-level directors, 
Manuela, who enthusiastically described the history and structure of the organization.   
 Per both Manuela and the organizational brochure with which she provided me, BTJ is 
organized around specific worksites. She explained the process for developing a new branch and 
the rules around the scope of projects and their connectedness to problems experienced in 
specific sectors. Manuela described the types of ideas given support, mentorship and recognition, 
again, all tied to particular worksites. Brigades are formed across sectors, and worksites are 
presented with national lists of problems to be solved.  BTJ members gain local, regional and 
even national recognition at conventions. There are no monetary prizes awarded, but recipients 
gain the honor of recognition, including a small token of achievement. One such recent winner, 
Manuela informed me, worked at a heavy equipment-manufacturing site. This site suffered a 
small but serious problem that caused significant delays in timely production: this was the lack 
of a particular screw not made in Cuba. This screw needed to be imported, and the sourcing and 
waiting for delivery resulted in significant delays and loss of productivity. The young man 
responsible for designing and making a prototype for this screw was Manuela’s first exemplar of 
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former BTJ prize recipients. She showed me an example of the specific medal awarded to this 
important young man, explained the prestige involved in the prize, and the support he would get 
from older mentors in the technology sector. She then mentioned, in an offhanded way, an 
example of another prizewinner: a young worker who developed a vaccine to treat cancer.  
 The rulebook for BTJ, given to each member, begins with the foundational history of the 
organization. BTJ was (naturally) the brainchild of Fidel, just five years after “El Triunfo.”  
For the objectives and functions the BTJ is converted into a bastion of the most novel and 
practical criterion for science and technology, giving to them the enormous assignment to 
carry forward the scientific revolution in our country…  BTJ includes youth between the 
ages of 17-35, organized in sectors and spheres of work…we are integrated in the politics 
of science, technology, and innovation of the country as a plan for economic development 
(BTJ, 2017:2-3; my translation, but the language in original Spanish is just as stilted).  
 
 Manuela’s casual description of the two noteworthy prize recipients mirrored the broad 
vision for the organization described in the pamphlet. Yet, the order of the story, the casual way 
in which a screw took precedence over a cancer vaccine, signaled, for me, the possibility that 
some broader form of disruption was at stake here. The serial description of the same prestigious 
award for innovation for 1) a screw and 2) a cancer vaccine, in that order, unsettles the 
categorical tendencies dominant in science and technology.  
  According to BTJ’s criteria for significant recognition, the inventor of both the cancer 
vaccine and the screw are on par with one another.  Such an evaluative schema can be read as 
consistent with socialistic principles elevating proletarian labor. Manuela’s explanation 
highlights how an organization like BTJ recognizes innovation (in this case, reverse engineering) 
according to a set of values guided by pragmatic utility. The value of producing a screw in Cuba, 
rather than importing a part, disrupted a supply chain dependency. Further, one might imagine 
that the structure of such categorization serves as a means of de-alienating of the laborer from 
her labor.  And it also is intelligible in the sense of the famously bricoleourian Cuban problem-
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solving capacity: the ability to resolver through combining, repurposing, accepting help.  BTJ 
exemplifies one of the particularities of science and technology in Revolutionary Cuba: a 
socialist-inflected blending of the industrial with the technoscientific.  A screw and a cancer 
vaccine on the same plane of worthiness.  
  Perhaps there is a certain (romantic?) obviousness in a simple metal object like a screw 
garnering a prestigious award in the context of socialist science and technology. Metal, after all, 
is a quintessentially industrial material, indexing proletarian factory labor. When a small metal 
object like a screw comes to mind just before a biopharmaceutical innovation like Cimavax, this 
moment disrupts the conflation of technological advances with exponential growth in 
complexity.  In what follows, we shall see a different type engagement with Cuban technoscience 
through another form of metal: aluminum.  
 
Tin Foil 
 Frenetic synthesizer music announced the beginning of a new program on one of the state-
run TV stations.  The screen flashed neon green and a roll of aluminum foil materialized, 
extruding, crumpled, from its long, rectangular box.  Low-budget visual effects blinked the roll 
of foil through multiple angles over a vivid green monochrome background, spinning it, then 
fading out to introduce today’s program: a talk show for Cuban youth. The teen host, sporting a 
sculpted blonde hair-helmet, flashed a charming smile in his neatly pressed red polo shirt and 
khakis as he excitedly introduced the program and today’s special guest: a young woman, a 
national expert, here to talk about something of great excitement and national importance: 
aluminum.  
 The episode highlighted the crucial role played by aluminum in the Cuban economy, from 
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household pots to the iconic individual Cuban cigar containers.34⁠  Video clips showed scenes of 
factory workers driving forklifts, on assembly lines, using heavy machinery.  These scenes, 
accompanied by electric guitar-driven hard rock, were interspersed with banter between host and 
guest about the scope and varied impact of the metal. Through the program, the imagined youth 
audience should receive the message that working with aluminum is not only vital to the country, 
but also, apparently, cool.  As I watched the show, my initial reaction was laughter, the 
incongruousness of a teen interest show with a focus on aluminum: it struck me as absurd.  Yet, 
as the aluminum episode replayed itself in my memory several times over the following year, I 
decided to turn my attention toward it in a more systematic way.   
 During breaks in my fieldwork in Cuba, I watched as much state TV as I could. I saw many 
educational programs on topics ranging from water processing to package design. My Cuban 
friends would roll their eyes at these types of programs, bemoaning what they considered the 
inferior programming available on state TV. Those with the means turned, instead, to “el 
paquete” a widespread system of pirating distributed via thumb drive “subscriptions” sometimes 
selling for the relatively astronomical sum of one dollar per week.  Yet, this particular episode 
illustrates something about the principles undergirding the continuing development and 
expansion of Cuban technoscience.   
 Shows like this youth TV program dedicated to aluminum are one example of many state 
efforts to reach a new generation with weak to no ties to what is still simply called “El Triunfo,” 
meaning the Cuban Revolution. Needless to say, many, if not most, Cuban youth are in no way 
out of touch with the intricacies of popular culture in all its commoditized and social media 
 
34 These types of education programs are common. Over the course of my fieldwork I watched 
programs about water infrastructure, pharmaceuticals, and design. This particular program, 
however, was the only one I happened to watch particularly aimed at youth. 
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broadcasted form and are unlikely be influenced by such a program. But the extent to which a 
program like this inspires young people in Cuba to get excited about aluminum is not the point.  
Instead, I will argue that the aluminum youth program, along with the screw and the cancer 
vaccine at BTJ, gestures toward the utopic, somewhere between the possible and the impossible. 
For my purposes here, this program represents more than a stale out of touch state-led effort to 
keep young people excited about industrial jobs. Instead, this program relates to Haraway’s 
“storytelling otherwise,” and in the world portrayed by the program, forklift drivers and factory 
workers are afforded status and visibility; industrial labor is portrayed as a desirable option for 
contemporary youth culture. 
 The encounter with the Youth Technical Brigade (BTJ) and the youth television program 
on aluminum offer a view of a Cuban socialist technoscience where manual labor with industrial 
material is afforded value and status alongside digital culture and biotechnology.  They disrupt 
the idea that innovation is only available within elite, discrete zones of high resource. Perhaps 
they even afford a glimpse of an alternate universe of technoscience?  
 
Leather and Metal: Cuban Galaxies  
 
“Step on up, ladies and gents, right this way, but only if you’re xenoids, it goes without 
saying. We don’t want any humans…A once-in-a lifetime business opportunity! An offer you 
won’t be able to turn down! (2).” This is the opening passage from a book by Yoss, one of 
Cuba’s most well-known Science Fiction writers.  He introduces his readers to a future Earth, 
inhabited by humanoid beings from other solar systems.  
… For rent, one planet that learned to play the economics game according to one set of 
rules but discovered once it started playing that the rules have been changed…For rent, one 
planet, for you, innocent child of a culture and a race that won the lottery, for you privileged 
only because you’re from some other solar system, because you grew up under the light of 
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some other sun… (Yoss, 2014: 2). 
 
 Earth, as imaged in Planet, is a thinly veiled Cuba in the immediate post-Soviet era, 
suddenly grappling with privatization and the lack of things like food and fuel, once provided by 
the state. Yoss’s cynical vision of an entire planet for rent, available to the highest bidder, subject 
to the whims of an alien race with un-paralleled resources, could be read broadly as a parable for 
many parts of the Global South on the receiving end of imperialist and capitalist schemes. Yet, 
many details in the story are unmistakably local in character.  (Planet is the only one of Yoss’s 
books not to be published in Cuba.) The worlds Yoss creates in Planet for Rent, as well as his 
other works, including Super Extra Grande, País Grande País Pequeño (Big Country, Small 
Country), for example, are worlds imaginable only in the context of a post-Revolutionary Cuba, 
a context defined, in many ways, by the surprising resistance of the Revolution, warts and all.   
 When Yoss writes, “the rules have been changed,” he suggests a form of trickery, a bait 
and switch. In the setting of Planet for Rent, the unspoken game to which these rules apply might 
be read most accurately as the market, controlled by the xenoids, with seemingly endless 
resources and corresponding advanced technology and power.  The xenoids change the rules of 
the game, and they are seemingly beholden to no-one. If we think with Yoss in the context of 
Cuban science, we might consider ways in which the “game” operates for research and 
development in the setting of the market, and who is making, then changing, the rules. How do, 
and how should, humans (read Cubans) figure into the game? What would a Yossian read of the 
expansion of Cuban pharmaceuticals look like?  
 In a future depicted in Planet, Alex, a self-taught physics genius from the boonies of a 
Spanish-speaking country, is recruited for secret military research and, after many years, 
endeavors to leave Earth and seek asylum on another planet with another species. In his asylum 
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interview, he explains Earth’s system of free education and scientific training available to human 
students who can learn the theory but never have access to the latest technologies; who work 
with decrepit lab equipment; who, given their economic circumstances, will never have access to 
the latest scientific developments.  Yet, he continues, 
medical students do have the luxury of working with real patients from the start. Of 
course, those patients are humans on Social Assistance, which provides them with free 
medical care. New medications are also tested on them. Since a human life has so little 
value, while there’s always a need for doctors and new medicines, nobody 
complains…Maybe that’s why Earth’s doctors and medical system are so famous 
throughout the galaxy. They don’t lack for experience, that’s for sure (2014:176).  
 
My initial reading of Yoss’s work in 2016 informed the preliminary data I collected in the 
Cuban health system in general, interviewing and observing doctors and nurses in neighborhood 
consultorios and simply spending time with a random assortment of people I met through social 
contacts.  In 2017, when I began focusing on the heart of my project, the expansion of Cuban 
novel biopharmaceuticals, Yoss’s SF parable of 20th century Cuba afforded new insights, a way 
into thinking about the “game” Cuba was attempting to enter in partnering with RPCI for the 
clinical trial of Cimavax.  I would soon have an opportunity to dig deeper.  
 The Cine Yara is one of the most important theaters in the Vedado neighborhood, and it 
constantly pulses with life and action either inside or outside its doors. In December 2017,  I set 
out to see Sergio/Sergei (2017), a film about an amateur radio operator in Cuba accidentally 
making contact with a stranded Russian cosmonaut. As I stood in line, a familiar figure caught 
my eye. Having seen his photo on the back of one of his books, Yoss’s image was emblazoned on 
my brain. He stood halfway down a line that curved twice around the block at the Yara, compact 
and muscular, long coarse hair flowing behind him, signature bandana tied around his forehead, 
wearing a lot of leather. Yoss strode up and down the line, sussing out the scene and situation. 
When he strode away from the malecón up La Rampa, I knew if he wasn’t getting in, there was 
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no way I’d get in either. So I took off after him. Unfortunately, that night, I failed. He 
immediately disappeared out of view down some dark alley in Vedado. Fortunately, as it turns 
out, if you hang around Vedado enough you can’t not see Yoss. He’s always around and 
incredibly noticeable. And he knows everyone. A week later, I had another opportunity. Yoss said 
he was pleased and surprised to meet North Americans in Havana who recognized him and had 
read his books.  
While meeting Yoss was never part of my research design, I soon realized I wanted to 
include him as an interlocutor. A biologist by training, he was fluent in a broad range of topics. 
From the latest scientific developments in Cuba, the history of Soviet science and SF, to global 
and local politics, Yoss was up to date and ready with an incisive analysis and strong opinion. As 
a writer both critical of, and sympathetic with, the state and yet operating inside it, a public 
intellectual and a trained scientist, his perspective on the relationship between science and the 
state, among other areas, afforded a unique counter-perspective to many of my other 
interlocutors who were more likely to be figures working closer in and around the biotech sector 
in general. Over the course of two years, I formally interviewed Yoss four times and had several 
other informal conversations and exchanged emails in which we discussed themes related to SF 
and Cuban science, medicine, socialism and the Soviet Union. The final interview in March 2020 
included having him read what I’d already written about him and engaging in lively discussion 
about the themes I’d drawn out in my analysis.   
 In our first conversation, as I explained my research, Yoss explained back to me his 
assessment of the importance of anthropologists. Like almost all Cubans I encountered, and 
unlike the vast majority of Americans I know, Yoss was relatively well-versed in cultural 
anthropology and the social sciences in general.  When I asked about interviewing him for the 
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research project and I proposed making his interviews anonymous he balked, saying, “I wouldn’t 
say anything to you that I wouldn’t say in front of the government or anyone else,” discouraging 
me from trying not to identify him in my dissertation.  
 In a manner not entirely uncommon in Cuba, Yoss’s daily activities include a broad range 
of interests. In addition to his background in biology, he is a heavy metal enthusiast, singing in a 
metal band, and an avid weightlifter, spending significant time at his neighborhood gym. But his 
passion, and his vocation, is writing, mostly SF, but also erotica. When me met for our first 
interview in the garden of the writer’s union, the dark intensity of his carefully crafted 
appearance (mesh tank top, purple pants, and a studded belt) jarringly gave way to a disarmingly 
broad, dimpled smile. As we talked, various members of the writers and artists union walked by 
to greet him, as he is a well-known figure there.   
 Yoss emphasized the perspective that he, as a Cuban, brings to his SF. In his book, Super 
Extra Grande (2015), he depicts a future where intergalactic space travel is first achieved by an 
Ecuadorian scientist. This has far reaching consequences in the imagined history of 
interplanetary communications, and Spanglish becomes the Lingua Franca. When we spoke 
about his inspiration for that plot decision, Yoss suggested, “probably we Cubans, living on an 
island, have a more realistic form of thought about how to travel faster than the speed of light 
because it is farther than we can see. We can’t see further than that sea which is our border.” 
Later, commenting on Super Extra Grande, Yoss proposed, “the idea that the medium that 
permits humanity to escape the Solar System from the threat of overpopulation could be 
discovered in a small country like Ecuador, and is shared practically, is an attitude of resistance 
(1/16/18).” 
 In framing the plot decision as an “attitude of resistance,” where technoscientific 
   137 
innovation from the South might be shared broadly, Yoss gestures toward a particular entity 
against which this resistance is applied. Yossian thinking asks: if technology developed and 
shared from the Global South is liberating resistance, who or what is being resisted?  Thinking 
Cuban biomedicine with Yoss not only renders more visible the power relations inherent in 
technology dissemination, but also what such resistance might look like. He continued:    
It is an inversion of the relations between the center and the periphery and for this reason, 
in certain measure, modifies the concept of democratic space that until now has not been 
sufficient in our planet. The relation between the First and Third world is inverted 
completely, and the hegemony of the First World completely disappears once the Third 
World also has access to this. I think it is realistic from the perspective of the new scientific 
advances of the last twenty years that you’re seeing each time more radical discoveries are 
being made by scientists far from the centers of investigation in developed countries (Yoss, 
1/16/18).   
 
 Yoss’s intervention disrupts the normative configurations of power and technology 
aligning with so-called scientific centers and peripheries.  The attitude of resistance to which 
Yoss refers relates back to the idea of the game and the rules of the game from the opening 
passages of Planet. When the rules of game are capricious, subject to the whims of, and favoring, 
the xenoids (read Americans and Western Europeans) with their unlimited power, the response is 
resistance. More than modifying, as Yoss says, it exposes the falsity of the idea of science and 
technology as a form of a democracy of the best ideas, in the context of space as the geographic 
terrain of interest.  In creating a world in which intergalactic travel is discovered by a scientist 
from the Global South, Yossian thinking highlights how something like medical solidarity 
disrupts the unspoken assumptions undergirding narratives of technoscientific achievements. 
Through his SF, Yoss writes out, and thus renders more visible, the normally unspoken idea, that 
the market is a supposedly neutral and democratic space where the best scientific ideas might 
flourish. Instead, he makes the game legible and, in showing resistance, exposes that hollow 
upon which such assumptions are based.      
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Yoss’s invocation of the idea of the “inversion of the relation between the center and 
periphery” had clear resonance with the emerging narrative about Cimavax coming to RPCI. 
In Super Extra Grande, Yoss imagines a technoscientific breakthrough emerging from the 
Third World inverting power relations, disrupting the hegemony of the First World. Thinking 
along with Yoss’s SF, in its utopic inversion of technology transfer, disrupts assumptions 
about where scientific breakthroughs will happen and how they will or won’t be shared.  This 
“storytelling otherwise”  renders visible the limitations of a worldview in which a geographic 
region’s wealth automatically confers technoscientific prowess.   
He continued, 
Considering that in science fiction you have, above everything, a social component that 
is a way to use the capacities of the sciences to reflect on the consequences in the future 
of our actions in the present. We see it as a literature of consequence perhaps because we 
are a country that at, at some rate, acts without thinking of the consequences. Many of 
the science fiction writers in Cuba are trained as scientists. I’m a biologist, many are 
doctors, engineers. But there are others with training in what are called the “soft” 
sciences: sociology, history, anthropology and I think that we all have increasingly more 
centered our science fiction in these “soft” sciences the human consequences of scientific 
discoveries. In this way, I for example, studied biology because I wanted to have a 
scientific base to write science fiction. But at times I feel regretful that I did not study 
sociology or anthropology. (Yoss, 4/18/19).   
 
 Yoss’s comment of acting “without thinking of the consequences” is a common theme in 
analyses of many of the Revolutionary government’s projects, and, in particular, an accusation 
against Fidel Castro’s tendency to generate ambitious projects without necessarily having the 
financial capital required to initiate or sustain the efforts. Put another way, a utopic, not 
pragmatic, plan, an aspiration. The Cuban biotech endeavor exemplifies the audaciousness and 
the tenacity of such a utopic ambition. Cuban biotech is now into its fourth decade, persisting, 
despite political and economic ups and downs, expanding and creating new futures.  
Yoss later reflected on his university degree in biology, considering,  
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Twenty-five years have passed since I graduated…and my base of biology is basically 
obsolete. Nevertheless, I continue to make a science fiction not only for my scientist 
colleagues. Perhaps at times my scientist colleagues read my stories and feel a type of 
complicity. They tell me about something, and I know what it is, but I also want people 
who don’t have any scientific training to understand. Some have told me that when I 
write science fiction, I give people a series of cardinal points so they can improve their 
scientific preparation… it also worries me that modern society has a type of abyss that 
continues to grow larger between the technical culture, what you could call “the geeks,” 
and the humanist culture, or what you might call “the bohemians.” There are people 
who can speak to you about television and nuclear energy, but they don’t know anything 
about literature or history. They don’t understand how the television they use works.  
Science fiction at least can become a bridge between these two extreme cultures. And I 
do believe I contribute a little to reduce this distance (Yoss 4/18/18).  
 
In Cuba, in my experience, what Yoss calls an “abyss” is significantly smaller than what I 
encounter in the US. That is to say, a wider swath of the population has a robust, 
interdisciplinary, way of thinking.  In the realm of Cuban biotech, Dr. Agustin Lage, head of 
BioCubaFarma and the lead scientist working on the Cimavax collaboration, told me, “I’m a 
believer in recombinant knowledge.” In that moment, we were talking about an anthropology of 
science. But he used that example to highlight to me his purposeful curation of combinations of 
scientists with diverse backgrounds in the service of advancing Cuban biotechnology. This is 
why he took the unusual approach of appointing a physicist to lead the Center for Molecular 
Immunology (CIM).   
Yoss is part of a robust SF tradition in Cuba, where the state regularly publishes 
collections of SF short stories, runs workshops and hosts conferences.  Journalist Rachel Price 
includes SF writers Jorge Enrique Lage (a nephew of Dr. Agustin Lage) and Eric Mota in her 
examination of creative responses to the climate crisis from Cuba (2016).  Prices highlights a 
recurrent trope in which Cuba has been imagined as lab, a zone of and for experimentation and a 
space of imagination. Where Yoss hopes his SF offers a “series of cardinal points” to improve 
scientific preparation, I find Yossian thinking exposes the unspoken assumptions and ideas about 
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who produces and controls technoscientific advances, the processes through which certain 
advances are or are not shared and who stands to benefit.   
 
Cuban Technoscience as Utopian Disruption 
 The three ethnographic engagements: BTJ, The Screw and the Cancer Vaccine and Yossian 
thinking are disruptive in their inversion of categorical hierarchies. Science Fiction theory has 
much to say about the role of such shifts or inversions. In writing of utopian thinking in SF, 
Jameson takes the figure of disruption to describe the potential of powerful shifts in conceptual 
categorizations. He writes,   
Disruption is, then, the name for a new discursive strategy, and Utopia is the form such 
disruption necessarily takes, and this is now the temporal situation in which the Utopian 
form proper-the radical closure of a system of difference in time, the experience of the total 
formal break and discontinuity- has its political role to play, and in fact becomes a new 
kind of content in its own right. For it is the very principle of the radical break as such, its 
possibility, which is reinforced by the Utopian form, which insists that its radical difference 
is possible and that a break is necessary. The Utopian form itself is the answer to the 
universal ideological conviction that no alternative is possible, that there is no alternative 
to the system. But it asserts this by forcing us to think the break itself, and not by offering 
a more traditional picture of what things would be like after the break (2007: 232).  
 
Thomas More’s Utopia (1517) is arguably the earliest iteration of SF, as well as 
inspiration for long-running and robust scholarship and debates about socialism. In his close 
reading of Utopia alongside Benjamin’s writings on Fourier, Abensour writes, “Utopia is like a 
mask covering a new kind of thought, one meant to shake orthodoxy, to undermine the beliefs 
and institutions of its time…the utopia as narrative device functioning like the extended ruse of 
political thought (2017:17).” Utopia is, in many ways, the Ur-text of Haraway’s “storytelling 
otherwise.”  
 The Cuban Revolution was a utopian vision, built by subverting the key premises on 
which the pre-revolutionary reality was constructed, redistributing land and property, inverting 
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social hierarchies. Cuban science bears the marks of the utopian impulse. Thinking through SF 
draws attention to the entanglement of utopian thought and socialist thinking undergirding the 
design of the Cuban biotech sector. Jameson (2007) analyzes the stakes of utopia construction 
through particular historical moments from More’s Utopia to contemporary SF, through 
movements including futurism, modernism and post-modernism, structural and post 
structuralism, as well as contemporary SF which has yet to be categorized. From Jameson’s 
intervention in SF and utopia, I find four themes of particular interest to an analysis of Cuban 
science: 1) utopia as disruption; 2) the relationship between utopias, SF and socialism; 3) utopia 
as closed system; and 4) the role of the collective in utopias, in particular, the relation between 
socialism and nationalism.  
Addressing both the association between socialism and utopia as well as the figure of 
disruption, Jameson asserts: 
The relationship between Utopia and the political, as well as questions about the practical-
political value of Utopian thinking and the identification between socialism and Utopia, 
very much continue to be unresolved topics today, when Utopia seems to have recovered 
its vitality as a political slogan and a politically energizing perspective...What is crippling 
is not the presence of an enemy but rather the universal belief…that the historic alternatives 
to capitalism have been proven unviable and impossible (Jameson, 2007:xii).  
 
For Jameson, it is neither the form nor content of any given utopia as such but rather the 
mechanism of utopian thinking itself that serves as disruption. After several chapters unpacking a 
variety of utopian models found in SF and philosophy, he writes, “We have come laboriously to 
the conclusion that all ostensible utopian content was ideological, and that the proper function of 
its themes lay in critical negativity, that is, in their function to demystify their opposite numbers 
(Jameson, 2007:211).”  
  Where Bloch (cf Jameson, 2007) argues that the utopian impulse lurks rather obviously 
behind the fields of science and medicine in general, in the case of Cuban Revolutionary science 
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and medicine, utopian desire is not located in the covert or suppressed discursive zones but, 
instead, on the surface as raison d’etre, part and parcel of the political project. Cuban medical 
solidarity and universal healthcare are overt expressions of a will to utopia. The term, “political 
will,” examined in detail in Chapter Four, is a popular phrase used by the Cuban state and its 
representatives, as well as international organizations like the Pan American Health Organization 
and the WHO, as an explanation for the success of Cuban science and medicine. Arguably, this 
term can have different valences, including, potentially, politically repressive ones. Yet, the term 
also signals a utopic aspiration, and, as Jameson points out, the critical negativity of the utopic 
will which serves equally well to critique its opposite: the capitalist system of market-based 
science and medicine.   
More writes his Utopia as a closed, self-sustaining system, separated by a trench to form 
an island. Whether by state supporters, detractors, official spokespersons or average people on 
the street, Cuba is frequently narrated as a closed system.  Cuba is geographically separated by 
water, economically isolated by the US economic blockade, politically closed off as the lone 
socialist survivor in the Western hemisphere. The biopharmaceutical industry itself is 
characterized by all official representatives as special and effective because of its design as a 
ciclo cerrado or “closed cycle,” where the state controls all elements from research and 
development, manufacturing, clinical trials, regulation, distribution to the citizenry and 
commercialization to the exterior.   
 Jameson writes of the relation between the individual and the collective in utopia-making 
as a crucial point of inquiry. He examines factors which tend to strengthen the collective, in 
particular, the tendency for nationalism to bolster a flagging collective in the face of external 
pressures, observing “many of the successful socialisms have combined with the energies of 
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nationalism to produce even stronger collective visions (2007: 226).” This is certainly the case in 
post-Soviet Union Cuba. A growing revisioning of the Revolutionary project has emphasized its 
ties to José Marti over socialist ties to Marx or Lenin, stressing continuity with the hero, poet, 
scholar and martyr of the Cuban war for independence from Spain. Indeed, “soy Martiano” 
(which sounds like, “I am a Martian” but means, I am a follower of Jose Marti”) is a phrase I 
heard repeatedly asserted by Cubans of all stripes and political preferences.  Over the course of 
five years of fieldwork stints, I saw a gradual near elimination of Lenin busts once relatively 
plentiful with a simultaneous proliferation of Marti busts.  
Utopian thought is foundational to SF as well as ingrained in socialist thinking, informing 
the myriad constructions and iterations of both. The figure of utopia in the Cuban biotech sector, 
in both its explicit and implicit forms, could be read as that “break” to which Jameson refers. As 
is explored throughout this dissertation, the expansion of Cuban biopharmaceuticals emerged 
through a rather unique set of circumstances. Yet, thinking Cuban biotech as a form of the 
“break” might generate the much-needed disruption and cognitive estrangement of those who 
both create and critique pharmaceutical development and expansion, as well as technoscientific 
advancements in general.           
 SF critic Darko Suvin (2019) uses the term, “cognitive estrangement,” to talk about the 
ability of SF as genre to unsettle perception through the creation of invented worlds.  
“Estrangement always comports and signals the fact that a semantic shift, one putting a dominant 
stifling norm into doubt, has occurred (Suvin, 2019:142).”  Jameson elaborates, “Suvin’s 
principle of “cognitive estrangement”-an aesthetic which, building on the Russian Formalist 
tradition of “making strange,” as well as the Brechtian Verfremdungseffekt, characterizes SF in 
terms of an essentially epistemological function- thus posits one specific subset of this generic 
   144 
category specifically devoted to the imagination of alternative social and economic forms 
(Jameson, 2007: xiv).” 
 Suvin’s concept of cognitive estrangement specifies one possible effect of SF. While 
cognitive estrangement clearly has kinship with the anthropological approach in general, it 
differs in being fundamentally untethered to actually existing worlds or realities. A pitfall of the 
anthropological approach to an “other” is an analysis pre-emptively hemmed in by the 
expectation or worldview of the observer.  Thinking Cuban biopharmaceutical expansion through 
SF unsettles a conceptual attachment to what might be considered the realm of the possible, 
opening a space to peek into the zone of what might be considered impossible. When thought 
specifically through utopia, as Jameson argues, “[t]he Utopian form itself is the answer (my 
emphasis) to the universal ideological conviction that no alternative is possible.” For example, 
there is widespread acceptance by both observers and critics alike that capitalism is inevitable. 
This can have the effect of erasing or rendering less visible both resistance, as well as 
alternatives, to capitalism.  
In the Introduction as well as Chapter Two of this dissertation, I discuss the concept of 
crosshatching from China Mieville’s The City and the City (2009), where two realities are 
simultaneously comprehended and “seen,” without dissolving any contradictions or tensions 
between them. Jameson proposes something along the lines of crosshatching without naming it 
as such in his treatise on utopias, addressing the contradiction between ideas of utopias as mere 
wish fulfillments versus utopias as solutions for addressing social ills like corruption and 
injustice (2007).  He advocates, “I fear the only way of dealing with this contradiction is to think 
both perspectives together simultaneously (2007:43).”  Thinking with SF in general, with 
Mieville’s crosshatching and the SF of Yoss in particular, enables the type of estrangement 
   145 
developed by Brecht but refined for SF by Suvin necessary to appreciate the stakes of what is 
distinctive about Cuban biopharmaceutical development and expansion.  
While SF has long-standing champions like Donna Haraway within the social sciences, a 
recent increase in SF/anthropological entanglements has prompted concern among some 
anthropologists like Matthew Wolf-Meyer who warns, “[m]aybe I’m a prude, but it strikes me 
that as a social science, anthropology should be wary of SF precisely because it is 
science fiction and not social science. This is not to deny the powers of speculation, but to warn 
against them (Wolf-Meyer, 2018).” A special issue of Paradox entitled “The Futures Industry” 
examines the capacity of SF as genre to interrupt what Sherryl Vint (2015) describes as 
capitalism’s colonization of the future. She asks, “[c]an science fiction foster a critical 
understanding of the intersection between political economy and contemporary technoscience, or 
does its own status as an entertainment commodity inevitably compromise its utility as a tool for 
social critique (2015)?”  Vint gestures toward deployment of SF as a tool for conceptual de-
colonization of a future imagined through market modalities. She complicates her idea by 
considering whether SF, existing as it does as a commodity itself, may inherently be a corrupt 
form through which to imagine such a future not constructed around the market. The prospect of 
using SF to disrupt the extent to which the future has been colonized through the market, and the 
practice of imagining how modes of de-colonization might take shape, calls for a broad sampling 
of ideas, both those “really existing,” and those circulating in the world of ideas. Where Wolf-
Meyer warns anthropologists against thinking with SF, I would argue that SF should at least be 
afforded the space and consideration given to the philosophers, social theorists and authors of 
“literary” fiction with which the discipline has often entangled itself in the service of analyzing 
ethnographic data. In thinking, or writing, SF, anthropologists can both draw from and create 
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narratives which may well push into realms considered utopic or impossible. Thinking through 
or with SF and using concepts like disruption, cognitive estrangement and utopia construction 
are additional tools with which anthropologists can observe, interpret, analyze and extrapolate.  
Proposing Cuban science as a form of utopic disruption does not mean idealizing it or 
ignoring the complexities through which it emerged and continues to expand and adapt. I have 
argued for using China Mieville’s concept of crosshatching to hold these complexities in one’s 
conceptual field as a type of “seeing” the situation of Cuban technoscience. The story of 
innovations like Cimavax in Revolutionary Cuban science is often narrated to emphasize those 
elements considered contradictory, ironic, placed in juxtaposition, or, even, incommensurable.  
These themes include socialism and capitalism; the celebration of both tobacco and lung cancer 
treatments; economic impoverishment and advanced science and technology; democracy and 
authoritarianism; surveillance and liberty. The question of whether and how Cuban socialist 
pharmaceuticals might come to influence the hegemonic profit maximization model of the 
multinational pharmaceutical industry exists at the boundary between the possible and the 
impossible.  That is a zone worth exploring, anthropologically.   
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Chapter Four 
 Capitalizing on Socialism: The Visibility of Value 
 
Cimavax Swag 
 
The Meliá Havana Hotel towers over the waterfront in Miramar. Its pristine landscaping 
and curved driveway meander uphill to an elegant covered entry, where tour buses and new 
luxury cars idle, waiting to ferry wealthy tourists or Cuban notables around town. Hotel staff 
patrol inside and out: tending the shrubbery, assisting with taxicabs, vaguely vigilant, assessing 
who does or does not belong. The lobby fountains and glass-ceiling atria soar above a polished 
glass bar as a string trio plays Broadway show tunes and a pianist dutifully hammers ubiquitous 
sure-fire crowd pleasers like Chan Chan.35  
On this June day in 2017, several conferences are simultaneously underway at the Meliá.  
The convention for Colombian oncologists is recognizable by its look and masculinity: about 
twenty men, mostly in their 40s and 50s, wearing summer suits or dress-shirts and slacks. This 
conference is sponsored by CIM, RPCI, and Colombia’s Delta Laboratories, aimed at convincing 
these Columbian oncologists to start using Cuban cancer vaccine therapy, distributed in their 
country through Delta. The CIM counterparts, on the other hand, are majority women. From 
RPCI today, epidemiologist Dr. Mary Reid is the lone representative. Outside the conference 
room, two young women run the check-in, signing in participants and handing out lanyards and 
swag bags. Each bag contains two water bottles, a geo-locator device and two pens, all marked 
with a purple label and a CimaVAX-EGF logo; the piece de resistance: a large, hard-bound 
book. The book’s purple cover features a giant yellow scanning electron microscopy image of 
what appears to be the anti-EGF antibody, overlying a diagram of an organic chemical molecule, 
 
35 Chan Chan is a traditional song made popular internationally by the 1999 documentary The 
Buena Vista Social Club. 
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itself overlying images of a range of high-tech equipment. Twelve pages of glossy pictures of the 
DNA double-helix, scanning electron microscope images of enormous, brightly-colored cells and 
antibodies; smiling headshots of key researchers at RPCI, CIM and one of the major Havana 
oncology wards; a schematic of Cimavax’s mechanism of action; images of a mother holding her 
young child; a scientific article; directions for administration; and a diagram depicting statistics 
and buzzwords like “survival,” “quality” and “security.” 
 Conferences like this are a feature of the new directions for Cuba’s pharmaceutical 
industry, which has partnered with foreign businesses to expand the reach of their products 
(PAHO, 2018). While Cubans working in medicine, science and technology have been sent 
abroad since the first years of the revolutionary government’s tenure (Brotherton, 2013; Burke, 
2013; Gleisjes, 2002; Briggs, 2011), Cuban pharmaceuticals are increasingly going global today. 
An expanding array of medical treatments are making inroads around the world, in Latin 
America, Asia, Africa, and even preliminary ventures into North America despite the US 
embargo.  
How does the Cimavax swag bag figure into the landscape of globalizing 
pharmaceuticals? The expansion of Cuban biomedical science beyond its borders is worthy of 
close examination, not only for the ways it stands to change local conditions, but also for its 
potential impact on its relations with the multinational pharmaceutical industry and global 
commercial biomedical endeavors. The growing presence of commercialized Cuban biomedicine 
does not conform to most of the popular or academic coverage and analysis of global 
commercial pharmaceuticals and medical services in that they were not developed around market 
concerns and they are not beholden to generating shareholder value.  Instead, the profits 
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generated from the sale of these medicines funds further scientific research as well as clinical 
care.   
The question of how and why tiny socialist Cuba has established any commercial 
footprint at all off the island is in itself a puzzle worthy of closer examination.36 Since the 
collapse of the Soviet Union, predictions of Cuba’s capitulation to free market forces are a 
regular refrain in the US media coverage of the island. Yet, reading the story of the 
commercialization of Cuban biomedicine as a “turn to the market” is not only an 
oversimplification, but a mischaracterization, distorting a series of important distinctions which 
have the capacity to offer new insights and perspectives from a granular examination of the 
intricacies of Cuba’s endeavors in turning a profit from their biomedical sector.  This chapter 
explores the seemingly strange bedfellows of socialism and biopharmaceutical expansion in 21st 
century Cuba.  I focus on a relatively recent phenomenon: the availability of Cuban medical 
services and pharmaceutical products for sale to people with the capacity to pay, both on and off 
the island.    
 
36 A word like “commercialized” is a powerful term carrying a significant charge, especially to 
people across the spectrum of political attachments to particular conditions on the island. An 
outsize proportion of discourse related to health and medicine in Cuba is tethered to rigid 
analytic frameworks and suppositions about the economic and political future of the island that 
bear little resemblance to the conditions I encountered in my fieldwork from 2015-2018. I 
therefore want to introduce a term like “commercial” very carefully and with context.  When 
possible, I will use the term either spoken by my Cuban contacts or derived from printed 
materials produced in Cuba.  Commercial is a visible term on many buildings and signs around 
the island often used to describe a sub-set of state agencies or mixed state-private businesses 
involved with selling. Likewise, it is not an accident that I avoid the word “consumer.” Another 
seemingly banal word, consumer significantly frames the analytic possibilities extant in a close 
examination of the conditions and ideas around the exchange of Cuban drugs, healthcare and 
money, as they are currently emerging on the island and beyond. What drew me to and continues 
to engage my curiosity about the evolving conditions of the biopharmaceutical sector in Cuba are 
precisely those ways in which it escapes the usual conceptual scaffolding entailed in the 
“business” of healthcare. 
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When situated in relation to the problem space of global pharmaceuticals and for-profit 
health care, the logics undergirding Cuban commercial biomedicine depart in important ways 
from the for-profit biomedicine of both the Global North and South (Sunder Rajan, 2006, 2017; 
Biehl, 2007; Hayden, 2013). Through interviews and observations with pharmacists, doctors and 
lawyers working in the commercialization of Cuban biomedicine, I found evidence to suggest 
that the expansion of Cuban pharmaceuticals on the global market relies on a continuity of the 
socialist project. Cuban pharmaceuticals generate value through a set of features connected to 
21st century Cuban socialism.  Cuban pharmaceuticals are rendered valuable (as opposed to 
profitable) by making these socialistic features visible, but not labeling them as such.  
Examining the relationship between socialism and the production of commercial 
biomedical value in Cuba, I focus an ethnographic lens on the scientists, clinicians, bureaucrats, 
and drug marketers working in Cuban biomedicine in order to show how the expansion of novel 
Cuban therapeutics, as well as the commercialization of medical care to a population of 
foreigners in Cuba, is informed by a model of ideological, albeit permissive, state control. What 
is most unique to this model is the way that it at once incorporates and benefits from economic 
growth while not being exclusively, even largely, driven by profit.  Instead, it is fueled by a 
pragmatic and ideological model driven by intensive state investment in training in the 
biomedical sciences, government funding of research linked to national health priorities, clinical 
research apparatus linked to the universal health program, an extensive network of international 
relationships developed through south-south solidarity and one-party control. Cuban 
pharmaceuticals are expanding their global footprint by generating value in a novel way, yet this 
way is tied to the persistence of socialism.   
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Solidarity Rx: From Medical Internationalism to International Medicines 
Cuba is widely known for sending health professionals and other specialists to work in 
developing countries across the globe. Some have called this medical internationalism (Kirk and 
Erisman, 2009), others medical diplomacy (Feinsilver, 2013; Bernstein, 2013). As detailed in the 
Introduction, I have chosen the term medical solidarity. Medical solidarity covers a broad range 
of efforts; sending medical and nursing professionals to developing countries to provide primary 
and specialty (including surgical) care; providing disaster relief from hurricanes and earthquakes; 
and fighting infectious diseases including the Ebola epidemic and COVID-19 pandemic. The 
nature of these medical solidarity campaigns has been analyzed from a variety of perspectives, 
with Cuban press and left-leaning publications tending to frame these endeavors as altruistic, and 
mainstream US media and international publications either categorizing the work within the 
rubric of humanitarianism or else highlighting a transactional benefit for Cuba (Brotherton, 
2013). The tension underlying this distinction reflects the ongoing, often unacknowledged 
remnants of the Cold War, which, in terms of US-Cuba relations, is still far from over.  
To the untrained eye, Cuba’s medical solidarity might resemble programs carried out 
under multinational political and philanthropic organizations like UNICEF or the Gates 
foundation, under the banner of what is usually called global health and generally framed as 
“humanitarian.”  This other brand of international medical assistance has long been critiqued by 
pioneering medical anthropologists for its ties to colonialism or statecraft.  Recent works by 
Murphy (2017), Crane (2013) Dubal (2018) and other anthropologists have explored how 
strategic efforts in what are referred to as global health and humanitarian campaigns remain 
rooted in a politics in which influence, control and even, at times, profit (Fassin, 2011; Adams, 
2016), underlie aid efforts alongside the concern for human life.  To consider how Cuban 
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medical solidarity differs, for example, as south-south cooperation, with its focus on training 
foreign health professionals, exposes the often hierarchical and dominating campaigns flown in 
from the Global North. The Cuban politics of medical solidarity, therefore, render visible by 
contrast the American-anticommunist roots of humanitarian care in global health.37 This 
distinction between Cuban medical solidarity and global health projects stemming from the US is 
relevant to the newly expanding market of Cuban innovative pharmaceuticals. My interviews 
with key personnel working in Cuban pharmaceutical development, commercialization and 
regulation highlight how these decades of medical solidarity laid the foundation for today’s 
expanding market for Cuban pharmaceuticals. That is, the current and future potential success of 
Cuban pharmaceuticals are facilitated by a certain visibility of the goodwill and reputation 
developed over these six decades of medical solidarity. 
 
Enclosed Ecosystem 
Both the innovadoras, or novel Cuban biopharmaceuticals, like Cimavax as well as 
bioequivalent/reverse engineered drugs are part of what is widely described by official 
representatives of Cuban state biotech and the MINSAP as a consequence of the Cuban 
“ecosystem” of healthcare.  In terms of the novel, patented biopharmaceutical sector, this feature 
is promoted for its design as a “closed cycle.”  The closed cycle, practically speaking, means that 
the state or, more specifically, the Communist Party, is ultimately in charge of all aspects of 
research, development, clinical trials, regulation and commercialization. While each sector has a 
 
37 My use of the term humanitarian marshals its deployment as charity missions, including the 
valid and excellent critiques of humanitarian interventions by scholars like Malikki (1996) and 
Dubal (2018), which highlight the structural violence undergirding both the infrastructure and 
implementations of many of these interventions. 
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significant degree of independence in how they use the money they are allocated, they ultimately 
report and respond to the directives of the party.  The one-party system shapes the types of 
problems prioritized for basic research, it controls the public health system (MINSAP) through 
which local clinical trials take place, it controls approval of new drugs and devices which can be 
included into the universal free healthcare system as well as sold to foreigners and exported to 
other countries and it controls how these drugs can be advertised and priced.   
The June 2017 Meliá conference on Cimavax for Colombian oncologists summarized 
eighteen years of research conducted in Cuba, highlighting the integration of cutting-edge 
biotechnology research with the MINSAP system of universal healthcare delivery. The first 
sessions involved talks covering the scientific evidence in support of Cimavax, given by Drs. 
Lage and Crombet from CIM and Dr. Mary Reid from RPCI.  The last talk of the afternoon had a 
different flavor. A manager from CIMAB, the agency responsible for the commercialization of 
products from CIM, delivered an impassioned overview of the island’s biotech sector as part of 
the government-funded “Cuban Health Ecosystem.”  His first slide read: 
Ecosystem of Cuban Health:  
 
• health care is a right, available to all equally and free  
• health care is responsibility of the state  
• preventative and curative are integrated  
 
Second slide:  
 
• huge investment of government since the 1980’s 
• human capital 
• national health system first priority driving innovation 
• strong IP progression of innovative pipelines 
• national collaboration rather than market competition 
• affordable clinical development up to phase II 
• closed loop organization 
• propriety know how and tech for biotech manufacturing 
• gaining international competitiveness: innovation, quality, production, scale up, cost 
optimization, flexible business models  
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(Melia Hotel, July 18, 2017).  
 
 
The speaker walked a fine line, attempting to communicate the quality and cutting-edge 
nature of Cuban biotech, while simultaneously emphasizing the affordability of the product.  
Compared to several of the other speakers of the morning, who focused more on clinical trial 
results, his presentation included a pointed critique of the multinational pharmaceutical industry 
putting profit before patients.  He delivered his presentation with an energized intensity about 
him, juxtaposing NASDAQ indicators for biotech with the “inflated cost of biologics.” He ended 
his presentation by focusing on innovation itself, emphasizing that, contrary to popular belief, 
many examples of major innovations were originally funded by the state, concluding his 
presentation by showing a slide of an iphone and ipad and quoting a 2017 article from the Oxford 
Review of the Economic Policy highlighting the role of government in financing technoscientific 
innovation.  As the two slides summarized above attest, if manager’s presentation to the 
Colombian oncologists could be thought of as a type of sales pitch, he clearly linked the value of 
Cimavax to this “ecosystem” of Cuban health. His bullet points highlighted ways in which value 
can be generated from both the care and control of the socialist state through the closed system.  
The idea of the closed system is a utopic construct: a self-sustaining cycle free from 
negative outside influence (see Chapter Three; Jameson, 2007). The CIMAB manager’s 
presentation conveyed the value of this closed system through its defining features characterized 
by both care and control. These include the political commitment of the state to provide free and 
accessible healthcare; the available “human capital” of cadres of doctors and scientists, 
continually trained en masse  through the free education to the graduate and professional level; 
and the benefits of national collaboration instead of competition.  The  Cuban closed ecosystem 
is also defined as much by what is kept out: corporate influence and competition.   
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Long Term Relationships  
As I would learn later from Jorge, an executive from the Colombian pharmaceutical 
distributor company, Delta, the impetus for the conference for the Colombian oncologists was a 
reluctance on their part to prescribe Cimavax. Cuba and Colombia had negotiated this 
agreement, brokered by Jorge. Jorge’s personal connection to Cuban biotech dated back to the 
late 1980s, just before the Special Period, when he traveled there as a shoe salesman for a shoe 
conference. Jorge recounted his visit to a Cuba already struggling under shortages and economic 
deprivation as a result of diminished Soviet support, which was about to completely collapse. In 
addition to the shoe conference, Jorge had an ulterior motive. His grandfather had established the 
biggest pharmaceutical distribution company in Colombia. His father was a doctor. Jorge did not 
want to be a shoe salesman much longer. He had heard the reports of Cuba’s hepatitis B and 
meningococcal B vaccine. From the lobby of the famous Hotel Nacional, he got out a phone 
book and began looking for some contact in the pharmaceutical sector.  He ended up calling the 
state entity called Labiofarm. Today, Labiofam is most associated with having developed 
Vidatox, a homeopathic remedy made from the venom of a blue scorpion, sold to foreigners for 
about $200 for two ounces. During Jorge’s visit, however, Labiofam was in the business of 
veterinary medicine.  
Like many stories I heard about science and business in Cuba, a positive personal 
connection generated a long-lasting relationship characterized by both friendship and interest 
(socios, see Chapter Two), of both the scientific and commercial variety. Jorge recounted 
walking miles to meet the director of Labiofam, arriving parched, and being offered a glass of 
lemonade and very pleasant company. While he quickly realized that Labiofam, with its then 
focus on veterinary medicine, would not be the right entity to collaborate with his grandfather’s 
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company, he was enamored with the director, and moved by the state of poverty in which he 
found the man, who had virtually no clothes. Jorge told me how he went back to the hotel to the 
famous cabaret La Parisien and partied all night. He was awoken in the morning by a phone call 
from the director letting him know he had an appointment with Medi-Cuba, Cuba’s principal 
pharmaceutical exporter. Jorge recalled that when the director of Labiofam arrived to take him to 
his appointment with the director of Medi-Cuba, Jorge emptied out his suitcase and gave the man 
all the clothes he brought. Jorge’s relationship with the Cuban biopharmaceutical sector 
continued evolving, now going on forty years.  
According to Jorge, patients in Colombia were requesting Cimavax as part of their lung 
cancer treatment, yet despite its ready availability in their country, their oncologists would not 
prescribe it. He explained this was not necessarily due to their skepticism about Cuban science, 
but more a pitfall of the cheapness of Cimavax. The Colombian private insurance system of 
reimbursement, as Jorge explained it, is based on the cost of the treatments.  In this case the more 
expensive the treatment ordered by a physician in Colombia, the higher her reimbursement and, 
also, the inverse: a physician ordering cheaper treatment takes home less money.  This sticky 
issue illustrates some of the complexity behind the integration of products from the Cuban 
ecosystem of low-cost innovative pharmaceuticals. In other words, the cost of cheapness.  
 
The Politics of Cheapness  
 In the media blitz in the months following the December 2014 rapprochement negotiated 
between Barak Obama and Raul Castro, the theme of money featured prominently.   
How did Cuba end up with a cutting edge immuno-oncology drug? Though the 
country is justly famous for cigars, rum, and baseball, it also has some of the best 
and most inventive biotech and medical research in the world. That’s especially 
notable for a country where the average worker earns $20 a month. Cuba spends a 
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fraction of the money the US does on healthcare per individual; yet the average 
Cuban has a life expectancy on par with the average American. (Wired. Patel, May 
11, 2015). 
 
  Numerous news outlets repeated the claim that the vaccine “costs one dollar to 
manufacture” (Cheng and Kananathan, 2012; Lee, 2015). The theme of cheapness was one I 
encountered among Cuban researchers in the biotechnology sector as well as people involved in 
the collaboration at RPCI working on the Cimavax trial. Dr. Lage, the former head of CIM and 
current head of BioCubaFarma, had an image he used in numerous slide shows called “The 
Pharmaceutical Tsunami.”  He emphasized the cumulative impact of the seemingly exponential 
escalation of drug costs alongside an aging population. Cuban innovative pharmaceuticals, he 
suggested, offered an answer to this crisis. Along with the conference at the Hotel Meliá for the 
Colombian oncologists, every talk I witnessed given by the CIM researchers emphasized the cost 
of pharmaceutical treatments, including patented biological immune-oncology treatments 
developed by multinational corporations, and the corresponding cheapness of Cuban treatments, 
featured prominently alongside points of data emphasizing efficacy. Similarly, over dinner with  
people from both RPCI and CIM working on the Cimavax project, they speculated on how to 
promote Cimavax in a field crowded by immuno-oncology-treatments. Their solution was in 
pricing. Cimavax was novel, yes, but not so novel as to outshine its competitors. What it could 
offer was cheapness. 
 The supposed cheapness of Cuban innovative pharmaceutical products and biomedical 
services cannot really be separated from Cuba’s political economy: socialism. The willingness of 
non-citizens to spend money on Cuban medicine and medical services on and off the island and 
the agreements made by a number of countries to buy and distribute Cuban medicine support the 
theoretical viability of this commercialization effort, suggesting it could be a significant player in 
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the arena of global pharmaceuticals and biomedical services.  Yet, the prospects and possibilities 
here are not entirely comprehensible given the assumptions most people carry about what 
socialism is, how it works to distribute healthcare resources, and how much these contravene 
assumptions about how capitalism does the opposite.  
 
Care and Control: Accessibility, Security and Reputation Create Cuban Brand Value  
 Originally trained at the University of Havana as a pharmacist, Egor now works in 
advertising. His employer, CIMAB, has only one client: a major Cuban biotech research 
institute. CIMAB is the Cuban entity charged with commercializing patented pharmaceutical 
products developed at CIM, located in the polo cientifico zone in the Playa district of Havana, a 
zone peppered with hospitals and research centers but also notable for its lavish houses and 
rolling estates. Nestled deep in the outskirts of Playa, the CIMAB headquarters blends in with 
the neighborhood, resembling just another large, old, run-down house. Inside the entry, the only 
clue to the identity of the business is a small glass case featuring several packages of CIM’s 
showcase products: Cimavax and Cimaher, vaccines for lung and breast cancer, respectively.  
I interviewed Egor at CIMAB in April of 2018.  The receptionist welcomed me into the 
entryway of the house, clearly expecting me, and invited me to sit on a folding chair in the hall 
near the glass case of Cimavax and Cimaher. Eventually Egor descended the stairway above me 
and after brief greetings and pleasantries, led me to the back of the house to a conference-type 
room, around a large table with numerous chairs. He explained the closed ecosystem I’d come to 
hear so often, where the state controls “the full cycle” of pharmaceutical development and the 
commercial side of the system is used to fund the national health service. Eventually, we came to 
the topic I wanted to hear him elaborate on: his job of converting Cimavax from a part of the 
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bolsa of medicines available to Cuban citizens for free from the state to something which can be 
marketed and sold to foreigners on the island and, more importantly, through third party 
distributors in other countries to enter the global pharmaceutical market. He started:  
We had to learn the hard, crude world (of advertising) and how it functions to 
promote the commercialization of medications to the exterior. We had to know it 
because we all have to finance the costs that we have to get medical products to 
Cuban patients through financing with the sale in the exterior. To sell off the island 
we have to compete with the same rules.  
 
Describing the world of advertising in these terms, Egor laid bare some level of disdain 
for the business of selling medications on the market.  I later ask about what distinguishes 
Cimavax from a drug with a related mechanism of action, Tarceva (Genentech), but a different 
mode of delivery (pill). After reviewing distinguishing elements of the molecular mechanisms of 
action, Egor settles on the issue of safety. “I think the principle advantage that Cimavax has is its 
security. It has a mechanism of action with low toxicity.” This is, in fact, a key factor stressed in 
all medical presentations and advertising materials I observed developed regarding Cimavax. 
Particularly in comparison to chemotherapy or radiation, this vaccine is reported to have almost 
no side effects. Of course, as outlined in detail in Chapters One and Two, the vaccine is non-
curative and is designed for uncurable stage four cancers as a life-prolonging treatment adjuvant, 
so comparisons to the toxic therapies meant to eradicate are unfair.  Nevertheless, the claim to 
the safety and security have a strong resonance with a commonly repeated narrative of the safety 
and security of the Cuban state. Especially within the Caribbean and Latin America, Cuba has 
positioned itself as the tourist destination for safety and security, thus the safety profile of 
Cimavax dovetails nicely with this facet of a cultivated national image meant to attract tourism 
and business.   
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The ability to sell Cuban medicines, especially within the Global South, is propelled by 
Cuba’s medical solidarity. Egor drew the connection between this history and the recognition of 
something that might be called a “brand” of Cuban medical services. He explained:   
I think that in Latin America in general there is a tacit recognition of the quality of 
Cuban medicine and products from Cuba. One that, little by little, has come into 
acceptance. The fact that there are so many Cuban doctors giving service in 
countries in Latin America and Africa above everything a little bit validates for me 
the fact that the people of other countries recognize that Cuban public health has a 
lot of quality and also that products that come from Cuba have a lot of quality.  
(April 2, 2018).  
 
 Egor’s comment highlights both quantity and quality of as important metrics 
contributing to the awareness and recognition of Cuban physicians, and, by extension, to Cuban 
products. Later in the interview, we discussed the RPCI clinical trial of Cimavax and the idea 
that Cuba’s first cancer vaccine may eventually be available in North American markets.  He 
speculated on the ramifications of a broader future market for Cuban innovative medicines, 
specifically, on the possibility of entering the North American market.  
I think, defending the probability that one day we will succeed in registering a 
product in the United States, that the value that will have is much more to have an 
impact in the political, ideological and social point of view, then the potential 
earnings that we would have... We haven’t arrived at this moment and we will have 
to compile the interests of Cuba as a country with a tradition of trying to benefit the 
patient before private interest or that the investor will have to be aligned with 
us…But I think Cuba will always defend the idea that the therapy should be 
available and accessible, even if that means earning less (April 2nd, 2018). 
 
Egor’s statement suggests a double move of valuing Cimavax while de-linking value 
from profit. He suggests the greatest impact of the vaccine may not be its financial benefit for the 
Cuban state, but rather, the political and social impact of having a Cuban vaccine on the North 
American market. Second, he asserts a (theoretical) commitment to defending the principles of 
socialized medicine through limiting the potential profit of the vaccine by setting an affordable 
price point. CIMAB is tasked with rendering commercial products from patented 
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biopharmaceutical treatments produced under a set of conditions which do not quite map on to 
the research and development environments off the island.  Egor describes his product as 
effective, affordable/accessible, innovative (if not quite at the cutting edge of cancer treatment), 
safe, and recognizable for quality by reputation through its connection to Cuba’s history of 
medical missions.   
CIMAB, as a state-run business entering the playground of the multinational 
pharmaceutical industry, is searching for avenues in this market. Does this translate to Cuban 
pharmaceuticals positioning themselves as the affordable, morally just (or, perhaps, 
revolutionary?) alternative to the multinationals, the Linux to Microsoft; the Better World 
Driving Club to the AAA; the Ben and Jerry’s to Hagen Dazs?  Or is CIMAB drawing on a 
playbook so radically other that it cannot rightly be compared? I would argue that careful 
attention to the conditions through which Cimavax and Cimaher were developed offers a vantage 
point unavailable within the sphere of socially responsible capitalism. The value of these cancer 
vaccines, which renders them potentially able to generate income from their sale, is derived from 
features connected to the socialist project like the mass training of basic and clinical researchers, 
the state-sponsored medical solidary, and also, arguably, the low salaries of professionals (in the 
context of the theoretical position of state as provider of basic elements of living like housing, 
medicine, and food, the latter having disintegrated greatly since the 1990s). The themes of safety 
and security raised by Egor also gesture toward another feature of Cuban socialism: the control 
of a one-party authoritarian state. This becomes uniquely visible through the Cuban drug 
regulatory agency.  
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CECMED: One Party Value, OR, The Stability and the Will of the State  
Since the second half of the twentieth century, the history of the pharmaceutical industry 
is inseparable from the history of its regulation. Accounts from anthropologists, historians, and 
physicians have traced the curious dance between companies and public regulatory agencies 
(Biehl, 2007; Sunder Rajan, 2006; Greene, 2016; Nik Kah, 2014; Lakoff, 2006; Silverman and 
Lee, 1974). Federal and international regulatory bodies enable, constrain or otherwise configure 
the ways in which pharmaceuticals interact with the types of people who recommend medicines 
and the people who take them into their bodies. The triangulation of political parties, regulatory 
agencies and the pharmaceutical industry has significantly shaped how different interpretations 
of or directions for economic ideologies (sometimes influenced by a narrow group of thinkers 
like the Chicago School of Economics in the 1950s) carry an outsize influence in the enactment 
of regulations which may either facilitate or hinder the movement of pharmaceuticals toward a 
public of potential users. The interface of political and legal approaches via drug regulation 
significantly shapes the types of drugs and patterns of use and distribution globally. Yet, much of 
the scholarship on the interaction between pharma and regulatory bodies has been examined and 
analyzed in the context of a liberal, market based political economic system.  
In a centralized, single-party socialist system like Cuba’s, the interaction between the 
party and the regulatory body takes a different form and inserts a corresponding set of logics into 
the process of pharmaceutical regulation. The Cuban agency responsible for the regulation of 
pharmaceutical and medical devices (the equivalent of the US’s FDA) is called CECMED, 
(Center for State Control of Drugs, Equipment and Medical Devices).  CECMED is located in 
the Miramar neighborhood of the municipio of Playa, Havana, notable for its abundance of well-
appointed, large mid-century homes. The pre-revolutionary home to Cuba’s wealthy elites, 
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Miramar turned into a zone for diplomats in the 1970s and 1980s but increasingly is returning to 
a neighborhood of the relatively wealthy: Cubans who rent out their luxurious homes to foreign 
businesspeople. Miramar is a zone where the rise of inequality in Cuba’s late-hybrid socialism is 
on full display. Two buildings stand out from the immediate surroundings: the jutting behemoth 
of the Russian (Soviet) Embassy, designed to resemble a sword plunged into the ground and the 
best place to bunker down in the event of a nuclear attack; and the jarring 1980’s style blue 
mirrored  tower of CECMED, looming over the neighboring schools and homes. A school bus 
emblazoned with the CECMED logo sits parked outside, in front of the small garden where the 
shrubbery has been topiaried to spell out: CECMED.   
On my third trip to Cuba for fieldwork I lived in Miramar, just around the corner from 
CECMED.  After running through all of the possible connections I could think of between my 
acquaintances, friends and colleagues in both Cuba and the US, I failed to find anyone who could 
facilitate any contacts for me at CECMED.  Eventually, I resorted to an approach seemingly 
guaranteed to fail: knocking on the door.   
Cuban state agencies are often highly restricted and policed, and yet the island is small 
enough that personal relationships tend to facilitate institutional connections to a large degree. 
So, it happened that I knocked on a locked door and someone opened it that day to peer outside.  
The receptionist who opened the door was dressed in a style I found common for both young and 
middle-aged women in administrative and service positions: a skin-tight red dress and jeans 
jacket.  I identified myself as a professor of nursing (true at the time) and medical anthropology 
graduate student (the combination tended to open more doors), offering the requisite business 
card required for social and business transactions alike. Much to my surprise, she invited me in, 
returning to her post at the small white desk in the large, sparse, modern lobby with white 
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pleather furniture, featuring a large portrait of sage, elderly Fidel, done in oils. Two middle age 
male security guards leaned against the desk, chatting with her. They checked my credentials and 
made a phone call, summoning a pharmacist named Yoandra to meet me. Yoandra inspected my 
business card and remarked on how much she loves San Francisco, and, to my great shock, she 
asked: “would you like to interview me?”  Relative to my experiences cold calling many other 
Cuban biomedical institutes to inquire about interviews, this was almost (or probably) too easy.38  
This first meeting initiated a relationship which blossomed into a cordial friendship over 
the next few months, as Yoandra was an effusively warm, enthusiastic, knowledgeable and 
insightful interlocutor.  I interviewed her three times over three months, each time for about one 
and a half hours, as well as establishing occasional phone and email correspondence and social 
visits including other workers at CECMED.  Over the course of three visits to CECMED and a 
social luncheon amongst four of us, Yoandra and her coworkers acquainted me with the history 
and patterns of work in this center of regulation of pharmaceuticals and medical equipment. 
Yoandra was my primary contact. Animated and fast-talking, she conveyed abundant passion for 
her work, a job she’s held for nearly seventeen years. Trained as a pharmacist, she now works in 
the international relations department of CECMED. Her work entails participation in bi and 
multi-lateral negotiations over the movement of pharmaceuticals and medical devices into and 
out of Cuba.  This position in international relations put Yoandra in regular contact with 
foreigners, meeting regularly in-person and via Skype with her counterparts across Latin 
 
38 A colleague from the former Soviet Union has remarked that, due to the ease of my entrance 
into CECMED via Yoandra, she may have been acting as an informant of the state. In the two 
years since our first contact, I have maintained a friendship with Yoandra that has transcended 
the initial relationship of anthropologist-interlocutor. The issue of surveillance and informants is 
fraught. Whether or not this may have been the case, I am not convinced that would alter my 
analysis or even my friendship with Yoandra.  
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America, North America, Asia and Europe. While many countries send representatives to the bi 
and lateral agreements to which CECMED is party, Cuba’s relatively well-developed 
pharmaceutical sector gives it an outsize role in these negotiations.  
 Yoandra’s desk is covered with trinkets, hinting at the global connections she’s forged 
over her years of work. Her desk holds a large flat screen computer monitor, stacks of paper, and 
multiple souvenir paperweights/knick-knacks, mostly from China: a Chinese calendar, a 
porcelain figure of a woman with a parasol, a miniature Buddha. Her trinkets mirror some of 
Cuba’s most important commercial trading partners. Our first meeting took place minutes after a 
powerful thunderstorm left the streets flooded, and the office space exuded a potent, damp heat.  
The AC was not working that day, Yoandra explained, apologizing and opening the window. She 
poured me the tiny cup of requisite sweet, strong coffee, to help “acercarnos.”  
 Yoandra shared some of her personal career journey with me, from her early aspirations 
to become a medical doctor to the change of heart and the direction she took toward pharmacy 
studies in her pre-university year. Eventually, we moved in to talking about her job at CECMED 
and some of the features of the Cuban biopharmaceutical sector.  I asked Yoandra why Cuba, 
unlike the majority of countries in its GDP bracket, has been able to develop innovative 
pharmaceuticals. She responded:  
In all the models that we have, the different characteristics are marked by the 
economic and political system that we have here in Cuba. That in some moments 
our own difficulties that we have made us grow and arrive at the industry we have. 
If we didn’t have people trained for this, we wouldn’t have arrived at the Center for 
Molecular Immunology. Theoretically [our model could be replicated]…but in all 
countries with a market that large and with a market open to the pharmaceutical 
world, they are very powerful and have many interests so I’m not sure if it would 
work (January 23, 2018). 
 
 In her reference to Cuba’s closed system, Yoandra’s description mirrored the depictions 
of the Cuban ecosystem of the closed pharmaceutical cycle controlled by the state. Her narrative 
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also dovetailed with another refrain I encountered across many sectors on the island: a story of 
national struggle and resourcefulness in the face of the ongoing US blockade, in particular, since 
the loss of Soviet economic support. Yoandra’s characterization of Cuba’s success in 
pharmaceutical innovation fit almost too neatly into the stories I heard of how people kept their 
1950’s cars running into 2018, initially using any random item to hold the car together, then, 
over the decades, installing Mitsubishi engines, and even, depending on their financial situation, 
air conditioning units and video screens with bluetooth controls.  The story of Cuban biotech 
merged with numerous others I encountered: from artists, dancers and musicians to taxi drivers; 
a picture of triumph after struggle, a David and Goliath tale, with adversity resulting in 
innovation, giving weight to a moral claim for the accomplishments of the biopharmaceutical 
sector on the island, and the hopeful success of its global efforts.    
 In our first meeting, Yoandra shared with me the draft of a 2015 WHO document titled 
“Cuban Experience with local production of medicines, technology transfer and improving 
access to health.” The 80-page report was reviewed by the directors of CECMED, CIM, 
BioCubaFarma, the umbrella agency for all the commercial endeavors on the island, and 
MINSAP.  The document walks through the basic design of the system, in language similar to 
that which I’ve heard in conferences, conversations, and other interviews.  
Political commitment 
Owing to a particular political system, major critical success element is attributable 
to the government’s commitment in driving the national vision for health sector 
development. Having identified the health needs and gaps in the health delivery 
system, the Cuban government developed a national strategic plan that was 
implemented through restructuring of the national drug industry that commenced 
after the revolution in 1959. 
Health sector was among six key strategic areas that were reformed. 
Implementation of these reforms was made possible through centralisation of the 
economic policy and by creating good trade relations with the Eastern European 
socialist countries (WHO, 2015). 
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 “I think the theme of the mode that you have to see behind it is the political force that 
pushes…(Yoandra, January 23, 2018).”  Yoandra essentially distilled the paragraph from the 
WHO document.  She did not elaborate on how such a push might be felt, or why it might be 
effective. Yet, thinking through the structure of the Cuban pharmaceutical sector in its relation to 
regulatory bodies and political parties suggests some possible mechanics of this “political will.”  
Although some of the economic reforms enacted over the last decade facilitated a loosening of 
central control in several economic sectors, including to some extent within the health sector, the 
biomedical sector remains explicitly, visibly centralized. That is, along with economic reforms 
enabling greater institutional discretion, the closed cycle remains a visible and valuable. While 
the economic and political reforms allowed for greater oversight and budgetary control to occur 
within particular institutions, these institutions were tasked with carrying out the priorities 
established by the Party. Yoandra explains how these reforms work at CECMED:  
For us here in the Cuban MINSAP, the responsibility for quality, security, and 
efficacy of the medical products used and any difficulties arising from them went 
to CECMED… It is a level of independence not seen in many other countries. For 
example, in the Americas, which is what I know best. I know that many other 
countries, all the requirements and regulations emitted by the authorities have to go 
up before congress to get approved. This greatly delays the process in which a drug 
goes from a new regulation to entering a living being. That, for me, is backwards 
because you really can see a velocity that appears and a large amount of new 
products are going to be delayed years in regulations that at times you have to study 
to see more how to regulate (Yoandra, February 19, 2018).  
 
 CECMED, as a regulatory agency, was given the independence, responsibility and 
authority to move the regulatory process along, both to facilitate clinical trials as well as to allow 
new drugs to get into people to address health problems prioritized at a national level. Yet, does 
the idea of a central authority driving innovation and controlling regulation conjure images of 
Lysenko-ism, where an ideologically driven scientific program subjects a population to 
experimental conditions meant to advance a political agenda? Could swaths of the Cuban 
   168 
population be unnecessarily exposed to unsafe medications?  In a word, no. A centrally 
controlled pharmaceutical development and regulation system runs counter to received wisdom 
about the necessary conditions of scientific innovation idealized as freedom, competition and 
financial incentive, as well as the assumptions about regulatory agencies as necessarily 
independent from the sector responsible for pharmaceutical development.  Yet, in the model of 
the closed cycle, where basic and clinical research on new medicines and technologies are linked 
to a national health program, where health statistics have taken center position on a global stage 
as a badge of national honor, the conflicts of interest seen in private sector development and 
public sector regulation look different. How, then, might regulatory integration confer value to 
Cuban biotech? In contrast to relationship between regulatory bodies and politics elaborated in 
scholarship on the history of pharmaceutical regulation, when Yoandra describes something like 
a political will, she is referring to a politics designed to integrate the party with the science with 
the regulation.   
One thing that marks the difference is that we have a stability of government that 
you don’t see in almost any other country.  For many years we have the same 
government and the same president and the institutions have the same leader for 
many years. This maintains a line and a stability that other countries don’t have. In 
other countries the director of the regulatory authority changes according to the 
political party of the president in office…because then you have to start over from 
the beginning…There has to be a force or a particular historic situation, a political 
force interested because this is how you link the political system with the industrial 
system. The Cuban thought is salubrista39 at the political level. You have to see the 
economic and political system even if it is not in the direct interest of the 
government of business (January 23, 2018).  
 
 
39 The word salubrista is difficult to translate directly in a manner that conveys its significance. 
Literally, it means something like “health-focused.”  However, it also contains a moral valence 
as well as the sense that this type of thought is lived or that the type of thought is an essential 
part of the character. 
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 In Yoandra’s telling, Cuban pharmaceutical and medical products are inseparable from 
the political and economic conditions on the island, including a government run by the 
Communist Party for over sixty years.  She connects the one-party system to regulatory stability, 
which she identifies as an area of value for Cuban biomedicine in comparison to industries based 
in countries with multi-party democratic structures.  Such stability contains value in its 
predictability. Yoandra’s comment is more than a theoretical defense of single-party rule.  She 
draws from her practical experience negotiating bi and multi-lateral agreements over seventeen 
years with primarily democratic countries, witnessing first-hand some of the downsides as the 
changes in government every four years generate upheaval in previously negotiated treaties 
supporting the entrance and exit of particular pharmaceuticals, interrupting her sense of progress 
in health and medicine.  If democracy40 allows voters the opportunity to decide on new political 
parties and new directions for a country, Yoandra highlights a potential hazard of democracy to 
scientific progress.41 She frames the Cuban context of pharmaceutical development and 
regulation as explicitly tied to the political domain.  The idea of the state as timeless42 confers an 
aura of stability into a domain otherwise susceptible to volatility and unpredictability. Could this 
imply that such a “political will” enters in some way into the pharmaceutical itself?  Could such 
a politics, in turn, contribute to the production of value for the pharmaceutical itself? If the 
 
40 That is, democracy as an ideal-type, at least. Recognizing that the forms of extant democracy 
are often manipulated to support existing wealth and power structures, multi-party states where 
political parties at least take turns does create zones in which political change is seen and felt, for 
better or worse. 
41 Another example is the Trump administration’s withdrawal from the Paris Climate Accords 
and the WHO. 
42 Several scholars of post-socialism specializing in the former Soviet Union have addressed the 
production of The “timeless” state as central to the maintenance of state control. Yurchak (2006) 
examines the apparent incommensurability between the shocking/not-shocking collapse of the 
“timeless” Soviet state. Ssorin-Chaikov (2006) and Verdery (1999) also address the production 
of timelessness through art exhibits and artifacts. 
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calculation of value relates to the calculation of price, how might the visibility of one-party 
control confer value to Cuban pharmaceuticals?   
 Yoandra describes the moral economy linking innovation with local needs and problems.  
Both her comments, as well as the WHO statement, construct the idea of “political will” as a 
socially beneficial force, aimed at addressing the health problems on and beyond the island. The 
drugs must get to the people in need.  This is not revolutionary in itself, as it largely replicates 
the argument of the multinational pharmaceutical industry in their efforts to get a drug to market 
more quickly as rooted in benefit to patients. And it is not untrue either.  Yet, where drugs and 
profit are intimately linked, the line between easing regulatory burdens for beneficence and to 
move a drug onto the market to maximize shareholder profit is blurred. In Cuba’s case, such a 
de-linking enables another view to evaluating pharmaceutical intervention.  Much of the 
scholarship and analyses of the relationship between the science and the state has presumed a 
liberal democratic model, even more so since the end of the Cold War. Conventional wisdom 
might assert that Socialist-state models of scientific innovation gave birth to Lysenko-sim, 
presuming they are doomed to the dustbins of history. Yet, in Cuba, socialist science is not only 
generating technoscientific innovation, it is also suggesting new ways of creating product value.  
Pharmaceutical regulation is enacted conceptually and mechanistically through the 
integration of science, politics and bureaucracy. Yoandra’s version of CECMED illustrates the 
ways in which commercial value can be produced through pharmaceutical regulation, in the 
Cuban case, by integrating regulation with the care and control of the socialist state.  Cuban 
biomedicine derives value by simultaneously containing and exceeding the socialist state in ways 
that are meant to be legible and visible to outsiders.   
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 Yoandra described some of the new, broader changes to the regulatory processes among 
the countries with which Cuba has bi and multi-lateral agreements. These changes hinge on what 
she describes as mutual recognition. She explains, 
Now they are talking about regulatory convergence that happens through a process 
of building confidence, that you know each other, you do interchanges, you do an 
in-depth study of the methodology and procedures that they utilize. At the end we 
converge and the two make our internal processes and we arrive at the same place. 
We can have trust in each other to see that we mutually recognize each other. That 
is what they talk about most now. That talk about convergence and mutual 
recognition. They talk convergence and it is not that I harmonize my regulation to 
yours. Instead, it is I recognize, or I know how you do your process and the terms 
are equal to mine. We have to have confidence in the process of this authority that 
they are efficient, they go to the same place and can say that this product was 
registered in Brazil, I’m going to ask that the manufacturer register in Cuba and 
that this expediently brings a certificate registrant for both. This is basically what 
we are pushing the region to do with what we are the authority of reference is 
regulatory convergence (February 19, 2018).  
 
 Yoandra points to a new direction for CECMED and its partners, particularly in the 
Americas. This is a choice based on expedience, as harmonization is more difficult to achieve. 
Yet, it is also based on, as she puts it, mutual recognition. This is a lateral, anti-hierarchical 
approach. This recognition, facilitating CECMEDs success in regulatory convergence with its 
trading partners in the Global South, is shaped, in part, by the visibility of the socialist features of 
the Cuban pharmaceutical sector. This visibility does not necessarily include the words socialism 
or communism. Instead, it references features such as a closed system, solidarity and the political 
stability of one-party control. This visibility may share similarities with the idea of brand 
recognition, yet it is shaped in a novel way. The value of the Cuban brand of socialism is also 
visible in the sector which most closely resembles a true private sector within the Cuban state 
system of bioscience: medical tourism.      
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Servicios Medicos Cubanos: Wealth Redistribution 
Passing through the immigration and baggage claim zones of Havana’s Jose Marti 
International Airport in 2018, travelers would confront a twenty-foot glossy poster of a beautiful 
woman in a flowing tunic, palms extended, eyes closed, brows slightly furrowed, as if in 
exultation. A green ribbon twists over her figure, fading into the main text of the advertisement: 
Cuba: Un destino de salud para todos. The font of para todos is larger than that of destino de 
salud. In the center are four bullet points translated as: 1) Medical services in Cuba, 2) 
Professionals, technicians in health assessment in the exterior, 3) Academic services and 
investigation in Cuba and the exterior and 4) Services in medical attention for nationals and 
foreigners. In the lower right-hand corner is the website: www.smcsalud.cu. SMC is the acronym 
for Commercializadora de Servicios Medicos Cubanos, SA, or Commercializer of Cuban 
Medical Services. Increasingly visible across the Cuban landscape, the SMC logo promotes 
medical services, pharmacies, educational and professional training, signaling a growing new 
chapter in Cuba’s prodigious biomedical sector. While advertising materials featuring tawny and 
toned dream selves in low-cost tropical climes are an established part of the landscape of the 
medical tourist industry, SMC does not fit the mold of typical for-profit clinics aimed at 
foreigners. It sells something exceeding the categories of health, youth and beauty. Thirty years 
after the collapse of the Soviet Union, most advertising in Cuba promotes either tourism or 
socialism. The typical landscape of billboards either features beaches or slogans reading: 
Socialismo o Muerte, 50 Años de Revolución, featuring young, vigorous Fidel, defiant middle-
aged Fidel, and sage, elderly Fidel. Against this landscape of sparse advertising, the new signs 
hailing prospective consumers for SMC are a jarring departure from the typical billboards on the 
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island, suggesting the cynical possibility that Cuba’s famed universal health system is fated to 
death through free market commercialization.   
The SMC logo distinguishes its products and facilities from those of Cuba’s free 
universal healthcare system available to its citizens. SMC is intended for the foreigner, or more 
specifically, the person paying in CUCs, Cuba’s convertible currency, which is pegged to the US 
dollar, rather than the other of Cuba’s two currencies, the moneda nacional. While SMC 
resembles a private-sector business, it is actually part of Cuba’s Ministry of Public Health, 
(MINSAP). Like all of Cuba’s state-run commercial-type entities, profits of SMC are meant to 
generate income for the state socialist government, funding the continuity of its free health 
system. The health care providers, researchers and academics in SMC are trained in and work for 
the same entity as those who educate and care for Cuban citizens. They survive on the same 
salary structure and are held to similar contractual obligations in terms of work hours and 
assignments, despite working in the relatively cash-rich tourist sector.    
The healthcare providers of SMC offer medical services in hotels and resorts as well as 
the handful of private schools in Havana, all under the auspices of MINSAP. SMC also includes 
a set of pharmacies called Novafarma, where European medicines are sold alongside Cuban 
innovadoras. SMC offers services in several of the major hospitals serving Cuban citizens, in 
special wings like the Sala Ami at the cancer hospital INOR. La Pradera is a luxury 
hospital/resort only for CUC-paying patients, where SMC highlights its services ranging from 
neuromuscular rehabilitation and cancer care to eastern massage and integral psychological 
evaluation, alongside images of fountains, swimming pools, and hotel-style rooms. For the most 
part, the services provided are the same as those as those in the free universal health program 
available to Cuban citizens. The features distinguishing SMC from the Cuban universal 
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healthcare system are elements rendering them legible as commercial entities. Concierge-like 
staff at the entrances, embedded salons, faux-leather furniture and televisions in the waiting 
rooms, and a pool at the hotel-like setting of La Pradera translate MINSAP functions into sell-
able care.  While the “branding” of SMC superficially resembles the medical tourist marketing 
one might find in Mexico, Brazil or Thailand, a more considered examination exposes key 
distinctions affording a reimagination of the constitution of value in commercial medicine. In 
this case, the bells and whistles of pools and hair salons are superficial dressings for what is 
really profitable at La Pradera.  SMC’s success depends on potential clients’ recognition of the 
socialist features undergirding the program.  Like the vignettes above, these features include the 
reputation of Cuban healthcare providers within the Global South developed through south-south 
medical solidarity. This recognition is further shaped by the visibility of high numbers of doctors 
and nurses, a feature of the free higher education and coordinated system of training and 
healthcare delivery orchestrated by the state. SMC is also made valuable through the reputation 
of security and stability derived from the control of the Communist party. Whereas, in recent 
years, Cuba has made no secret of plans to generate state income through providing physicians 
for oil in the case of Venezuela, the subtext of south south solidarity limits the extent to which a 
term like profit could be used to describe these ventures. SMC, on the other hand, is a service 
oriented specifically towards foreigners with money. The model is an explicit model of wealth 
redistribution. In attracting foreign consumers with money who pay for what is normally 
delivered for free, generating income for the state as provider, SMC redistributes wealth.  This is 
an adaptation which puts Cuban late socialism in contact with commercial, market-driven 
healthcare, but does not follow the logics of medical tourism or commercialized biomedicine 
more generally.    
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Despite the well-documented brain drain of Cuba’s medical professionals (Brotherton, 
2012; Burke, 2013) and the near evisceration of leftist Latin American Bolivarian economic 
support, Cuba’s medical system remains a centerpiece of the Revolutionary government’s sixty-
year tenure. The preservation of this centerpiece is therefore paramount for the Cuban state. 
Thus, despite the visible tensions of free market forces in nearly all sectors on the island, the 
publicly funded health sector continues to grow into the 21st century. The consultorios, 
neighborhood-based primary care hubs found every few blocks, their crumbling exteriors giving 
way to organized, spare, interiors, remain staffed by doctors and nurses providing neighborhood-
based primary care and usually living on site. Secondary policlinicos are also abundant, offering 
basic specialty and diagnostic neighborhood services in larger cities or as regional centers in the 
provincias. General and specialized hospitals are broadly distributed throughout the island, with 
an especially high concentration in Havana. Robust access to medical services is a signature 
achievement of ‘El Triunfo de la Revolucion’ and the system of universal, free healthcare is 
among its most popular benefits to Cuban citizens.   
The path through which the Cuban public health system entered into the business selling 
healthcare to foreigners emerges out of a set of social conditions inversely related to those 
underlying most for-profit medical systems. Cuba continues to have a huge number of medical 
professionals, ranking either first or second in number of physicians per capita (CIA, 2018; 
WHO, 2018).  All physicians, by law, work for MINSAP or a government run research facility, 
as private practice is against the law. Cuba continues to train thousands of healthcare 
professionals, including foreign nationals who will return to their countries of origin to practice. 
The mass training of biomedical professionals and researchers traces its roots to the early days 
following the Cuban revolution.  The revolutionary state’s educational program, beginning with 
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the literacy campaign in the first days after “El Triunfo,” prioritized access, not only to basic 
education but to university, graduate and professional level training. In the first years of the 
Revolutionary government’s tenure, Che Guevarra espoused the goal of establishing a nation of 
doctors. Despite his lack of actual experience as a practicing physician, Che as the ideal of the 
physician-revolutionary created a model of nation-building which continues to find expression 
across the island, from medical solidarity to this new effort of SMC.   
The advertisement for SMC in the airport emphasizes Cuba as a healthcare destination 
“para todos” (for everyone).  This is a sign among a landscape advertising “Socialismo o 
Muerte” (socialism or death) along the route from this same airport, throughout Havana and the 
rest of the country.  At first glance, SMC emulates a familiar form of advertising with glossy 
photos, eye catching imagery and easy to digest bullet points. Yet, the degree to which SMC 
might succeed in hailing prospective patients depends on the extent of the potential recipient’s 
recognition of its connection to the adapting socialist project.  
 
SMC Epilogue: The Moral Economy of “Free” Health Care (Or, Disciplining With Numbers)  
 SMC signals its distinction from the free MINSAP clinics available to Cuban citizens and 
foreigners with residency status afforded by the carné identification card. In recent years, 
another form of advertising has cropped up within some medical centers aimed at Cuban 
citizens. In Hermanos Ameijeiras, a hospital offering cutting edge medical and surgical care, in 
separate wings, for both Cubans and foreigners, the emergency waiting room for Cuban nationals 
has a list of prices for services and procedures. This list of prices does not reflect an actual 
system of exchanging money for medical treatment for Cubans, unheard of as of yet in the 
MINSAP system.  Rather, it is intended to have a disciplining effect in reminding Cuban patients 
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that in other systems, diagnostic tests often involve money. The specific amounts listed don’t 
come with any reference point or explanation. They are simply suggested amounts in dollars for 
what a particular test might cost if it were to cost something. On the one hand, the two wings of 
the hospital are providing comparable medical services with equally trained physicians receiving 
comparable remuneration, but the materiality of the experience including the infrastructure and 
equipment differ. On the other hand, neither system can be truly compared as one falls squarely 
within the realm of socialized medicine and the other is a hybrid entity in which the commercial 
side funds the non-commercial side. This logic of value differs from those analyzed by 
anthropologists like Dumit and Sunder Rajan.  Yet, if salary and service are controlled for, does 
that not convey the impression that one is paying for the sleek brochure, the pleather couch and 
TV in the waiting room?  In the case of “free” MINSAP care for Cuban citizens versus fee for 
service care in SMC, the corps of experts trained for free in the socialist education system 
supports the maintenance of the socialized medical system for Cuban citizens. SMC, as a state-
run business venture, capitalizes on socialism. 
 
Medicine and Money: The Double Promise 
 The “double promise” is a phrase adopted by Fidel Castro as he initiated the biotech push 
of the 1980s. The “doubling,” refers to the optimistic idea that science and technology will 
inevitably improve social and economic conditions. This is the Cuban iteration of a practical and 
philosophical conundrum of how and when medicine and money should relate to one another, a 
challenge often taken up across disciplines by scholars, medical practitioners, policy-makers, 
journalists and the lay public. How much should drugs cost? What should a surgeon’s salary be? 
How much should a hospital stay cost? Who should bear the cost of research, practice or care?  
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These are questions tugging at ideological and ethical commitments, their answers revealing the 
structure and priorities of any given biomedical context.  Medical anthropologists and STS 
scholars have examined pharmaceuticals as an extension of capitalist expansion. The concept of 
pharmaceuticalization, developed by Biehl in his work on AIDS and antiretroviral provision 
(2007), emerged in response to Zola’s (1972) term medicalization, where aspects of social life 
come to be considered medical problems (Maturo, 2012). Pharmaceuticalization is the 
repackaging of social concerns into problems amenable to pharmaceutical remedy. 
Pharmaceuticalization conceptually includes the critique of profit over care. Anthropological 
scholarship of pharmaceuticalization includes an explicit critique of capitalist expansion.  
 Dumit’s Drugs for Life (2012) emphasizes a fundamental contradiction at the heart of the 
research undergirding the medicines we consume everyday: they are linked to a system in which 
money must be generated from their sale. Since the advent of major pharmaceutical research in 
the first half of the 20th century, even in publicly funded academic medical centers in the US, 
drug innovation is conceptually linked to pharmaceutical markets. Is there or isn’t there a 
“market” for any given drug? What or where is the market for a novel molecule? What 
applications might be more lucrative?  What will the market impact be? Dumit links the rise in 
treatment of chronic asymptomatic conditions to what Ulrich Beck (1986) described as the “risk 
society,” where relation to risk becomes a new dominion in capitalism. Along these lines, a 
number of other scholars have examined the facets of pharmaceutical spread through clinical 
trials, informal markets and the courts (Petryna, 2009; Peterson, 2014; Sunder Rajan, 2017 
Hayden, 2013).  Is Dumit and by extension Beck’s conceptual overlap of expanding fields of risk 
and markets for medicines reconcilable with Cuba’s for-profit endeavors as described by Fidel 
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Castro’s “double promise,” where improving the health of the (socialist) state supports the 
economic and political stability of the (socialist) state?   
 
Socialism Through Composite Value  
Anthropologists have emphasized what is masked by multinational pharmaceutical 
development and expansion. They have explored the ways in which diagnostic categories and 
populations become linked for the purpose of selling pharmaceutical remedies (Healy, 1999; 
Metzl, 2009; Whitmarsh, 2008); the exploitation of vulnerable populations of the global south in 
clinical trials for medications destined for the global north  (Petryna, 2009); the “chemical 
arbitrage” lurking behind drugs circulating in the global south (Peterson, 2014); or the charisma 
in generic or “similar” medicine (Hayden, 2010).  Sunder Rajan, for example, argues that 
“(v)ision, hype, and promise…are fundamental drivers of this kind of valuation and are central 
animating factors in drug development (2006:18).” Dumit exposes the hidden ideological terrain 
behind the growth of the pharmaceutical industry. “The phenomenal size and continued growth 
of the pharmaceutical industry…depends on the ability to continually change and enlarge the 
definition of health so that more and more drugs can be prescribed to those who can pay 
(2012:19).”  Dumit, Sunder Rajan and others argue that these aspects must be obscured since 
they do not support the acknowledgeable purpose of pharmaceutical development—the health of 
the individual patient.  
Cuban innovadoras and state-run commercial entities like SMC, by contrast, rely not on 
masking but precisely on the visibility of the drivers of innovation outside of the health of the 
individual patient. Classical Marxism directs us to consider what is “hidden” in the commodity 
fetish (Marx, 1867,2018). Cuban therapeutic vaccines are being marketed globally by making 
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their connection to socialism visible, although, crucially, not named, and this produces value. 
This value can be thought using Guyer’s (2009) notion of composite.  In contrast to standard 
Marxist theory in which a commodity and its price function as a fetish obscuring social relations, 
Guyer argues that price is a composite of components which are increasingly visible to the public 
through exposure to online pricing schemes via eBay and Craigslist.  Such visibility exposes 
both the moral economy and the politics of pricing to potential buyers. Cimavax as a commodity 
has a particular type of visibility in its valuation, one linked to the ongoing socialist project. In 
the case of Cuban biopharmaceutical commercialization efforts, composite allows us to see how 
Cimavax becomes valuable in a novel way. As the ethnographic vignettes above show, it is the 
visibility, rather than the invisibility, in this case, of socialist features: medical solidarity, state 
innovation, one party control, political will and redistributing wealth, among others, facilitating 
the expansion of the Cuban biomedical system beyond treating Cuban citizens through the 
Ministry of Public Health (MINSAP) toward broader, non-Cuban, populations. This expansion is 
the result of a new way of thinking of value, based on the visibility of socialist features.   
 Barry’s (2005) examination of the molecular chemistry takes on composites via the 
pharmaceutical R&D. Chemistry, he argues, produces substances the properties of which cannot 
be deduced from general laws. Further, the properties of the emergent substance cannot 
necessarily be expected to behave in the same ways they did inside the laboratory once they enter 
other environments.  Barry combines Gabriel Tarde’s definitions of invention, never in itself de 
novo creations but instead always composites of other inventions, with Whitehead’s (1978 cf 
Barry, 2005) history of chemistry to consider molecules as events rather than elements. Barry 
proposes a conceptualization of the molecules used for pharmaceutical research as societies, 
subject to change according to their particular historic form. Such ‘societies’ become enriched, 
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taking on new information. Thinking with Barry, if a Cuban patient receives Cimavax in his 
local polyclinic and a Canadian national receives it through SMC in La Pradera, is this the same 
molecular “society” entering both people?  If Cimavax is a molecular society, it would 
undoubtedly bear some traces of the particular conditions through which it came into existence.  
Following this train of thought, would the Cuban conditions of pharmaceutical innovation which 
resulted in the development of Cimavax persist in this vaccine through its introduction into 
differing clinical contexts in which the milieu might be more or less aligned with these 
conditions of possibility?   
Thinking with both Guyer and Barry offers one way of thinking through how Cimavax, 
along with Cuban innovadoras and SMC, are expanding beyond the Cuban population, even 
creating some profit, in novel ways. The expansion of Cuban biomedicine is generating value in 
a new way, in connection with the 21st century Cuban socialist project, without explicitly naming 
it as such. Guyer’s development of composite pricing also offers another way to think about the 
supposed cheapness of Cimavax. In the case of socialist pharmaceutical expansion, what does 
price show?   
 
Conclusion 
 The trilogy of acronyms explored here (SMC, CIMAB, and CECMED) each offer insight 
into nature of the commercialization of Cuban socialist biomedicine. Together, these examples 
configure a conceptual map of how Cuban pharmaceuticals and medical services derive value 
from their connection to the socialist project. Fidel Castro’s vision of the “double promise” of 
biotechnology envisioned a Cuban biopharmaceutical industry to improve the health of the 
population as well as to generate income for the island.  While the question of how Cuban 
   182 
socialism has survived is not reducible to a pat answer, the encounters described above reveal 
and offer texture to some of the ways Cuba’s biomedical advances and its persisting socialist 
project have mutually supported one other.  Cuban biomedicine is distinctive and valuable 
precisely because of its connection to socialism and this connection is neither explicit nor 
superficial. As elaborated by Egor at CIMAB, the value of Cuban innovadoras is derived from a 
set of conditions inseparable from both the mechanisms and the ideological position of the 
socialist state. Through CECMED, the double-edge of the care and control of the socialist state 
confers value through the “political will” pushing biomedical innovation to improve the health of 
the nation, along with assuring safety and stability enacted as pharmaceutical regulation 
facilitated through the one-party rule of the PCC. At SMC, we find a system where profits go 
back into the socialist state which provides free healthcare and higher education, continually 
training more scientists and doctors (plus artists, musicians and others) and continues to develop 
more novel biopharmaceuticals directed at problems facing the Cuban population.   
 In illustrating ways in which the value of commercialized Cuban biomedicine is 
constituted by ideology, innovation and care, these cases act as cognitive catalysts, re-imagining 
the relationship between biotechnological advances, population medicine, profit and the state. 
They challenge the normative language and fixity of intellectual scaffolding undergirding many 
analyses of the exchange of medicine and money by highlighting how Cuban medicine and 
medical services are constituted as valuable.   
 In North America and Europe, pharmaceutical innovation has increasingly moved from 
the university to the private sector. The measure of success of a new molecule stands in relation 
to its marketability. While the institutional incentives for discovery are not entirely removed 
from real world health problems, a drug’s capacity to move forward is tied to its potential to 
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generate profit. Cuba’s biopharmaceutical sector is entwined with its political economic system, 
both directly and indirectly. Directly, its germination stemmed from Fidel Castro himself, in a 
move intended to support both the medical needs on the island as well as to eventually become 
an income stream for the government, the “double promise.” This chapter demonstrated ways in 
which both remnants and iterations of a political orientation related to the socialist project 
continue to exert an influence and insert a type of value into the unique drugs and medical 
services developed on the island, even as they are pushed into new commercial realms.   
One recurrent critique of the Cuban government I heard from several of my Cuban 
interlocutors outside the health system was skepticism that the profits were indeed going back 
into the health system. They believed the state was deriving significant income from SMC and 
the innovadoras yet not reinvesting it (at least not sufficiently) back to the system. These people 
judged the dilapidated facilities meant for Cubans as evidence of corruption in the system. 
Indeed, lack of transparency fuels some of the broader critiques of the Cuban state off the island. 
It is certainly possible that prospective consumers of the Cuban “brand” might be deterred by 
concerns around the issue of transparency and this could decrease the value of the brand in both 
the economic and ethical sense of the word. However, calls for transparency in Cuba, like calls 
for democracy, are often wielded as a blunt instrument of Cold-War era critiques. My attention 
to the commercialization of Cuban biomedicine seeks to avoid a common pitfall of many social 
science scholars based off the island, where their work is hastily received as either critique or 
propaganda. Rather than examining the commercialization of Cuban biomedicine as either 
celebration or denigration of the Cuban Communist Party’s healthcare program, I find it 
instructive in its articulation of medicine and money in a context not fundamentally shaped by 
the firm and the market.   
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The words socialism, communism or any related concepts are decidedly absent from any 
of the efforts to commercialize Cuban biomedicine I encountered throughout my research. Yet, 
as my interlocutors describe, the production of value for Cimavax and other novel cancer drugs 
is facilitated precisely by the Cuban socialist system. The next several years hold the potential 
for Cuban biomedicine to significantly expand its commercial footprint off the island, following 
connections facilitated by medical solidarity and Cuban brand value. If Cuba’s commercialized 
biomedical sector continues expanding both on the island and overseas, how might this socialist-
inflected reimagination of value impact the new markets it encounters? 
A robust body of research within medical anthropology and STS scholarship examines 
how the profit motive reshapes definitions of health and illness and fuels the expansion of 
commercial biomedicine into nearly every nook and cranny of the globe. Pharmaceutical 
interventions have changed the nature of life and illness and death. Pharmaceutical development 
pegged to market expansion fuels inequality, engendering an uneven terrain of therapeutic 
categories and treatment access. Drugs of uncertain benefit but certain profit become the 
prescription du jour until evidence of their eventual negative side effects grows impossible to 
ignore (OxyContin, Valium, Thalidium, just to name the most obvious, but the list is extensive).  
Drug pricing regimes render certain lives unworthy of saving (HIV, Hep C), or lack of market 
incentive restricts drug development in the first place (until new incentives for micro-markets of 
rare drugs became a hot financial item in themselves, see Junghans (2018).  Yet, as the branding 
of Cuban biomedicine illustrates, identifying capitalism as the source of the problem provides 
only a partial solution to the conundrum of understanding the relationship between medicine and 
money. What anthropologist Sharon Kaufman (2015) has so elegantly demonstrated through her 
ethnographic analysis of Medicare funding of high-tech medical interventions in the elderly is 
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that the relationship between money and medicine enfolds multiple, often competing ethical 
regimes, as well as logics of value.    
 The branding of Cuban biomedicine renders the relationship between medicine and 
money visible in a unique way. The Cuban government manages a commercial-type for-profit 
healthcare and pharmaceutical system to fund its national universal health system. In examining 
and sharing the case of Cuban pharmaceutical innovation and commercialization, my aim is to 
open up a new direction for medical anthropology and STS research, including not only stories 
of resistance, but also examining how systems develop and compete using a radically altered 
playbook. If capitalism, as Marx, Sunder Rajan, Zizeck and many others have accurately pointed 
out, is endlessly mutable and constantly adapting, why would we not seek evidence of mutability 
in the socialist enterprise?  
Pharmaceutical development, regulation and commercialization are enacted conceptually 
and mechanistically through the integration of science, politics and bureaucracy. The idea that 
science is politically neutral remains a cherished belief for many, yet one long undermined by 
scholars of STS and anthropologists of science (Haraway, 1991; Nader, 1996). As Haraway and 
Nader would remind us, that science is conducted by people who bring their worldviews into the 
lab, and, who decides what to study is not a neutral zone devoid of power, privilege and 
perspective. A centrally controlled pharmaceutical development, regulation and 
commercialization system runs counter to received wisdom about the necessary conditions of 
scientific innovation idealized as freedom, competition and financial incentive. If Cimavax and 
other Cuban cancer vaccines continue making inroads into new territories and populations, what 
role might the accompanying political adjuvants play on the global pharmaceutical stage? 
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Conclusion 
 
 
In this dissertation, I have offered an ethnographic examination of the global expansion of 
socialist pharmaceutical innovation. I have chosen a broad approach to a narrow subject. My 
interlocutors ranged from highly specialized pharmaceutical researchers to tobacco farmers to a 
science fiction writer. In drawing these perspectives together, I offered what might be described 
as a kaleidoscopic portrait of the counter-current expansion of Cimavax, the Cuban innovadora, 
toward the resource rich environment of a top cancer center in the US, the Roswell Park Cancer 
Institute (RPCI). My unorthodox approach was shaped both by my idiosyncratic interests as well 
as by the opportunities and constraints generated by the upheavals in US-Cuban relations and 
politics during the five year period of my research. Perhaps, taking a page from Jameson (2007), 
these methodologic disruptions fueled my own desire to produce something theoretically 
disruptive.  
I have argued that Cuban biopharmaceuticals are reshaping ideas about cancer, vaccines and 
value. The Cuban biopharmaceutical sector is fueled as much by its connection to socialism as 
by ties to the market, in a departure from the logics driving expansion in the multinational 
pharmaceutical industry. My ethnography illuminates the aspiration among Cuban cancer 
researchers for treatments like Cimavax to reimagine the experience of advanced, incurable 
cancer as part of the normal social: recognizing and accepting the slipperiness and continuity 
between living and dying. I introduced a way of thinking about the complex and enduring 
relationship between humans, tumors and tobacco, suggesting the term biocompanion as a way 
to account for the temporo-spatial relationship between these entities. I have emphasized the 
importance of the vaccine form to the success of Cimavax specifically and of Cuban socialist 
pharmaceuticals in general.  I have shown how Cimavax, and the Cuban socialist pharmaceutical 
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industry in general, generates value in new ways that exceed the framework of market logics, by 
making their socialist features visible yet not explicit. Cuba is actively partnering with private 
companies around the globe. Yet, both the aims and the interest which fuel these partnerships 
cannot be characterized accurately according to the logics of the market.  
In the case of Cuban innovadoras, the terms of their success depend on the nature of the 
evaluation. Certainly, there is modest randomized controlled trial data demonstrating clinical 
efficacy (Zhou et al, 2016; Rodriguez et al, 2016; Saavedra and Crombet, 2017), and powerful 
anecdotal data from Cuban and non-Cuban patients (Jacobs, 2018). Regardless of the ultimate 
outcome of the RCPI trial (still in process at the time of this writing) and whether or not access 
to the US market is ever achieved, my findings suggest that Cimavax and other Cuban 
innovadoras are worthy of careful attention as much for their disruptive powers as for their 
clinical efficacy. The collaboration with RPCI, regardless of the outcome, has raised the stakes 
and the visibility of Cuban innovadoras. This, in itself, is an important type of success.  
 The circulation of Cuban innovadoras changes the terms, in some small way, of debate. The 
“closed ecosystem” of the Cuban socialist biopharmaceutical sector generates drugs which do a 
different type of work from those produced by the multinational pharmaceutical industry. They 
may be cheaper to make, they may be easier to administer and perhaps they are only moderately 
effective. Yet their very existence disrupts the conventional wisdom that competition and deep 
pockets are the key to drug development. As Dania put it, by not following “the fashion,” the 
results of Cuban socialist pharmaceutical science may follow a different, often slower, timeline. 
But this slower timeline may yield quite useful fruits.      
Cimavax is part of a movement in Cuba and elsewhere to reframe cancer as a chronic 
disease: treatable, enabling a future where people, and their tumors, continue living and dying 
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together. Cimavax enables Cuba to promote both cigars and cancer treatment. The aspiration of 
cronicidad, promoted by Cuban oncology researchers, is to enfold advanced, incurable cancer 
into the normal social. It gestures toward a possible future where our bodies as always already in 
a state of biocompanionship with our tumors, coming and going, living in their own temporality.  
I have suggested the term biocompanion to account for the relations between humans, tumors 
and tobacco, recognizing the long-standing, complex and enduring connection with this plant, 
uniquely visible in the Cuban context. Cimavax is not a panacea for cancer, nor is it likely to 
substantively change the terms of Cuba’s economic situation, even if it is approved for use in the 
US. Similarly, Cimavax is unlikely to make a significant impact on the nature of pharmaceutical 
expansion written by the multinationals globally. Instead, it reimagines the terms of the cycles of 
treatment: offering the dual possibility of simultaneously living with and dying from cancer.    
 Cuban innovadoras are not all vaccines, yet the vaccine formulation of the country’s 
novel immunotherapeutics has thus far been the most potent signifier of its biopharmaceutical 
sector’s successes. Cimavax is a biotechnical adaptation of socialism in 21st century Cuba. As 
Esposito’s (2011) development of immunitas suggests, Cimavax achieves its directives indirectly, 
an embodied instantiation of socialist technoscientific innovation. It draws strength from the 
moral valence of the politics of vaccination, resonant with sacrifice for the greater good.   
This dissertation has shown specific ways in which Cuban biopharmaceutical science, 
including the expansion of its products and services, is entwined with Cuban socialism. Cuban 
biomedicine is, in fact, the most explicitly socialist sector on the island, where socialist features 
are integral to Cuban “brand value.”  Cuban cancer vaccines are expanding globally through a 
network grown originally from medical solidarity. Decisions on where and how to expand are 
not made according to market calculations. Instead, they draw on alternate logics based on 
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mutual recognition. This does not necessarily mean a lack of calculation, political or pragmatic. 
Yet, in contrast to many iterations of global health and development, as well as the logics of 
multinational pharmaceutical expansion, the nature of medical solidarity is not characterized by 
power imbalance, control, or dominance. With the RPCI trial of Cimavax, a new possibility of a 
South North technology transfer is in process. It remains unclear, as of today, what the fate of the 
Cimavax trial will be and how its outcome may or may not substantively change the Cuban 
socialist model of pharmaceutical expansion.  
 On November 9, 2016, the day after the election of Donald Trump, I had a conversation 
with the RPCI Cimavax investigators, Drs. Kelvin Lee and Mary Reid. They contrasted the RPCI 
team’s technical expertise with the practical know-how and resourcefulness of their Cuban 
counterparts. In Dr. Reid’s terms, “I think one thing that’s different, is that we would have spent 
a lot more time interrogating how things work.” On the one hand, Dr. Reid’s comment references 
some of the temporal differences in the Cuban pharmaceutical system through which Cuban 
innovadoras moved more quickly into patients than might happen in the US, given the 
integration of clinical trials in the public health system (Reid Henry, 2010; Graber, 2018).  On 
the other hand, Dr. Reid notes a distinction marked by the time to interrogate the “how” behind 
the “whether or not something works.” Her comment suggested that perhaps Cuban 
biopharmaceutical science is less thorough or rigorous. She went on,  
Because they are great, they can do high frequency… to see what happens… that’s why 
the partnership is so good because we can interrogate what it [Cimavax] does at a molecular 
level. So even without this modern technology, they developed a fabulous drug. They have 
new labs, more money and a great drug production facility, but they did that in the face of 
scrambling for every device. We would never push into this kind of trial unless we knew 
more about how it works. But they don’t have the technology or the time (Reid, 11/9/16).     
 
 Both Drs. Lee and Reid emphasized the Cuban benefits of resources untethered by market 
constraints –a benefit that enabled them to pursue products without regard to profit. Yet they also 
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asserted that what RPCI brought to the table was deeper theoretical and molecular knowledge. 
The ideas expressed by Drs. Lee and Reid, both of whom are self-described admirers and 
proponents of Cuban science, reflect a hierarchical valuation of modes of knowledge-making, in 
this case, molecular knowledge over clinical data. Their comments gesture toward a broader 
issue of how a particular discovery might be deemed a scientific breakthrough, what it looks like, 
and when it should be acknowledged as such. Even as they praised their Cuban counterparts, 
they simultaneously emphasized a deficit in theoretical knowledge on the part of the Cuban 
team.  
 Medical anthropologists, ethnobotanists, STS and other scholars have long examined so-
called “traditional,” “ethnic,” “alternative” “natural” or “other” modes of knowledge making. 
Levi-Strauss’s bricoleur (1962), remains a potent signifier of an “outsider” mode of problem 
solving, one associated with “other” ways of knowledge making.  In the realm of mythical 
thought, Levi-Strauss noted,   
The characteristic feature of mythical thought is that it expresses itself by means of a 
heterogeneous repertoire which, even if extensive, is nevertheless limited. It has to use this 
repertoire, however, whatever the task in hand because it has nothing else at its disposal. 
Mythical thought is therefore a kind of intellectual ‘bricolage’- which explains the relation 
which can be perceived between the two (1962:17). 
 
 Drs. Lee and Reid gesture toward the idea of a limit in the tools or resources available in 
Cuba, impacting the ability of the scientists at CIM to profoundly interrogate their molecules, 
suggesting a lack of theoretical depth behind their achievements. Yet, they also noted a freedom 
of guaranteed state funding untethered by market concerns. Where a classic anthropological 
move might posit Cuban biopharmaceutical researchers as modern bricoleurs, I propose, instead, 
considering the resource-rich science of the Global North or so called “scientific centers” as 
performing intellectual bricolage as described by Levi Strauss. That is, “usual” biotech and 
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pharmaceutical research might have, in Levi Strauss’s terms, an “extensive repertoire” in some 
domains, while still being limited conceptually in others, if said repertoire insists in innovation 
tethered to profitability. Cuban socialist biopharmaceuticals, in their disruptive capacity, offer a 
subtle shift in what Yoss describes as the “rules of the game” (Yoss, 2014:2; Jameson, 2007), as 
applied to the multinational pharmaceutical industry.43 If we think Levi Strauss alongside 
Jameson, with both limit and disruption as variables, Cuban biopharmaceutical research shows 
us how scientific innovation may be just as likely (or unlikely) to emerge irrespective of the 
access to financial resources, depending on what constrains the idea of the possible or the 
impossible.44 Taking seriously this zone between what seems possible and impossible may be 
vital for the survival not only of humans and other bio-entities, but for this planet and other 
territories into which these entities expand in the future.     
In Planet for Rent by Yoss (2015), intergalactic species coexist throughout the galaxy, 
including on a future earth, which resembles Cuba in the early post-Soviet era. One species, the 
xenoids, are the colonizers, whose powers are demonstrated shortly after first contact when they 
threaten, and then follow through with, sinking the entire continent of Africa, instantly killing 
millions.  At the end of Planet, which reads as an interwoven series of short stories, Yoss writes:  
Once, Earth was brimming with futurologists...the decision about the future depended 
entirely on man. The choices seemed very limited: either rational development at a 
dizzying pace, or suicide. But the xenoids showed up, and apparently, they didn’t 
know about futurology and didn’t care…Every morning, every human wakes up in 
fear and hope, discovering, to his dismay but also relief, that he is still there (225).  
  
 In Planet, the xenoids (read Americans, Europeans, now China) are, themselves, 
 
43 See Chapter Three for further discussion of Yoss’s Planet for Rent and its relation to Cuban 
biopharmaceutical science.  
44 Rabinow (1996) uses Levi-Strauss’s concept of “the swerve” in his analysis of the factors 
contributing to the discovery of PCR in the centers of biotechnology in California in the 1990s.   
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devoid of future. If we think Cuban biopharma through Yoss, the xenoids might be 
something like the American market. The xenoids/market evacuates the future, leaving in 
its wake the black hole of endless corporate profit. Futurology, to use Yoss’s term, is the 
space for a more radical vision of an imagined future writ large. Cuban cancer vaccines 
may have only moderate clinical efficacy, yet we might think with Yoss to read their 
potency in another way: toward a future otherwise evacuated by xenoids. The aspiration 
of cronicidad, Cuban medical solidarity and brand value through socialism are powerful 
insofar as they allow us to think toward a more humane future.  
My most recent trip to Cuba, in March 2020, coincided with the dramatic escalation of 
the COVID-19 pandemic. Three days after my arrival, Cuba discovered its first four cases, three 
of which were said to be in Italian tourists. On the fourth morning, I awoke to some good chisme 
(gossip). Over breakfast, Yamilka, the proprietress of the casa particular in which I stayed 
during this trip, asked me if I heard the yelling in the middle of the night. The apartment building 
had an open air light well, an efficient conduit for all sorts of noises from floor to floor. Last 
night, Yamilka had been awakened by a torrent of yelling, back and forth, between the guests 
and host of the upstairs apartment/casa particular. Apparently, one of the guests had a fever, 
and, amidst the COVID concern, the host wanted her to seek medical attention. The guest and 
her boyfriend repeatedly declined. The host was not deterred. She called for the paramedics. 
Shortly thereafter, an ambulance arrived, with two paramedics in full hazmat suits, who marched 
in and escorted the two guests into the ambulance, transporting them to the local hospital, where, 
goes the story, they were tested for COVID. The following morning, police came to the 
apartment to inform the host that her guests had tested negative.  
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In the weeks since that trip to Cuba, news stories have proliferated telling of the Cuban 
response to this global crisis. In the first month of outbreak in January, China tried Cuban 
interferon to aid in the treatment of critically ill patients with COVID-19.  On March 21st, the 
British cruise ship, MS Braemar, carrying at least 50 passengers sickened with the virus, denied 
port in every other Caribbean country, was granted entry and medical care in Cuba (Kornbluh, 
2020). Cuba sent doctors to Italy, a wealthy country that was struggling in the throes of the 
pandemic. At the time of this writing, Cuba has sent 579 physicians to 14 countries around the 
world to help in the fight against COVID-19 (Petkova, 2020).  
In taking a broad approach to this ethnographic engagement with novel Cuban 
biopharmaceuticals, my dissertation suggests that a significant element of the impact of these 
socialist therapeutic cancer vaccines is in their ability to provoke something beyond antibodies to 
epidermal growth factor: disruption. We might think Cimavax and the other innovadoras 
emerging from the Cuban biopharmaceutical sector as quasi-utopic pharmaceuticals. In this 
utopic zone, ideas and technologies emerge from all places and are evaluated broadly, with 
expansive criteria, tethered to a vision for a collective future worth living. This zone might 
change the conditions for living and dying, what counts as life, how we live with other forms of 
life, in fleeting and enduring companionships on this one planet we find ourselves stuck on, at 
least for the moment.  
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